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Abstract
Radiotherapy of cancer is a rapidly advancing technology and has led to an increased number of long-
term survivors. It is, however, often intertwined with undesirable side effects, such as secondary cancer,
which can occur several years or decades after the treatment. It is therefore crucial to estimate secondary
cancer risk after radiotherapy in order to deliver the best possible treatment to the patient. This is
especially important for pediatric patients and young adults that have a long lifetime expectancy.
Particle therapy is a new treatment modality that offers superior dose conformity and efficient sparing
of normal tissue compared to photon therapy, and has in particular been proposed for the patient group
mentioned above. However, due to limited clinical and epidemiological studies of particle therapy, the
carcinogenic potential of ion radiation is not yet fully understood. Therefore, radiobiological models
are needed for evaluating the systematics of carcinogenesis related effects after particle irradiation.
In this work, a novel method for simulating the relative biological effectiveness of particle radiation
with regard to neoplastic cell transformation as initial step in tumour development was implemented.
This was performed by employing a radiobiological model for estimating biological effects after particle
radiation (local effect model). The induction of lethal and mutagenic events were considered as statis-
tically correlated processes that both originate from DNA damage. In order to correctly describe the
joint probability of these two processes, the local effect model was applied twice. Additional to mod-
elling neoplastic cell transformation and tumour induction after particle radiation, secondary cancer
risk estimates for various scanned proton and carbon ion beam treatment plans were compared. In a
first step, treatment plans were analysed for an idealized geometry in order to assess the underlying
systematics of cancer induction. In a second step, secondary cancer risks were compared for 20 patient
proton and carbon ion treatment plans.
The results show good agreement between experimental and simulated neoplastic cell transforma-
tion in vitro and tumour induction probabilities in animal models for particle radiation, allowing the
application of the implemented method for estimating secondary cancer risks after particle radiother-
apy. With this method it was possible to assess secondary cancer risk dependence on several factors
such as treatment plan geometry, fractionation scheme and tissue radiosensitivity. A lower secondary
cancer risk was estimated for carbon ions compared to protons at the lateral field margins in the en-
trance channel due to reduced lateral scattering of carbon ions, while an increased risk was found closely
behind the tumour due to fragmentation of carbon ions. The observed general systematics enabled to
consistently explain secondary cancer risk after proton and carbon ion beam therapy and is in agree-
ment with results from previous studies. For the considered patient treatment plans, reduced median
secondary cancer risks were predicted for proton therapy compared to carbon ion beam therapy for the
majority of the organs under consideration. The methods established in this work provide a foundation
for quantitatively describing carcinogenesis related effects after particle radiation and for optimizing
treatment strategies based on individual patient plans with regard to secondary cancer risk.
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Zusammenfassung
Der stetig wachsende Einsatz von Strahlentherapie zur Krebsbehandlung hat in den letzten Jahren zu
einer erhöhten Anzahl an Langzeitüberlebenden geführt. Strahlentherapie geht allerdings häufig mit
unerwünschten Nebenwirkungen, wie zum Beispiel Sekundärkrebs einher, welcher häufig erst nach Jah-
ren oder Jahrzehnten sichtbar wird. Es ist daher von äußerster Dringlichkeit das Sekundärkrebsrisiko
nach Strahlentherapie abschätzen zu können, um eine bestmögliche Behandlung des Patienten zu ge-
währleisten. Dies ist insbesondere für pädiatrische Patienten und junge Erwachsene von Bedeutung, die
eine hohe Lebenserwartung haben. Teilchentherapie ist eine neue Therapiemethode, die eine erhöhte
Dosiskonformität gegenüber Photonentherapie aufweist, sowie eine bessere Schonung des Normalgewe-
bes, und die speziell für die oben genannte Patientengruppe vorgeschlagen wurde. Aufgrund mangelnder
klinischer und epidemiologischer Daten, ist das karzinogene Potential von Teilchenstrahlung noch nicht
vollständig aufgeklärt. Daher sind radiobiologische Modelle notwendig, um die Systematiken von kar-
zinogenen Effekten nach Teilchenstrahlung zu evaluieren.
In dieser Arbeit wurde eine neue Methode zur Simulation der relativen biologischen Wirksamkeit
von Ionenstrahlung in Bezug auf neoplastische Zelltransformation als initialen Schritt der Krebsent-
wicklung implementiert. Diese Methode beruht auf einem radiobiologischen Modell, dem Lokalen Ef-
fekt Modell, welches biologische Effekte nach Teilchenstrahlung vorhersagt. Es wurde angenommen,
dass die Induzierung von letalen Ereignissen und Mutationen zwei statistisch korrelierte Prozesse sind,
die beide auf DNA-Schäden als Ursprung basieren. Um die Wahrscheinlichkeit dieser Prozesse korrekt
zu beschreiben, wurde das Lokale Effekt Modell zweifach angewendet. Zusätzlich zur Modellierung von
neoplastischer Zelltransformation und Tumorinduktion nach Teilchenstrahlung, wurden die Sekundär-
krebsrisiken für verschiedene Behandlungspläne für Protonen- sowie für Kohlenstofftherapie verglichen.
In einem ersten Schritt wurden Behandlungspläne für eine idealisierte Geometrie analysiert, um die
zugrunde liegenden Systematiken der Krebsinduktion zu ermitteln. Im zweiten Schritt wurden Sekun-
därkrebsrisiken für Protonen- und Kohlenstofftherapie für 20 Patientenpläne verglichen.
Es konnte gezeigt werden, dass die vorhergesagten Wahrscheinlichkeiten für Zelltransformation in
vitro und Tumorinduktion in Tiermodellen mit den experimentellen Daten übereinstimmen. Dies er-
laubt die Anwendung des Modells für die Abschätzung von Sekundärkrebs nach Teilchentherapie. Mit
Hilfe des Modells wurden Abhängigkeiten von Sekundärkrebs von verschiedenen Faktoren gefunden,
wie zum Beispiel Behandlungsplangeomtrie, Fraktionierung und Geweberadiosensitivität. Im Vergleich
zu Protonentherapie konnte für Kohlenstoffionen ein verringertes Sekundärkrebsrisiko an den latera-
len Feldrändern im Eingangskanal aufgezeigt werden. Dies ist auf die verminderte laterale Streuung
von Kohlenstoffionen zurückzuführen. Aufgrund der Fragmentierung von Kohlenstoffionen, wurde ein
erhöhtes Sekundärkrebsrisiko für Kohlenstoff direkt hinter dem Tumor vorhergesagt. Die Abschätzun-
gen für das Sekundärkrebsrisiko in verschiedenen Organen für die hier berücksichtigten Patientenpläne
sind allgemein niedriger für Protonentherapie im Vergleich zu Kohlenstofftherapie. Die in dieser Arbeit
vorgestellte Methode bietet eine Grundlage zur qualitativen Beschreibung von karzinogenen Effekten
nach Teilchenstrahlung und zur Optimierung von Behandlungsstrategien basierend auf individuellen
Patientenplänen in Bezug auf Sekundärkrebs.
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1 Introduction
According to the World Health Organization (WHO), cancer is the second leading cause of death
worldwide and is responsible for an estimated 9.6 million deaths in 2018 (WHO, 2019). This means
that about one in six deaths is attributable to cancer. Improved cancer treatment in recent decades has
led to decreased cancer mortality rates in the US (Siegel et al., 2019). Besides surgery and chemotherapy,
radiotherapy is an alternative way to treat cancer, where the cell killing effects of ionizing radiation
are exploited. Wilhelm Conrad Röntgen discovered X-rays in 1895 and soon afterwards they were
used in the medical field for diagnostic and therapeutic treatments, treating various diseases. The main
advantage of radiotherapy is its non-invasive character, allowing the treatment of cancers that would be
impossible to remove surgically. In 1952, the first human patients were treated by John Lawrence and
Cornelius Tobias with helium and deuteron ion beams (Tobias et al., 1952). Particle radiotherapy has
several advantages over photon radiotherapy: they display a beneficial depth-dose curve and a higher
relative biological effectiveness (RBE). Radiotherapy techniques are rapidly evolving and there are
now many different treatment modalities with varying radiation qualities applied in clinics worldwide.
Together with surgery and chemotherapy, radiotherapy is one of the most effective cancer treatments.
Between 2013 and 2014 45% of the patients in the UK that were diagnosed with cancer underwent
surgery as part of the treatment to remove the tumour, while 27% received radiotherapy and 28%
received chemotherapy (NCRAS, 2017). These numbers include patients that received combinations of
the three treatment modalities. In the last decades, particle therapy has become increasingly popular
and the number of proton and carbon ion beam therapy treatment centers is increasing (PTCOG,
2019a). From 1954 to 2018 over 180 000 patients were treated with protons and over 25 000 with carbon
ions (PTCOG, 2019b). Due to prolonged life-time expectancy (WHO, 2020), the risk of obtaining cancer
is increasing and thus the development of more efficient cancer treatment techniques is vital. At the
same time, successful cancer treatment has led to an increased number of cancer survivors (Parry et al.,
2011). Cancer survivors that underwent radiotherapy are at risk of obtaining a second cancer induced
by the radiation applied during the treatment. Thus, understanding the underlying mechanisms of
radiation on cells and the ability to predict secondary cancer risk after radiotherapy is crucial.
DNA damage is known to be an important cause of abnormal tissue growth (malignant neoplasms),
and is regarded as the main cause of radiation-induced carcinogenesis. Neoplastic cell transformation
arises from DNA mutations resulting from DNA damage and is an initial step of cancer development
(Reznikoff et al., 1973; Borek et al., 1978). It can lead to genomic instability in cells and evolve into
enhanced growth potential. The dose-response relationship for the carcinogenic potential of photon
radiation (Terzaghi and Little, 1976; Frankenberg-Schwager et al., 2006) and ion radiation (Yang et al.,
1985; Miller et al., 1995; Hei et al., 1988; Bettega et al., 2009; Suzuki et al., 1989; Han et al., 1998)
was established and allowed the quantification of cell viability as well as transformation probability
for cells exposed to ionizing radiation. Through in vivo experiments, typically conducted on mice, the
carcinogenic potential of ionizing radiation was investigated (Alpen et al., 1993, 1994; Upton et al.,
1964; Chang et al., 2016; Ullrich and Preston, 1987; Weil et al., 2009; Coggle, 1988). The dose-response
relationships of cancer incidence often show similar properties as the ones for cell transformation in
vitro, starting with an increase at low doses and a decrease, or at least flattening, of the curve at higher
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doses. This is interpreted as the impact of cell inactivation counteracting the spread of transformed
or malignant cells. Cell transformation is a rare event compared to cell kill and thus large amounts of
cells are needed in order to obtain statistically significant results. For this reason experimental data
on neoplastic cell transformation are scarce, especially for radiation with a high linear energy transfer
(LET). Due to ethical considerations, only a limited number of dedicated in vivo studies have been
performed and, therefore, modelling neoplastic cell transformation and tumour induction is essential in
order to investigate the underlying mechanisms and to extrapolate to radiation qualities where limited
knowledge is available, such as for heavy ions. This information is important for risk estimations of
patients treated with radiotherapy since a substantial number of cancer survivors suffer from secondary
cancers (Brenner et al., 2000; Murray et al., 2014). There is a non-negligible risk of radiation-induced
side effects after radiation therapy, increasing with the volume of the treated tumour (Schultheiss et al.,
1983; Burman et al., 1991). It is thus of great concern to understand the effects of particle radiation on
cells and tissues in order to give the best possible treatment to the patients with an acceptable risk for
acute and long-term side-effects. The pre-assessment of long-term side-effects of radiotherapy, such as
secondary cancer, is especially relevant for pediatric patients and young adults. Due to the long latency
time for tumour induction as well as the low incidence rate, epidemiological data is scarce when it comes
to new treatment modalities, such as proton and carbon ion therapy. Therefore, risk models are an
essential tool for estimating secondary cancer risks for different radiotherapy treatment techniques and
could even be incorporated into treatment planning systems as an additional optimization criterion.
However, there are many uncertainties when it comes to choosing a risk model and its parameters.
Again, lack of data is the main problem, resulting often in huge uncertainties of the available data.
Cancer risk estimates are not only important for patients undergoing radiotherapy but are also
relevant for astronauts on long-term space missions to the Moon or Mars, where they will inevitably get
exposed to low doses of high energy ion radiation over a long period of time (Durante and Cucinotta,
2008, 2011).
Few studies have proposed and validated models for predicting cell transformation and tumour in-
duction systematically for a wide range of LET values. Daşu et al. (2005) used a simple linear-quadratic
(LQ) risk model, which was originally proposed by UNSCEAR (1993), to simulate secondary cancer
induction probabilities in different organs at risk after photon and proton radiotherapy. Cucinotta and
Cacao (2017) modelled tumour induction in Harderian glands of mice with a physical model based on
a modification of the Katz model (Katz et al., 1972). Waligórski et al. (1987) simulated neoplastic
cell transformation in vitro for one set of heavy ion radiation from Yang et al. (1985) with the Katz
model (Katz et al., 1972). As different model approaches vary in their underlying assumptions and
techniques, the extension of existing models to carcinogenesis related events provides a new ground
for model testing and bears the potential of an improved mechanistic understanding. A great need
still remains for an extensive systematic analysis of in vitro cell transformation and in vivo tumour
induction after particle radiation in order to describe and predict the effects of heavy ions regarding
these endpoints. The local effect model (LEM), which is a biophysical model that was implemented
at the GSI Helmholtz Centre for Heavy Ion Research (Germany) in the 1990’s, has proven to be a
powerful tool for predicting the RBE of ion radiation based on the known photon dose response curve.
Its ability to predict cell survival of different cell lines after irradiation with various radiation qualities
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over a wide range of LET values has been demonstrated (Friedrich et al., 2013a). In its latest version
(LEM IV) (Elsässer et al., 2010; Friedrich et al., 2012a) it has been shown to be applicable for ions
relevant for therapy from protons up to oxygen ions (Grün et al., 2015; Krämer et al., 2016; Sokol
et al., 2017). Starting off from the assumption that the induction of lethal and carcinogenic events
originate from the same lesion types, i.e. radiation-induced DNA damage, it is a reasonable approach
to start the prediction of carcinogenesis-related endpoints with the LEM as well. First attempts in
modelling neoplastic cell transformation and tumour induction with the LEM have been made (Scholz
and Elsässer, 2007; Iancu et al., 2011). The purpose of this work is therefore to reimplement and extend
the method used in earlier works and to investigate the ability of the LEM to predict the oncogenic
potential of charged particles over a wide range of LET values. This is followed by the application of
this method to estimate secondary cancer risks after proton and carbon ion beam radiation.
To estimate the risk of tumour induction after exposure to ionizing radiation, many studies rely
on epidemiological data from the atomic bomb survivors life-span study (LSS) (Preston et al., 2007;
Grant et al., 2017) and recommend a linear-no-threshold (LNT) risk model (ICRP, 2007). The exposed
population received acute whole-body doses between 0.1 and 2.5 Gy and in that dose range the LNT
model describes the data well. It is mainly used in radiation protection where mostly low doses are
of concern, while its applicability for higher doses is debatable. In order to be valid for radiotherapy,
where doses as high as 80 Gy are used, these models have to be extrapolated for higher doses. Many
risk models assume a bell-shaped (Daşu et al., 2005; Schneider et al., 2005; Schneider and Walsh, 2008)
or saturative (Schneider, 2009) behaviour. These studies have inspired the development of non-linear
risk models, which have been used to estimate secondary cancer risks after radiotherapy (Mondlane
et al., 2017; Schneider et al., 2005; Stokkevåg et al., 2016; Timlin et al., 2011). The modelling of
secondary cancer risk estimates performed in this work was inspired by the studies of Mondlane et al.
(2017). It includes clinical data from twenty patients which were previously treated with conventional
photon radiotherapy. Ten of these patients suffered from liver metastases while the other ten patients
were diagnosed with prostate cancer. Two treatment modalities were used: radiosurgery for the liver
metastases patients, delivering high doses per fraction, and conventional radiotherapy for the prostate
cancer patients with 2.5 Gy per fraction to the prostate. A comparative study of the cancer induction
probabilities in several organs at risk was performed for the liver metastases and prostate treatment
plans that were generated for both proton and carbon ion beam therapy. Additional to the clinical data,
a risk analysis was performed on an idealized geometry in order to shed more light on the systematics
of radiation-induced secondary cancers after particle therapy.
The aim of this work is a better understanding as well as an improved prediction of cell transfor-
mation and tumour induction in organs after exposure to particle radiation. In chapters 2 and 3 the
theoretical background and methods are described, respectively. The validation of the applicability of
the LEM on neoplastic cell transformation was performed in section 4.1 and for tumour induction in
section 4.2. After the validation, the tumour induction probability of scanned proton and carbon ion
beam radiotherapy is assessed for an idealized geometry in section 4.3 as well as for patient data in
section 4.4, thus complementing the study of radiation-induced secondary malignancies after particle
therapy. This work contains both the validation and application of the LEM to model carcinogenesis
related effects for high-LET radiation. Chapter 5 discusses the results obtained in this work, followed
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by concluding remarks and future prospects (chapter 6).
4
2 Theoretical background
This chapter provides necessary background information about the physical and biological background
in which this work is embedded, as well as concepts required for understanding the subsequent chapters.
This chapter is divided into five sections. The first two sections (section 2.1 and section 2.2) outline the
physical and biological background of ionizing radiation. The two subsequent sections (section 2.3 and
section 2.4) focus on the biological and epidemiological background of neoplastic cell transformation
and tumour induction. Section 2.5 introduces theoretical models for simulating cell response after
irradiation with high-LET radiation. The last section (section 2.6) gives an overview of radiotherapy.
2.1 Radiation physics
Humans are exposed to various kinds of radiation. Ionizing radiation is defined as radiation with en-
ergy high enough to overcome the electron binding energy in an atom or molecule. The energy needed
to ionize a water molecule for example is about 13 eV. There are two main physical quantities that
characterize ionizing radiation: The amount of energy deposited in the matter per unit mass (dose) and
the energy deposited per unit path length (linear energy transfer). In this section the two quantities
are described in more detail.
The absorbed dose D is measured in Gray [Gy] and is defined as the energy E that is deposited in
matter by ionizing radiation per unit mass m (ICRU, 1980):
D = dE
dm
[
1 Gy = 1 Jkg
]
(1)
There are two types of radiation, densely and sparsely ionizing radiation. Densely ionizing radiation
consists of charged particles such as protons, alpha particles and heavier ions. They interact with
orbital electrons of atoms or molecules and cause excitations or ionizations. Since they only lose a
small part of their energy in a single ionizing event they can cause many ionizations along their path.
They are called densely ionizing, because the distance between ionization events is small and thus they
create many ionizations in a small volume. The ionization pattern is very inhomogeneous, showing
localized clusters of ionizations. Non-charged particles such as photons are considered sparsely ionizing
radiation and only interact weakly with matter. The spatial ionization density is low and relatively
homogeneous.
2.1.1 Photon radiation
Photons lose energy to the traversed matter mainly by three processes: Photoelectric effect, Comp-
ton scattering and pair production. The photoelectric effect dominates at low energies (below about
0.1 MeV). In this process, a photon is absorbed by an atom while an electron is emitted. The energy
of the emitted electron equals the energy of the photon minus the binding energy of the electron. At
intermediate energies (∼0.1-3.5 MeV) Compton scattering is dominant. A photon interacts via inelas-
tic scattering with a loosely bound outer-shell orbital electron of an atom. Part of the energy of the
incident photon is transferred to the recoil electron. At energies above 1.022 MeV pair production can
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occur and becomes the prevalent interaction process at energies above ∼10 MeV. In this process, the
energy of a photon is converted into an electron and a positron. The energy of the two generated
particles is 511 keV, respectively, thus the energy of the incident photon has to be at least 1.022 MeV.
Due to the conservation of momentum this process can only occur close to an atomic nucleus.
2.1.2 Particle radiation
Heavy particles interact with orbital electrons of atoms in matter mainly through inelastic scattering,
which causes ionization or excitation of the atoms. The interaction between the incoming particle and
the orbital electron can cause the electron to be ejected from the atom. This electron, also called δ-
electron, can then produce further ionizations. The energy loss resulting from these inelastic collisions
is described by the Bethe-Bloch equation (Eq. (3)). Light particles such as electrons can also emit
Bremsstrahlung when they are scattered in the strong electric field of an atom.
Linear energy transfer. Particles show a very different depth-dose distribution compared to that of
photons. The reason for that is the difference in interactions they undergo, as described above, which
leads to a different linear energy transfer (LET). The LET is closely related to the collision stopping
power and is a measure of the average energy locally transferred to the material by particle radiation
per unit path length of the particle track (ICRU, 1970):
LET = −
(
dE
dx
)
(2)
The mean energy loss per unit path length can be mathematically described with the Bethe-Bloch
equation (Bethe, 1930; Fano, 1963; Bloch, 1933):
− dE
dx
= 4pie
4
mec2
· Z
2
eff
β2
· ρNA · Zt
At
[
ln
(
2mec2β2
I(1− β2) − β
2
)]
(3)
with the electron charge e, the electron rest mass me, the speed of light c, the relative velocity β
(β = v/c), the effective charge Zeff of the projectile, the Avogadro number NA, the charge of the target
material Zt, the mean ionisation potential I, the density of the medium ρ and the atomic mass of the
target material At. The effective charge Zeff for low energies (i.e. when the projectile carries atomic
electrons) depends on both the atomic number of the projectile Zp and the relative velocity β. This
can be calculated with the Barkas formula (Barkas and Berger, 1964):
Zeff = Zp
[
1− exp
(
−125βZ−2/3p
)]
(4)
The deposited dose D can be calculated by means of the LET, the particle fluence F and the density
of the material ρ:
D [Gy] = 1.6 · 10−9 · LET
[keV
µm
]
· F
[
cm−2
]
· ρ−1
[
cm3
g
]
(5)
The energy loss per unit path length is therefore inversely proportional to the velocity of the particle
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and therefore to its energy:
− dE
dx
∝ Z
2
eff
β2
(6)
As a consequence of this relationship, the energy loss is small at small penetration depths where the
ions have their highest energy. As the ions traverse through matter they slow down and the energy
loss increases until it reaches a sharp maximum at the end of the particle track, the so-called Bragg
peak (Fig. 1). The depth in which the Bragg peak is located depends on the initial energy of the ion
beam, while the height of the peak is determined by the mass of the ion. This beneficial depth-dose
distribution of charged particles is used in radiotherapy since it enables the delivery of an increased
dose to the tumour, while sparing the healthy tissue in the entrance channel. In comparison, photon
beams deposit a higher energy in the healthy tissue inside the entrance channel as illustrated in Fig. 1.
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Figure 1: Depth-dose distributions for photons, protons and carbon ions with different initial energies.
Photons deposit their energy gradually along their paths while for ions the dose deposition is low in the
entrance channel and then reaches a maximum, the so-called Bragg peak. The location of the Bragg
peak is determined by the initial energy of the particles. Due to projectile fragmentation, carbon ions
also deposit some energy behind the Bragg peak.
In Fig. 2 the relationship between the three quantities beam energy, LET and depth in water is shown
for proton radiation. The left panel shows the dependence of the LET on the beam energy. With
decreasing beam energy the LET increases due to increased interaction with the surrounding matter.
The middle panel illustrates the energy loss as a function of penetration depth, while the right panel
shows the change in LET with increasing penetration depth. The LET increases slowly with depth and
ends in a sharp peak at the end of the particle track. Due to an increased LET, i.e. more interactions
with the surrounding matter, heavier particles need a higher initial energy to reach the same penetration
depth.
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Figure 2: Relationship between particle energy, LET and depth in water for a 200 MeV proton beam.
The data was calculated using the Energy vs. LET vs. Range calculator version 1.24.
Lateral beam spread. When particles traverse matter they undergo lateral deflections due to elastic
Coulomb interactions with target nuclei. This effect has been measured experimentally with proton
beams (Gottschalk et al., 1993) and described analytically (Molière, 1948). Based on the analytical
framework, three important conclusions about lateral scattering can be drawn:
• Particles show enhanced scattering in matter with heavy nuclei
• Scattering decreases for high-energetic particles compared to low-energetic particles
• Heavy particles show reduced lateral scattering compared to lighter particles. Consequently,
carbon ions exhibit a reduced lateral beam spread compared to protons, resulting in narrower
carbon ion beams (Schardt et al., 2010), which is a benefit of using carbon ions in radiotherapy
compared to lighter particles.
Fragmentation. Ions heavier than protons can undergo fragmentation when colliding with target
nuclei and thus generate projectile fragments. These fragments contribute significantly to the absorbed
dose (Lühr et al., 2012) and lead to dose tails at the distal end of the Bragg peak (Fig. 1), resulting in
out-of field dose.
2.1.3 Track structure
The dose deposited in the medium by ionizing radiation comes mainly from δ-electrons. The corre-
sponding dose deposition pattern that is formed by the δ-electrons is called track structure. The radial
ionization density inside the charged particle track decays approximately with 1/r2, with r being the
radius from the particle track (Kiefer and Straaten, 1986). The range of the δ-electrons is mainly
determined by the energy of the primary particle. Particles with a higher energy can transfer larger
amounts of energy to δ-electrons. Thus, high-energy particles produce δ-electrons with large ranges,
i.e. they distribute their energy over large distances from the particle track. Low-energy particles
produce short-ranged δ-electrons and thus deposit their energy in a small radius around the particle
track. Figure 3 shows the track structures of a single proton beam with an initial energy of 1 MeV
(Fig. 3a) and of a single carbon ion beam with an initial energy of 1 MeV/u (Fig. 3b). The blue dots
represent single ionization events. Carbon ions have a high ionization density close to the core of the
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track with only a few ionizations further away.
Amorphous track structure
The amorphous track structure is a concept that allows to analytically describe the dose distribution
in an ion track. It is a smooth function reflecting the probability for ionization events as a function
of the radial distance from the particle track. Different models use different parametrizations of the
amorphous track structure. An example, which is used in the LEM, is shown in section 2.5.2.
(a) Single track of a 1 MeV proton beam. (b) Single track of a 1 MeV/u carbon ion beam.
Figure 3: Track structures for two different radiation qualities. Each dot represents one ionization
event. Courtesy of Tabea Pfuhl. Calculated with the track structure Monte Carlo code TRAX (Krämer,
1995; Krämer and Durante, 2010; Boscolo et al., 2020).
2.2 Radiation biology
This section gives an overview of the biological response of cells to ionizing radiation and its mathe-
matical description. This section is based on the text books Hall and Giaccia (2006) and Van der Kogel
and Joiner (2009).
2.2.1 Cellular response
Since the 1920s it is known that there is a sensitive part in the cell that is mainly responsible for
the biological effect of radiation, such as cell killing (Crowther, 1924). Later, it has been proposed
that the cell nucleus, which contains the genetic information, is the critical target. Nowadays, it is
known that deoxyribonucleic acid (DNA) is the main target for biological effects. DNA is a long
polymer that consists of two intertwined strands. Both strands are made of phosphate-sugar backbones
and four bases: adenine, thymine, guanine and cytosine. The sequence of these bases comprises the
whole genetic information of the cell, and thus damage to the DNA can lead to loss of crucial genetic
information. The two DNA strands are coiled around each other and form a double-helix, which is
about 2 nm wide and, if stretched out, the length of the whole genome of a single cell is about 2 m
(Piovesan et al., 2019).
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The progress of the interaction of ionizing radiation with matter to cellular and organ damage is
shown in Fig. 4. The interaction happens on a time scale of 10−15 seconds. DNA damage occurs in µs
while visible organ damage can take years.
Figure 4: Standard paradigm of radiation damage. Reproduced from (Friedrich, 2016).
Ionizing radiation can interact with DNA either directly by ionizing the DNA or indirectly by forming
free radicals that damage the DNA. The direct effect is dominating for high-LET radiation, while for
low-LET radiation the indirect effect dominates (Dertinger and Jung, 1970). DNA damage is a change
in the structure of the DNA. This can be a chemical transformation of one of the four bases or a break
in one strand of the DNA (single-strand break (SSB)) or in both strands (double-strand break (DSB)).
In a normal human cell 10000 DNA damages occur per cell per day due to oxidative stress (Ames et al.,
1993). Most of these damages can be repaired by the cells’ repair mechanisms. However, exposure to
ionizing radiation can lead to an overload of DNA damage resulting in an excess of unrepaired DNA
damage. Base damages and SSBs play only a minor role when considering cell kill, since they are easily
repaired by the repair system of the cell using the opposite strand as a template (Prise et al., 1989;
Tounekti et al., 2001). A DSB is much more difficult to repair and more than one DSB in close vicinity,
called clustered DSB, is even more hazardous (Sage and Shikazono, 2017). DSBs are considered the
most biologically significant DNA lesion regarding radiation-induced DNA damage (Jeggo and Löbrich,
2007). The ratio of SSBs to DSBs per cell and per Gy is around 40 (Stenerlöw et al., 2003; Prise et al.,
2001) and the number of DSBs per Gy and per cell is 30 (Elsässer and Scholz, 2007).
As mentioned above, the cell is capable of repairing most of the DNA damages by activation of
its sophisticated repair mechanisms. DSBs are mainly repaired by two repair pathways, homologous
recombination (HR) and non-homologous end-joining (NHEJ) (Jackson, 2002). NHEJ simply rejoins
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loose DNA ends, which makes this process error-prone. However, NHEJ is fast and can be used
throughout the cell cycle. HR, in contrast, uses a sister chromatid as a template and can therefore only
be used in the S- and G2-phase of the cell cycle after the DNA has been replicated. HR is assumed to
be error-free but is also considerably slower than NHEJ. For more details see Featherstone and Jackson
(1999) and Van der Kogel and Joiner (2009).
2.2.2 Cell survival curves
One way to quantify the effectiveness of ionizing radiation is to measure the fraction of surviving cells in
culture after irradiation with a certain dose. Typically, a surviving cell is defined as a cell that retained
its proliferative capabilities. These cells form colonies that can be seen under the microscope. A common
value for the colony size is 50 cells. Hence, cell death is typically described by cell sterilization, i.e. the
cell may still be functioning but has lost its proliferative capability. The surviving fraction after dose
D is the number of reproducing cells divided by the number of cells seeded multiplied by the plating
efficiency (PE):
S(D) = # colonies counted after dose D# cells seeded× PE (7)
The plating efficiency is the fraction of cells that form colonies under normal conditions, i.e. without
exposure to ionizing radiation. Measuring the surviving fraction for several doses results in a cell
survival curve as seen in Fig. 5. The survival curve is commonly plotted on a linear-log scale and often
shows a shouldered curve for photons and low-LET radiation (black curve in Fig. 5). The exact shape
of the survival curve depends on the radiation quality and the cell type.
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Figure 5: Cell surival as a function of dose for 250 kVp X-rays (black) and helium radiation with an
LET of 90 keV/µm (red). The data points show experimental data from Miller et al. (1995) and the
dashed lines represent fits of Eq. (8) to the experimental data. The survival curve after radiation with
X-rays shows a pronounced shoulder while the curve for helium ions shows no shoulder.
For high-LET radiation, cell survival decreases nearly purely exponential on a linear-log scale (red
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curve in Fig. 5). Radioresistant cells show a more pronounced shoulder than radiosensitive cells. Fast
proliferating cells, such as spermatogonia and epidermal stem cells, are usually more radiosensitive,
whereas slowly proliferating cells on the other hand are more radioresistant. The shape of the survival
curves after high-LET radiation shows less dependence on cell type since the shoulder is almost non-
existent. Tumour cells are often fast proliferating cells and often have malfunctioning repair mechanisms
and hence do not show a pronounced shoulder.
2.2.3 Linear-quadratic cell survival model
The linear-quadratic model (Lea and Catcheside, 1942; Bedford and Hall, 1966; Chadwick and Leen-
houts, 1973; Barendsen, 1982; Fowler, 1989) is now the most widely used model for describing cell
survival. The cell survival probability, following irradiation with dose D, decreases according to the
LQ model as:
S(D) = e−(αD+βD2) (8)
The α parameter specifies the initial slope of the survival curve while the β term defines the slope at
higher doses (Fig. 6). The cell sensitivity is often given as the α/β ratio. Keeping β constant, a small
α/β ratio describes radioresistant cell lines, while a large α/β ratio denotes radiosensitive cell lines
(Fig. 7).
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Figure 6: Cell survival as a function of dose.
At low doses the survival follows a purely linear
curve in the semi-log plot (red line). At higher
doses the survival curve bends down and fol-
lows a quadratic shape (green line). The α
value determines the initial slope of the sur-
vival curve while β determines the bending of
the curve.
0 2 4 6 8 10
Dose [Gy]
10 5
10 4
10 3
10 2
10 1
100
Su
rv
iv
al
/  = 1 Gy
/  = 4 Gy
/  = 10 Gy
Figure 7: Cell survival as a function
of dose for three different α/β ratios with
β = 0.05 Gy−2. Cells with a low α/β ratio
are more radioresistant compared to cells with
a high α/β ratio.
There are several (not necessarily mutually exclusive) interpretations for the α and β parameters. One
is that α represents the effect from only one track (intra-track effects) while β represents the impact of
cell killing from the interaction of two tracks (inter-track effects). Another interpretation is that the α
term stands for directly lethal hits and β for the combination of two sublethal damages (Bodgi et al.,
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2016). An extensive review on the LQ model can be found in McMahon (2019).
2.2.4 Relative biological effectiveness
As described in the previous section, irradiation with different radiation qualities results in different
survival curves. In order to quantitatively compare different radiation qualities, the relative biological
effectiveness (RBE) was introduced. The RBE is defined as the ratio of the photon reference dose Dγ
leading to a certain effect (e.g. 10% survival) and the ion dose Di that leads to the same effect:
RBE = Dγ
Di
∣∣∣∣
isoeffect
(9)
In Fig. 8 the blue curve represents the photon reference dose-response curve while the red curve illus-
trates the survival curve after particle radiation. A lower dose of particle radiation is needed in order to
obtain the same effect as photon radiation. The RBE depends on the effect level under consideration,
i.e. at 50% survival the RBE is 6.5 while at 10% survival the RBE is 4.1, thus with decreasing effect
level the RBE decreases as well. Common effect levels are 100% survival (RBEα) and 50% survival
(RBE50). The RBEα is the ratio of the initial slopes of the ion and photon survival curves, and the
maximum RBE, whereas the RBE50 is the RBE at 50% survival.
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Figure 8: Schematic illustration of the RBE at two different effect levels, namely 50% survival and
10% survival. The RBE50 is 6.5 and the RBE10 is 4.1, showing that the RBE decreases with increasing
dose (decreasing effect level).
The RBE is a complex quantity which depends on several factors such as radiation quality, dose, number
of radiation fractions, dose rate, cell type and the end point under consideration (e.g. cell survival)
(Karger and Peschke, 2018). Figure 9 illustrates the RBE as a function of LET for five different ion
species.
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Figure 9: Schematic illustration of the RBE50 as a function of LET for five different radiation qualities.
At the same LET, lighter particles are more effective compared to heavier particles, because lighter
particles have a smaller track radius and therefore a higher ionization density inside the track. The
data was calculated with the LEM with αγ = 0.1 Gy−1, βγ = 0.05 Gy−2 as photon input parameters.
The RBE increases with LET due to increased ionization density leading to more complex damage
(Barendsen, 1968). After a certain LET value, however, the RBE decreases (Fig. 9). This effect is
called the overkill effect and can be explained by looking at the mean distance between ionization
events at 100 keV/µm, which is in the order of the diameter of the DNA. Thus, at an LET of about
100 keV/µm, particle radiation has the highest probability of inducing DSBs. At higher LET values,
the reduced distance between ionization events does not lead to an increased number of DSBs. In order
for radiation with a higher LET to produce the same effect as for radiation with 100 keV/µm, a higher
dose is needed since part of the dose is "wasted" and does not lead to more DSBs. In other words,
the dose does not fully contribute to the biological effect. Figure 9 demonstrates that lighter ions have
a higher RBE at the same LET compared to heavier ions and the maximum RBE is shifted slightly
towards higher LET values for heavier ions. This is because, at the same LET, lighter ions have a
lower energy and therefore a smaller track radius compared to heavier ions, which results in a higher
ionisation density at the same LET, and thus in a higher RBE.
2.2.5 Dose fractionation
It has been found that when irradiating cells in small fractions of ionizing radiation compared to a
single fraction, cell survival increases. A schematic illustration of the survival probability after multiple
fractions is shown in Fig. 10. The rationale is that normal cells are well-organized and have functioning
repair mechanisms while tumour cells are less organized and often have malfunctioning repair systems.
Irradiation in multiple fractions allows for repair of DNA damage between fractions and thus to an
increased cell survival. The main biological processes that affect the radiation tolerance of normal
tissue after fractionated irradiation are summarized by the four R’s of radiobiology, whereas the DNA
damage repair is the most important one. Two additional R’s have been added in recent years. Even
14
though they are not established yet, they are mentioned here for completeness.
• Repair of sublethal DNA damage leads to increased survival of normal tissue since the ability
to repair DNA damage is generally higher for normal tissue compared to tumour tissue (Withers,
1975).
• Redistribution of cells within the cell cycle. Cells have different radiosensitivities depending
on the cell cycle stage they are in during irradiation. Cells in late S-phase are generally more
resistent than cells in G0-phase. Because of cell cycle progression of surviving cells between
radiation fractions, dose fractionation allows redistribution of radioresistant S-phase tumour cells
into a more sensitive phase of the cell cycle (Withers, 1975).
• A prolonged treatment allows for Repopulation of normal cells to irradiated areas. However,
tumour cells proliferate as well and irradiated tumour cells may even proliferate faster than
unirradiated cells (Withers, 1975).
• Reoxygenation of tumour tissue. Hypoxic cells are more radioresistent than normoxic cells.
Cells inside a tumour are hypoxic, while the cells at the edge of the tumour are less hypoxic and
therefore more radiosensitive. The outer, radiosensitive layer is removed after one fraction and
the inner layer becomes less hypoxic (Withers, 1975).
• Intrinsic Radiosensitivity of target cells affects the response of cells to ionizing radiation and
was therefore added to the four R’s of radiobiology (Steel et al., 1989).
• Reactivation of anti-tumour immune response was recently added to the four R’s of radiobiology
because fractionation has an impact on the immune response activation (Boustani et al., 2019).
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Figure 10: Cell survival as a function of dose after multiple fractions, calculated with the LQ model.
With each fraction the survival curve becomes flatter.
In the LQ formalism, cell survival after n fractions of dose d (with the total dose D = d · n) can be
calculated as follows:
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S(d)n = e−n(αd+βd) = e−αD(1+
d
α/β
) (10)
Equation (10) is valid under the assumption of full repair between fractions and that no repopulation
occurs. A consequence of the curvature of the cell survival curve is that a single fraction of 2 Gy is
more effective than two fractions of 1 Gy. Thus, when changing the fractionation scheme, the dose per
fraction and hence the total dose have to be adjusted. From the LQ formalism follows (Voyant et al.,
2014):
D1
(
1 + d1
α/β
)
≡ D2
(
1 + d2
α/β
)
(11)
This means that for an original fractionation scheme of d1 = 2 Gy and D1 = 40 Gy and a desired new
fractionation scheme of d2 = 4 Gy, the new total dose D2 is approximately 27 Gy for an α/β ratio of
2 Gy.
2.2.6 Non-targeted effects
Non-targeted effects are cell responses after irradiation without an energy deposition in the cell nucleus,
i.e. effects that occur without DNA damage inflicted by the ionizing radiation directly. Such effects
have been observed in cell cultures and in in vivo experiments and include amongst others radiation-
induced bystander effects, genomic instability and abscopal effect (Kadhim et al., 2013; Desouky et al.,
2015). When unirradiated cells adjacent to or near irradiated cells show biological effects as if they
had been irradiated, then this is called bystander effect. Genomic instability (i.e. a high frequency
of mutations within the genome) is observed in the progeny of irradiated cells. The abscopal effect is
a hypothesis in treatment of metastatic cancer where a reduction of untreated metastases is observed
while only treating the main tumour. It was first introduced by Mole (1953).
2.3 Neoplastic cell transformation
In the previous sections, only a single end-point of ionizing radiation, namely cell survival, was con-
sidered. DNA damage can, however, lead to different outcomes, one of these being neoplastic cell
transformation. It arises from DNA mutations and can lead to genomic instability in cells, which
evolve into enhanced growth potential. It is considered a possible initial step in tumour development.
Normal cells form single layers in culture flasks. When a cell is surrounded by other cells it stops
proliferating, this is called contact inhibition. Transformed cells, on the other hand, are not contact
inhibited and continue proliferating, forming opaque multilayers that are visible under the microscope
(Fig. 11). Transformed cells were found to have a high chance of producing tumours after inoculation
into mice (Reznikoff et al., 1973; Borek et al., 1978).
The probability for neoplastic cell transformation is much smaller than the probability for cell
kill, and hence a large number of cells have to be irradiated in order to measure transformation with
sufficient accuracy. Consequently, these experiments are very time consuming and experimental data
on this end-point are scarce.
Similar to cell survival, cell transformation can be measured as a function of dose and follows a linear-
quadratic curve (Fig. 13). However, while cell survival decreases with dose, transformation is increasing
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Figure 11: Normal and transformed cell
cultures. The left petri dish shows a trans-
parent monolayer of normal cells, whereas
the right petri dish shows transformed
cells piled up into opaque multilayers.
Figure taken from Reznikoff et al. (1973).
with dose (Fig. 12). In the LQ formalism, the neoplastic cell transformation probability T as a function
of dose D is:
T (D) = αTD + βTD2 (12)
Since only surviving transformed cells can be measured, the fraction of visible transformed cells depends
on the survival rate. At high doses, cell survival is low and thus the fraction of visible transformations
is low as well. It is therefore not possible to count the true amount of transformed cells. Instead the
fraction of all surviving and transformed cells is divided by the fraction of surviving cells. This gives
the number of surviving (or visible) transformed cells per surviving cell and is an approximation for cell
transformation. For photons and low-LET radiation this approximation is valid, while for high-LET
radiation the two quantities deviate from each other. This is discussed in more detail in section 3.1.
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Figure 12: Cell survival (green), true neo-
plastic cell transformation (red) and visible
neoplastic cell transformation (blue) as a func-
tion of dose.
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Figure 13: Transformations per surviving
cell against photon dose. The data points are
taken from Miller et al. (1995). The red line is
a linear-quadratic fit to the data points.
2.4 Carcinogenesis
Cancer is a disease that affects the regulation of cell division and tissue growth. Cells which have
developed into cancer cells are typically fast proliferating and can invade nearby tissues. However,
only malignant tumours invade surrounding tissues. Benign tumours, in contrast, do not spread into
nearby tissues. Carcinogenesis is the process of cancer development, which starts with an initiating
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event, e.g. a mutation in the DNA. After some time another mutation might be induced and eventually
the cell has accumulated multiple mutations and starts to proliferate abnormally. This stage is called
promotion. The last step is called progression in which the benign tumour becomes malignant and
invades adjacent tissues and metastasizes (Weston and Harris, 2003). These steps are illustrated in
Fig. 14. Each of these stages is a multistep process. In order for a normal cell to become a tumour cell
it has to gain six essential capabilities, which are called hallmarks of cancer (Hanahan and Weinberg,
2000; Hanahan and Weinberg, 2011). These capabilities are highly variable and can occur at different
time points during tumour development. Another important aspect to mention is that mutations alone
are not sufficient to explain the clinically observed cancer rate. It is thus assumed that cancer cells
must have an increased mutability, for example due to a malfunctioning repair pathway (Hanahan and
Weinberg, 2000).
Figure 14: Two-stage model of carcinogenesis. An initiating event can cause a cell to become trans-
formed. The cell can then progress into a cancer cell through a second event.
2.4.1 In vivo experiments
It is well known that ionizing radiation is a possible initiator and promotor of carcinogenesis. This has
been demonstrated in several studies with animal models for photon radiation (Mole et al., 1983; Mole,
1953; Sasaki and Fukuda, 1999; Ullrich and Preston, 1987; Upton et al., 1964). In these studies mice
were irradiated with ionizing radiation of varying doses and LET values. For low doses an increase in
tumour prevalence with increasing dose was seen for different cancer sites. At higher doses a flattening
or even decrease in tumour prevalence was observed (see Fig. 15). Several studies have analyzed the
effects of HZE particles (i.e. high-energy ions heavier than helium) on tumour induction (Alpen et al.,
1993; Alpen et al., 1994; Fry et al., 1985; Trani et al., 2014; Ainsworth, 1986; Dicello et al., 2004).
These studies show a higher probability of inducing cancer for high-LET radiation compared to low-
LET radiation and a flattening of the dose-response curves at higher doses was seen in many cases.
2.4.2 Epidemiology
Data on the effects of ionizing radiation on human tissue is scarce, especially for high doses and radiation
qualities other than photon radiation. Two epidemiological studies of late effects after exposure to
ionizing radiation will be mentioned here: The atomic bomb survivor study, also called Life Span
Study (LSS), and the Childhood Cancer Survivor Study (CCSS).
The LSS is a follow-up study of survivors of the atomic bombings in Hiroshima and Nagasaki in
Japan 1945 and consists of more than 50 years of follow-up (1958-2009). The study includes 120 321
subjects of whom about 93 741 are atomic bomb survivors and 26 580 were not in either of the cities at
the time of the bombings (control group) (Mabuchi et al., 1994; Thompson et al., 1994; Preston et al.,
1994; Ron et al., 1994; Preston et al., 2007; Grant et al., 2017). This study is unique in regard that the
cohort population is healthy and was not selected based on some criteria. It includes both genders and
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Figure 15: Incidence of liver tumours as a function of gamma ray dose in female mice (data taken
from Sasaki and Fukuda (1999)). A fit to the data was performed (red curve) using the fit function:
I(D) = aD · exp(−bD2). A steep increase in tumour incidence is seen at low photon doses and a
decrease at higher doses.
all age groups, thus enabling quantitative risk estimates associated with exposure to low-LET radiation
as a function of age-at-exposure and attained age. It is a major source of human data used for radiation
risk assessment in establishing radiation safety standards. For risk assessment the dose to the survivors
have to be reconstructed based on the distance of the survivors from the hypocenters at the time of
the bombings. The received doses ranged typically from smaller than 5 mGy to about 3 to 4 Gy. The
mortality rate increases as a function of whole-body dose and lies between 20 to 70% for doses between
4 and 6 Gy and 50 to 100% for doses between 6 and 8 Gy (Macià i Garau et al., 2011). Thus, this
long-term follow-up study only includes persons with a low radiation exposure (compared to the high
doses to the tumour used in radiotherapy, which can be 80 Gy or more).
In epidemiology, risks are typically given as relative risks (RR) or excess relative risks (ERR),
where ERR = RR - 1. The RR is the rate of a specific outcome among groups having some some risk
factor (e.g. radiation exposure) divided by the rate of this outcome among groups not having this risk
factor.
The dose-response relationships for different tumour sites obtained from the LSS show a linear or
near linear or linear-quadratic curve between 0.1 and 2 Gy. For some tumour sites a flattening or even
decrease of cancer risk was observed at higher doses (Grant et al., 2017). The ERR for breast and
liver cancer incidence as a function of dose are shown in Fig. 16. However, all these data are inflicted
with large error bars. Based on the results from the LSS data the standard model for describing the
dose-response curve of tumour induction is the linear-no-threshold (LNT) model.
The CCSS includes 23 601 survivors of childhood cancer in North America and Canada. Most of the
primary diseases were leukemia and Hodgkin lymphoma. The patients were under the age of 21 when
diagnosed between 1970 and 1999. Eligible for the study were patients that had survived 5 years from his
or her date of diagnosis. The median follow-up time was 21 years (Robison et al., 2009). The secondary
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Figure 16: Excess relative risk as a function of dose for (a) breast and (b) liver cancer from the
atomic bomb survivor data: 1958-1998 (data taken from Preston et al. (2007)). A fit to the data was
performed (red curve) using the fit function: I(D) = aD · exp(−bD2).
cancer incidence for several cancer sites such as breast, thyroid, brain and bone were analysed for these
survivors. In contrast to the LSS, the childhood cancer survivor study includes organ doses higher than
50 Gy and hence allows insights into the dose-response relationship at very high doses. However, as
for the LSS the data in the CCSS show large error bars and the dose uncertainty ranges often span
more than 10 Gy. For all cancer sites except the thyroid a linear dose-response relationship was in
agreement with no flattening or decrease in cancer risk at high doses. The bell-shaped dose-response
curve is clearly visible only for thyroid cancer (Inskip et al., 2016).
In contrast to the LSS, the patients did not receive whole-body irradiations but high local doses
to the tumour. Thus organs close to the tumour received doses up to 50 Gy or more. Due to the
availability of treatment plans it is possible to reconstruct the dose in specific organs. The atomic
bomb survivors received an acute radiation exposure while the patients in the CCSS typically received
doses in multiple fractions. Thus the dose-response relationship may vary to that from the atomic
bomb survivors. Furthermore, the probability for obtaining cancer is strongly age dependent. The LSS
includes people from all ages while the CCSS only includes children and young adults under the age of
21 at the time of diagnosis. Additionally, the majority of the survivors in the LSS were healthy, while
the survivors in the CCSS were diagnosed with cancer and thus different genetics have to be assumed.
2.5 Modelling cell response for high-LET radiation
Because of the complex dependencies of the RBE for high-LET radiation and the absence of sufficient
experimental data, biophysical models play a key role for the estimation of clinically relevant RBE values
in treatment planning. An RBE model must account for physical (dose deposition), biological (DNA
lesions, repair) and geometrical (target geometry) aspects. In this section, two models for predicting
cell survival and one for predicting tumour induction after particle radiation are introduced.
20
2.5.1 Katz model
The Katz model is an amorphous track structure model (Butts and Katz, 1967; Katz et al., 1972).
For more details on amorphous track structure see section 2.1.3. The Katz model uses an analytical
approach to describe the dose response after ion radiation. In order to describe the transition from a
shouldered dose-response curve for low-LET radiation to a purely exponential function for high-LET
radiation two action modes were proposed: the ion-kill and the γ-kill mode. The ion-kill mode is
described by the single-target single-hit (STSH) model, while the γ-kill mode is characterized by the
multi-target single-hit (MTSH) model (Fig. 17). The critical target is assumed to be a substructure
of the cell nucleus with a diameter in the order of µm. There are multiple targets within a cell. In
the ion-kill mode a single hit to a single target is enough to inactivate the cell, while in the γ-kill
mode, multiple targets need to be hit for cell inactivation. The ion-kill mode is dominant for high-LET
radiation. The survival probability is described by the inactivation cross-section σ, representing the
ion-kill contribution, and the particle fluence F .
Πi(Di) = e−σF (13)
The survival probability in the γ-kill mode is as follows:
Πγ(Di) = 1− (1− e−Dγ/D0)m (14)
where m corresponds to the number of sub-targets in the cell nucleus and D0 is the final slope of the
survival curve at high doses, also known as the radio-sensitivity parameter. The dose Dγ is the part
of the total dose that is used in the γ-kill mode. When p is the probability for action in the ion-kill
mode, then (1− p) is the probability for action in the γ-kill mode and Dγ = (1− p) ·D is the fraction
of the dose that is used for γ-kill mode while Di = p ·D is the fraction used in the ion-kill mode. The
survival of a cell is the product of the survival probabilities of these two action modes:
S(Di) = Πi(Di) ·Πγ(Di) (15)
with Πi and Πγ being the probabilities for survival in the ion- and γ-kill mode. When irradiating with
photons only, p ≈ 0 and there is no contribution from the ion-kill mode. For high-LET radiation p ≈ 1
and only the ion-kill term remains, the dose-response curve is purely exponential. The probability for
action in the ion-kill mode, p is given by
p =
(
1− e
Z∗2
κβ2
)m
(16)
with the effective charge Z∗ and the relative velocity β of the ion and the dimensionless variable κ.
The parameter κ is one of the four fit parameters of the Katz model. The other three being σ0, m and
D0. The parameters σ0 and κ are obtained by fitting the respective functions to experimental ion data,
while m and D0 are obtained through fits to experimental photon data.
21
0 2 4 6 8
Dose [Gy]
0.1
1
Su
rv
iv
al
-kill
ion-kill
Figure 17: The γ- and ion-kill modes in comparison. The parameters are: n = 3 and D0 = 1.7 Gy.
At D = 0 the survival curve for the γ-kill mode is flat, while at higher doses the curve becomes purely
exponential. In contrast, the survival curve in the ion-kill mode shows no shoulder.
2.5.2 Local effect model (LEM)
Another RBE model is the LEM, which is a biological model that derives the RBE of ion radiation to
cells from the response of the cells to photon radiation. Up to now there are four versions of the LEM
with LEM IV being the newest version. The four versions are summarized in Tab. 1.
Table 1: The four versions of the LEM and their features.
Model
version
Included feature Reference
LEM I First implementation. Concept of local dose: the bio-
logical effect is entirely determined by the spatial local
dose distribution inside the cell nucleus.
(Scholz et al., 1997)
LEM II Increased yield of DSBs from clustered DSBs in close
vicinity (< 25 bps) is taken into account and radial dif-
fusion was added.
(Elsässer and Scholz, 2007)
LEM III Velocity-dependent extension of the inner part of the
track.
(Elsässer et al., 2008b)
LEM IV The final biological response of a cell to radiation is di-
rectly linked to the initial spatial DNA damage distri-
bution induced by radiation rather than the local dose
distribution itself.
(Elsässer et al., 2010),
(Friedrich et al., 2012a)
Basic concept. The local effect model uses the concept of "lethal" events, where each lethal event
leads to cell inactivation. It is not relevant how these events occur, since the information about the
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probability of cell inactivation and the corresponding average number of lethal events are obtained from
experimental photon survival curves. Thus, LEM implicitly reflects the results of the complicated un-
derlying biological processes such as complex strand breaks, DNA misrejoining and repair mechanisms.
This means that a lethal event may be the result of several sublethal damages that in combination
lead to cell inactivation. The number of lethal events after irradiation with X-rays is assumed to follow
Poisson statistics, since, due to the energy deposition pattern of photons, the lethal events are expected
to be distributed randomly in the sensitive target. Therefore, the fraction of surviving cells after photon
irradiation can be written as:
Sx(D) = e−Ex(D) (17)
where Sx(D) is the cell survival probability after a given photon dose D, and Ex(D) is the average
number of lethal events or the effect after that photon dose.
Ex(D) = −ln(Sx(D)) = αD + βD2 (18)
Here, α and β are the linear-quadratic parameters (section 2.2.3). The average number of lethal events
after irradiation with ions (Ei) can be derived by:
Ei =
∫
Vnucleus
Ex(d(x, y, z))
V
dV (19)
where V is the target volume and d(x, y, z) is the three-dimensional local dose. The main idea of the
local effect model is that the local effect E(d) is independent of the radiation quality and only depends
on the local dose. Therefore, Ex(d) = Ei(d).
Ei = −
∫
Vnucleus
ln(Sx(d))
V
dV (20)
with
Si = e−Ei (21)
the survival probability after ion irradiation can be assessed.
Equation (20) is the most general formulation of LEM I, which is still used in clinics. The ion effect
depends on three input quantities which will be discussed in detail:
• The geometry of the sensitive target
• The local dose distribution d in the sensitive target
• The experimental photon survival curve Sx.
Target. The critical target for cell inactivation is DNA in the cell nucleus. For simplicity, it is
assumed that the sensitive sites are distributed homogeneously over the whole cell nucleus and that
the cell nucleus is a cylinder with a default volume of 500 µm3. Changes of size and shape of the cell
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nucleus throughout the cell cycle are not considered. All particle trajectories are chosen parallel to the
cylinder axis.
Local dose distribution. The radial dose distribution inside the charged particle track falls off with
1/r2, with r being the radius from the particle track. The maximum radius of the track (rmax) is
determined by the initial energy of the ion track. Up to a minimum radius rmin, the local dose is taken
to be constant. The local dose can be calculated as follows (Elsässer et al., 2008b):
d(r) =

λ(LET/r2min) r < rmin
λ(LET/r2) rmin ≤ r ≤ rmax
0 r > rmax
(22)
The parameter λ in Eq. (22) is a normalization constant to ensure that the radial integral of the local
dose reproduces the LET and rmax is the maximum radius determined by the δ-electrons with the
highest energy. Figure 18 shows the local dose of a 10 MeV/u 12C beam as a function of the track
radius. It has been found based on experimental data (Kiefer and Straaten, 1986) that rmax depends
only on the energy E of the ion and can be parametrized by:
rmax = γEδ
with γ = 0.062, δ = 1.7. The maximum radius rmax is given in µm and E in MeV/u. The normalization
constant λ can be calculated with the following equation (Elsässer et al., 2008a):
λ = 1
piρ[1 + 2 ln(rmax/rmin)]
(23)
Figure 19 shows schematically the two-dimensional local dose distribution for carbon ions. At the core
of the ion tracks the local dose can reach high local doses of 1000 Gy and more.
Cell survival. Although in principal any representation of the cell survival curve after photon ir-
radiation Sx(D) can be used as the input for the local effect model, the linear-quadratic approach is
used, since it is well accepted and widely used in the literature. It has been found that cell survival
curves straighten at high doses, restricting the applicability of the LQ model at high doses (Kirkpatrick
et al., 2009). For doses higher than a threshold dose Dt the survival probability is written in the
linear-quadratic-linear (LQL) formalism (Astrahan, 2008):
Sx(D) =
e
−αxD−βxD2 D ≤ Dt
St · e−s(D−Dt) D > Dt
(24)
Here, s = αx + 2βxDt is the slope of the exponential tail for doses above the threshold dose Dt and
St = Sx(Dt) is the survival at the threshold dose Dt. In the semi-log scale the survival curve is linear-
quadratic for doses lower than Dt and becomes linear for doses higher than Dt.
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Figure 18: Radial dose profile for 12C with
E = 10 MeV/u, calculated using Eq. (22). At the
center of the ion track the local dose can reach val-
ues higher than 106 Gy.
Figure 19: Spatial microscopic dose dis-
tribution modelled for 15 MeV/u for car-
bon ions. Figure adapted from Krämer
et al. (2003).
LEM IV. In the newest version of the LEM an intermediate step was introduced. It was based on
the idea that the biological response of a cell to radiation is a consequence of the initial DNA damage
distribution induced by radiation rather than the local dose distribution itself. The assumption is that
the microscopic spatial distribution of DSBs and in particular their local density within a nucleus is
the relevant quantity that determines the fate of a cell. Analogous to the concept of the local dose, the
philosophy is that comparable DSB distributions lead to the same effect, independent of the radiation
quality leading to this DSB distribution. To determine the spatial DSB distribution, in each subvolume
of the cell nucleus the local dose is used to determine the mean number of DSB from experimental
photon data. From experimental data we know that the yield of radiation-induced DSB is approxi-
mately 30 DSBs/Gy/cell (Karger et al., 2006; Stenerlöw et al., 2003). With the average number of
DSBs per subvolume the DSB distribution can be determined by means of Monte-Carlo techniques. As
a measure of the local density of DSB, the number of DSB in a subvolume characterized by a cube of
side length lDSB = 540 nm is calculated. This subvolume corresponds to the volume of a 2 Mbps DNA
loop (Friedrich et al., 2012b). If one DSB is found in one subvolume it is calssified as an isolated DSB
(iDSB), when two or more DSBs are found within one subvolume it is classified as a clustered DSB
(cDSB). In order to determine the complexity of the damage, the cluster index C is introduced:
C = N
i
cDSB
N icDSB +N iiDSB
(25)
with N icDSB and N iiDSB being the number of subvolumes with clustered DSB and isolated DSB, respec-
tively. The photon equivalent dose Deq is defined as the photon dose that induces the same level of
complexity of DSB as the ion radiation:
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Deq := Cγ(Deq)
!= Ci (26)
The photon equivalent effect is then:
Eγ,eq = −ln (Sγ(Deq)) (27)
The effect after ion radiation Ei is obtained by linear scaling the photon equivalent effect with the ratio
of the sum of iDSB and cDSB after photon and ion radiation:
Eion =
(
N iiDSB +N icDSB
NγiDSB +N
γ
cDSB
)
· Eγ,eq (28)
The motivation behind the scaling process is that the DSB distribution of ion radiation is an extract
of the DSB distribution of photon radiation. For more details see (Friedrich et al., 2012b). With the
ion effect Ei the cell survival after ion radiation can be calculated by means of Eq. (24). The RBE is
then calculated as described in section 2.2.4.
The enhancements of the original LEM to LEM IV have been demonstrated to substantially improve
the accuracy of the model in biological experiments (Elsässer and Scholz, 2007; Elsässer et al., 2008b,
2010; Friedrich et al., 2012b). However, for carbon ion radiotherapy, LEM I is still used in clinics for
RBE calculations. It was demonstrated in Grün et al. (2012) that the differences in the predicted
absorbed doses leading to the same biological outcome between LEM I and LEM IV for typical tumour
volumes are less than 10%. In this work LEM IV is used for all RBE calculations.
Equation for Dt,S. An equation for the threshold dose for cell survival Dt,S was derived empirically
using a database of 855 cell survival curves (Friedrich et al., 2012b). Different ion species, radiation
qualities and cell types were used in these experiments. The relationship between the α/β ratio and
Dt,S follows a linear function, and Eq. (29) has been found to give the best agreement between LEM
simulations and experimental data.
Dt,S = 1.1
αS
βS
+ 4 Gy (29)
Single particle approximation. In order to simulate cell survival fast and efficiently the single
particle approximation was implemented, where the α and β parameters for ions are derived from a
single particle traversal through the centerline of the cylindrical cell nucleus. It was shown in Scholz
et al. (1997) and Friedrich et al. (2013b) that the full simulation and the single-particle approximation
usually yield similar results.
2.5.3 Cucinotta model
A sophisticated model to simulate both targeted effects (TE) as well as non-targeted effects (NTE) in
tissues after particle radiation is the model from Cucinotta and coworkers (Cucinotta et al., 2013; Cacao
et al., 2016; Cucinotta and Cacao, 2017). Targeted effects are responses of cells to ionizing radiation
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that are directly traversed by a particle while non-targeted effects are responses of cells that are close to
cells that experienced a particle traversal from ionizing radiation but are not affected directly themselves
(section 2.2.6). The model was initially proposed to model the risk of obtaining cancer after long-term
space mission, where astronauts get exposed to radiation from high-mass and high-energy particles.
TE model. The tumour induction dose-response function for high-LET radiation in the TE formalism
based on the Katz model (section 2.5.1) is given by
PTE =
[
P0 + σTF + βD2
]
· S (30)
The term inside the brackets refers to tumour induction while S refers to cell sterilization. The pa-
rameter P0 is the background tumour prevalence, σT is the tumour induction cross-section, F is the
particle fluence and β is the quadratic dose coefficient with β = βγ(1 − p). The term (1 − p) is the
probability for interaction in the γ-kill mode as described in section 2.5.1 and βγ is the photon dose
coefficient.
NTE model. For the NTE model an additional term for the contribution of non-targeted effects, η,
was added, resulting in
PNTE =
[
P0 + σTF + βD2 + η
]
· S (31)
where η is a function of LET and the number of bystander cells surrounding a cell traversed directly
by a particle.
Cell survival. The cell sterilization is represented in the Katz track structure formalism, as described
in section 2.5.1, and is given by
S(D) =
[
1−
(
1− e−D/D0
)mS] · e−σSF (32)
with σS being the cell sterilization cross-section and mS and D0 the cell sensitivity parameters.
2.6 Radiation therapy
Radiation therapy (RT) is the medical use of ionizing radiation to kill cancer cells while sparing normal
tissue. The goal of the therapy can be to cure the patient or to relieve symptoms such as pain (palliative
treatment). External beam radiation therapy, where the patient is exposed to an externally generated
beam, is the most commonly used treatment modality. The radiation can also be applied internally by
placing radioactive sources inside the patient (brachytherapy).
2.6.1 Photon therapy
The first implemented and still most commonly used treatment modality is RT with X-rays. The X-ray
beam is typically produced by a linear accelerator in which electrons are accelerated and then decel-
erated when colliding onto a high atomic number target. Part of the kinetic energy of the electrons is
27
released as photon radiation. The generated photon beam consists of various energies and in order to
obtain a beam with a uniform energy, the photons have to be filtered. Afterwards, the beam has to be
shaped in the form of the cross section of the tumour to get the highest conformity, this is done with
a beam-shaping device. The beam is shaped with multileaf collimators (MLC). The MLC has movable
leaves of high atomic number material (usually tungsten), which can block some parts of the radiation
beam. With this device it is possible to generate a beam that has the same shape as the tumour cross
section and can deliver the dose precisely to the tumour. For treating tumours it is beneficial to irradi-
ate from different angles. This way a higher dose conformatiy is facilitated. Therefore, the accelerator
with the beam transport system and the beam-shaping device has to move around the patient or the
patient has to be repositioned.
Four common photon treatment techniques are introduced here:
Three-dimensional conformal radiotherapy (3D-CRT) exploits patient-specific 3D images in
the treatment planning process to deliver a conformal dose distribution to tumours, while sparing
surrounding normal tissue. While the beam is changing its position around the patient, the shape of
the beam has to change according to the corresponding tumour cross section. In intensity modulated
RT (IMRT) the technique of 3D-CRT is improved. Here, not only the form of the radiation field is
adapted to the tumour but also the intensity of the beam is modulated within each radiation field, i.e.
different positions within each field are irradiated with different beam intensities. Overlapping multiple
IMRT fields from different angles results in a highly conformal dose distribution with increased sparing
of healthy tissue. In contrast to 3D-CRT multiple radiation fields are used. Volumetric arc therapy
(VMAT) is similar to IMRT with the main difference that the dose is not delivered in discrete angles
around the patient but instead the beam rotates continuously around the patient during beam delivery.
The main advantage is the reduced treatment time compared to IMRT as well as a lower dose in the
normal tissue. However, a larger volume of normal tissue is irradiated. Stereotactic body radiation
therapy (SBRT) is a special form of RT where the tumour receives a high dose in few fractions. Here,
the precision of the beam is of utmost importance. This technique is typically used when the tumour
lies inside or near a sensitive organ or for treating metastases and small targets.
2.6.2 Particle therapy
The main advantage of charged particles over photons is the inverted depth-dose profile as described
in section 2.1.2. Due to the sharp Bragg peak the dose can be applied more precisely in the tumour
with a lower dose in the surrounding normal tissue. Carbon ions offer further advantages over protons,
since they deposit a lower dose in the entrance channel and have an enhanced RBE. Lateral scattering
is reduced, which leads to a higher dose conformity. The benefits of carbon ions have been shown
in clinical studies (Tsujii and Kamada, 2012; Ohno, 2013). Recent studies have even analyzed the
applicability of oxygen ions in treatment planning (Tommasino et al., 2015; Sokol et al., 2017). The
drawback of particle therapy is that the equipment is complex and expensive. Furthermore, the RBE
is a complex quantity that depends on many factors, which makes accurate RBE models essential. Due
to the high dose conformity in the tumour and the high RBE at the distal end of the target, patient
positioning is crucial. Wrong positioning can lead to a high biologically effective dose in the healthy
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tissue behind the tumour. This is especially problematic for moving targets such as the lung. Projectile
fragmentation has to be accounted for as well when irradiating with heavier ions. These fragments can
result in an out-of-field dose deposition.
2.6.3 Treatment planning
The main objective of treatment planning is to maximize the dose in the tumour volume while mini-
mizing it in the surrounding healthy tissue and critical structures. For each patient an individualized
treatment plan is prepared. The method that is typically used is called inverse treatment planning.
Prior to the treatment planning, a computer tomography (CT) has to be made. A CT is similar to 3D
X-ray radiography. It produces cross-sectional X-ray images (or ‘slices’) that are processed into a three-
dimensional image. In the CT image, all regions of interest (ROIs), such as the target and organs at
risk (OARs), have to be delineated. The visible tumour volume is called gross-tumour volume (GTV).
In order to make sure that the whole tumour is irradiated and regional uncertainties in the volume
of the tumour are accounted for, the GTV is extended by a safety margin. This extended volume is
called clinical target volume (CTV). The CTV can be further expanded into a so-called planning target
volume (PTV) to account for uncertainties arising from errors in patient positioning and organ motion.
For the treatment planning the medical doctor prescribes a dose to the tumour and then the dose is
optimized using a treatment planning system (TPS). The constraints are that the dose inside the target
volume has to be between 95% and 105% of the prescribed dose. In certain cases there are constraints
to organs at risk where a maximum dose must not be exceeded.
Treatment planning with TRiP98
The treatment planning software TRiP98 (TReatment planning for Particles) was developed at the
GSI Helmholtzcenter for heavy ion research in Darmstadt, Germany, for conducting treatment plans
for heavy ion radiotherapy, in particular for carbon ion beam therapy (Krämer et al., 2000; Krämer and
Scholz, 2000). An active dose shaping technique as shown in Fig. 20 was implemented, which enables
to scan tumour volumes in three dimensions (Haberer et al., 1993).
Figure 20: Schematic illustration of the GSI magnetic raster-scanning system. Dipole magnets change
the lateral direction of the ion pencil beams. The depth of the ion beam is determined by adjusting the
initial energy of the ion beam. A high initial energy results in a larger range. The tumour is divided
into iso-energy layers or slices and each slice is subdivided into a grid. Each point in the grid (raster
point) is irradiated with a pencil beam. Figure modified from Krämer (2009).
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Compared to passive beam shaping where the target is irradiated with a broad beam shaped into the
cross section of the tumour, active beam shaping scans the tumour with ion pencil beams. These pencil
beams are very narrow ion beams, typically with a diameter of about 10 mm. A magnetic scanning
system is used to superimpose many pencil beams in the lateral direction, while the depth of the ion
beam is determined by changing the inital energy of the beam. In the dose optimization process not
the dose but the particle fluence is optimized for each energy layer. With this technique it is possible
to irradiate the tumour with a high degree of dose conformity.
A schematic overview of the general structure of TRiP98 is shown in Fig. 21. TRiP98 needs
patient-specific input parameters such as a CT, beam angles and target dose. Additionally, physical
parameters for different ion species (depth-dose profiles, RBE tables etc.) are needed. The optimization
process is performed with respect to the biologically effective dose Dbio.
Figure 21: Schematic illustration of the general structure of TRiP98. Modified from Sokol (2018).
TRiP98 optimizes the fluence of the particles so that a homogeneous RBE-weighted dose in the target
is reached. This is achieved by incorporating the RBE into the algorithm for dose optimization. The
RBE-weighted dose Dbio, also called photon equivalent dose, is the product of the absorbed (physical)
dose Dph and the RBE (Eq. (33)). The RBE-weighted dose is the ion dose that yields the same effect
as photon radiation.
Dbio = Dph · RBE (33)
In order to irradiate the tumour homogeneously, several Bragg curves are overlapped to create the
so-called Spread-out Bragg peak (SOBP) (Fig. 22). Figure 23 shows the distribution of the RBE-
weighted (solid line) and physical (dotted line) dose when irradiating a tumour with proton and carbon
ion beams. It can be seen that the absorbed dose is substantially lower for carbon ions compared to
protons, which is due to the increased RBE of carbon ions (Fig. 24). The RBE values for each particle
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and its energy are calculated with the LEM (section 2.5.2) and then loaded in TRiP98 as an RBE table.
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Figure 22: The superposition of fluence-weighted Bragg curves (red) forms the SOBP (blue) of the
prescribed dose in the target (modified from Wilma Kraft-Weyrather, GSI Darmstadt, Germany).
Heavy ions can undergo nuclear interactions with the target material and produce projectile fragments.
Target fragments are not considered in TRiP98. The particle beam consists of a mixture of different
radiation qualities and since the LEM can only calculate RBE values for monoenergetic ion beams a
method based on the work of Zaider and Rossi (1980) is used to calculate α and β values for mixed
radiation fields. This is done by calculating the dose-weighted mean values of α and β which can then
be used to calculate the survival.
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Figure 23: Physical (dotted lines) and RBE-
weighted dose (solid lines) as a function of depth
after irradiation with carbon ions and protons.
Carbon ions deposit a lower dose in the entrance
channel compared to protons.
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Figure 24: RBE as a function of depth af-
ter irradiation with carbon ions and protons.
The RBE for protons is about 1.1 but increases
rapidly at the distal end of the Bragg peak.
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2.6.4 Side effects of radiotherapy
There are several possible side-effects attributable to radiotherapy. They can be classified into acute
and late side effects. Acute side effects are effects that occur during or up to a few weeks after the end of
the treatment. They include nausea, hair loss, skin problems, fatigue, loss of appetite and others. When
irradiating the pelvis, rectal bleeding and inflammation of the rectum or anus can occur. After breast
cancer treatment, swollen arms, hands and breasts (lymphoedema) can be one of possible consequences.
Late side effects usually occur several months or even years after the treatment. They inlcude among
others dilated blood vessels (Telangiectasias), hardening of tissue (fibrosis) and the development of a
secondary cancer (NCI, 2018; Gegechkori et al., 2017).
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3 Methods
In this chapter, the mathematical framework for modelling neoplastic cell transformation (section 3.1),
tumour induction (section 3.2) and secondary cancer risk after proton and carbon ion beam radiotherapy
(section 3.3) will be introduced. If not otherwise stated, the theoretical framework was provided in
collaboration with Friedrich (2017).
3.1 Neoplastic cell transformation
As described in section 2.3, neoplastic cell transformation is an important initial step in cancer devel-
opment. Due to the low incidence rate of neoplastic cell transformation, a large amount of cells have to
be irradiated in order to get an observable effect, making the experimental set-up demanding. Conse-
quently, experimental data for this end-point are scarce, especially for high-LET radiation. Therefore,
a great need remains for a mathematical framework to predict cell transformation for various radiation
qualities.
3.1.1 Modelling neoplastic cell transformation
General framework
It was found experimentally that the photon dose-response curves for cell transformation often exhibit
a linear-quadratic shape similar to that of cell survival (section 2.3). This gives motivation to model
both cell survival and neoplastic cell transformation within the same linear-quadratic formalism. The
survival probability of cells after irradiation with dose D can be expressed with the LQ model as follows:
S = exp
(
−αSD − βSD2
)
(34)
The parameters αS and βS are the LQ model coefficients for cell survival as described in section 2.2.3.
Equation (34) gives the probability of a cell to be free of lethal events. Analogous to this, one can write
the probability τ of a cell to be free of transforming events as:
τ = exp
(
−αTD − βTD2
)
(35)
Transforming events are events that lead to mutations in the cell which then result in the cell becoming
transformed. In Eq. (35) the LQ model parameters αT and βT refer to cell transformation. The
probability of a cell to become transformed is then:
T = 1− τ = 1− exp
(
−αTD − βTD2
)
(36)
In the limit of low doses and small LQ model parameters, i.e. when the coefficient of the exponential
function in Eq. (36) is small, Eq. (36) can be approximated by a series expansion as
T ≈ αTD + βTD2 (37)
This approximation is often justified as the LQ model coefficients are typically small. When describing
observable cell transformation, Eqs. (34) and (37) must be combined in order to correctly describe the
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combined impact of the two processes on the experimental outcome, since only the surviving fraction of
the transformed cells is visible. The probability of a cell to both transform and survive can be written
as:
P = T · S =
(
αTD + βTD2
)
· exp
(
−αSD − βSD2
)
(38)
This concept of a competition between the induction of DNA mutations that lead to malignant cell
transformation and cell survival has been supported by (UNSCEAR, 1993) and is commonly used
to estimate secondary cancer risks after radiotherapy. This concept is also applied to neoplastic cell
transformation. The probability for visible transformations per seeded cell P increases up to a certain
dose and then decreases at higher doses when cell inactivation becomes dominant (see green line in
Fig. 25).
The probability for neoplastic cell transformation T is not directly measurable because inactivated
cells stop proliferating and do not form countable colonies. What is measured instead is the proba-
bility for visible transformations per seeded cell P and the cell survival S. From those quantities the
probability of transformations per surviving cell T˜ can be calculated as
T˜ = P
S
(39)
Since T˜ has the same form as T it can approximately be expressed within the LQ formalism as well by
T˜ = 1− exp
(
−α˜TD − β˜TD2
)
(40)
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Figure 25: Schematic illustration of visible transformations per seeded cell P and visible transfor-
mation per surviving cell T˜ as a function of dose. The lines represent the general trends of Eqs. (38)
and (40), respectively. The probability for transformation per surviving cell is monotonically increasing
whereas the probability for transformation per seeded cell is increasing with dose and decreasing at
higher doses due to increased impact of cell kill.
As can be seen in Fig. 25, T˜ is increasing monotonically with dose, while P shows a maximum and
decreases at higher doses. For low-LET radiation, due to the high number of ionisation events, the
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spatial distribution of energy depositions can be approximated by a Gaussian distribution and therefore
the probability for transformation and visible transformation per surviving cell are nearly identical, i.e.
T˜ = T , α˜T = αT and β˜T = βT. For high-LET radiation, however, this is not the case and will be
discussed in the following paragraph.
Characterization of dose-response curves for high-LET radiation
For high-LET radiation, due to the higher stochastic fluctuation of the number of particle traversals
in a cell, there is an enhanced spread in the expected number of DSBs per cell and with that also in
the expected probability of cell kill and cell transformation, respectively. This means that some cells
do not receive any particle traversals and thus no DSB, while others receive multiple traversals, and
hence DSBs. To account for the inhomogeneous distribution of energy depositions, cell survival can be
expressed in terms of hit statistics, i.e. the survival is written as the weighted sum over all possible
numbers of particle traversals k:
S = 〈S〉k =
∑
k
p(λ, k) · Sk (41)
In Eq. (41) the function p is the Poisson distribution of the particle traversals, i.e. when a cell is
irradiated with dose D, p gives the probability of the cell to be traversed by k particles. And Sk is the
cell survival probability after k particle traversals. The parameter λ in Eq. (41) is the mean number of
particle traversals per cell and can also be written as the total dose D divided by the dose per particle
traversal d:
λ = D
d
(42)
As described in section 2.1.2, the absorbed dose D can be written in terms of the particle fluence F ,
the LET and the density of the traversed matter ρ (Eq. (43)). The particle fluence is the number of
particles per unit area A and multiplying it with the nuclear area of the cell nucleus results in the
number of particle traversals in the cell nucleus: F ·A = λ. The absorbed dose D can then be written
as the number of particles that traverse the cell nucleus λ multiplied by the average dose of a single
particle d.
D = F · LET
ρ
= F ·A · LET
A · ρ = λ ·
LET
A · ρ = λ · d
(43)
Analogous to Eq. (41), the transformation probability T can also be expressed as:
T = 〈T 〉k =
∑
k
p(λ, k) · Tk (44)
In contrast to low-LET radiation, P for high-LET radiation is not equal to the product of the individual
expectation values for cell survival and cell transformation, those two quantities appear to be correlated
and hence
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P Ó= 〈T 〉k · 〈S〉k (45)
As a consequence of this correlation between cell kill and transformation, appropriate procedures to
calculate the expected number of viable transformations, i.e. transformations within surviving cells,
have to be considered. Thus, in this work the link between cell kill and transformation on the level of
individual cells is taken into account:
P = 〈T · S〉k =
∑
k
p(λ, k) · Sk · Tk (46)
The probability for visible transformations per surviving cell, T˜ , is according to Eq. (39) given by
T˜ (D) =
∑kmax
k=0 p(λ(D), k) · Sk · Tk∑kmax
k=0 p(λ(D), k) · Sk
(47)
With Eq. (47) an equation is established that allows to calculate the probability for visible transforma-
tions per surviving cell, based on the microscopic survival and transformation probability. Alternatively,
an analytic expression exists, derived by a series expansion of Eq. (47). For the simulations in the present
work, the numeric expression in Eq. (47) is used to simulate T˜ as a function of D, where Sk and Tk are
calculated with the LEM. In the subsequent step, Eq. (40) is fitted to T˜ (D) in order to obtain the LQ
model parameters α˜T and β˜T. The parameters introduced in this section are summarized in Tab. 2.
Simulating cell transformation with the LEM
The simulation of neoplastic cell transformation was performed in three major steps. In the first
step, Eqs. (34) and (36) were fitted to experimental photon data for cell survival and neoplastic cell
transformation, respectively, for three distinct experimental data sets (Yang et al., 1985; Hei et al., 1988;
Miller et al., 1995). That way the photon LQ model coefficients αγS, β
γ
S , α
γ
T and β
γ
T were obtained.
The threshold dose for cell survival was calculated using equation Eq. (29). The equation for the
threshold dose for cell transformation was derived as explained in section 4.1.1. The photon LQ model
coefficients and the threshold doses Dt,S and Dt,T were inserted into the LEM in the second step. The
LEM has to be used twice, once for simulating cell survival and once for simulating neoplastic cell
transformation. The probability of visible transformations per surviving cell T˜ was computed as a
function of the dose D as in Eq. (47). In Eq. (47), the sum from kmin = 0 until kmax was calculated,
where kmax was chosen to be kmax = 100 + λ for λ ≤ 100 and kmax = 2λ for λ > 100 so that kmax
was sufficient for convergence. In the last step, Eq. (40) was fitted to T˜ (D) in order to obtain the ion
LQ model coefficients for visible neoplastic cell transformation per surviving cell α˜ and β˜. With these
two coefficients and the photon coefficients for cell transformation, the RBE for visible transformations
per surviving cell can be computed. The RBE is usually determined for a certain effect level, e.g.
10% survival. Since the range of the transformation probabilities varies significantly between different
experiments, this effect level is not suitable for the considered transformation data. For this reason an
effect level for visible transformation per surviving cell that was covered by the experimental data of all
three data sets was chosen and set to 0.0005 visible transformed cells per survivor. The corresponding
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RBE is denoted as RBE0.0005. In order to calculate RBE values for cell transformation, LEM needs as
input parameters the photon LQ model coefficients as well as the threshold dose Dt,T. For cell survival
an empiric equation for Dt,S was derived (Friedrich et al., 2013b).
Table 2: List of parameters for modelling neoplastic cell transformation.
Parameter Description
S Survival probability
T Transformation probability (not measurable)
P Probability for visible transformations per seeded cell
P = 〈T 〉k · 〈S〉k for low-LET radiation and P = 〈T · S〉k for high-LET radiation
〈S〉k Mean survival probability over all possible DSB configurations
〈T 〉k Mean transformation probability over all possible DSB configurations
T˜ Probability for visible transformations per surviving cell (approximation for T )
T˜ ≈ T for low-LET radiation and T˜ = 〈T ·S〉k〈S〉k for high-LET radiation
αS, βS LQ model parameters for cell survival
αT, βT LQ model parameters for cell transformation
α˜T, β˜T LQ model parameters for visible transformations per surviving cell.
For low-LET radiation: α˜T ≈ αT and β˜T ≈ βT
Fitting procedure for experimental data
Experimental RBE values were determined from LQ model parameters which were obtained by fitting
the respective LQ functions to experimental photon and ion data using a least-squares method. All
photon LQ model parameters were restricted to positive values, because a cell population with a
homogeneous radiosensitivity was assumed. Cell populations with very radiosensitive and radioresistant
cell types can show an upwards bending of the cell survival curve and thus a negative β term. When
fitting the LQ model to experimental ion data, αT was always restricted to positive values. In a first
step, βT was not restricted. When the error of βT was larger than βT itself, βT was set to zero and a
linear fit was performed.
Error analysis
Since it is not possible to calculate error bars analytically for the LEM predictions a Monte-Carlo
method was implemented instead. This method propagates uncertainties directly. One hundred RBE
values were simulated for 100 possible photon α-β combinations. Those α-β pairs were obtained by
using the covariance between the LQ parameters, taken from the covariance matrix of the LQ fit. The
resulting RBE distribution has usually a long tail towards higher RBE values, which reflects the chance
of having small ion doses as denominator for the RBE calculation (Friedrich et al., 2010). The error
of the distribution was assessed by cutting off 15.9% of the data at the beginning and at the end of
the distribution, so that the 68.2% central quantile remains, in analogy to the standard deviation in
Gaussian error calculus. This process is illustrated in Fig. 26, where the blue bars show the RBE
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distribution and the red dotted lines represent the cut off values.
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Figure 26: Example of method for determin-
ing the error bars for the RBE values. The
black solid line shows the mean value, while the
red dashed lines represent the cut off values at
15.9% and 84.1%.
3.1.2 Experimental in vitro data
The data used for the in vitro validation for the cell transformation simulations was taken from Miller
et al. (1995), Yang et al. (1985) and Hei et al. (1988). The radiation qualities used in the experiments
with the corresponding energy and LET values are listed in Tab. 3. In all three studies, mouse embryonic
stem cells (C3H 10T1/2) were used for the transformation experiments. Miller et al. (1995) and Hei et al.
(1988) used light and low-energetic ions, while Yang et al. (1985) used heavy and high-energetic ions.
Due to the long time span between the experiments, Yang et al. (1985) measured an X-ray reference
curve for each ion experiment individually in order to obtain comparability. The X-ray experiments
were performed on the same day as the ion experiments and contained cells from the same population.
Miller et al. (1995) and Hei et al. (1988) measured a single X-ray reference curve.
Table 3: Ion types, LET values and beam energies used in the experiments of Miller et al. (1995),
Yang et al. (1985) and Hei et al. (1988).
Miller et al. (1995) Yang et al. (1985) Hei et al. (1988)
Ion
LET Energy
Ion
LET Energy
Ion
LET Energy
[keV/µm] [MeV/u] [keV/µm] [MeV/u] [keV/µm] [MeV/u]
2H 3.8 12.9 12C 10 474 1H 10 3.82
1H 15 2.25 20Ne 32 425 2H 40 0.5
2H 40 0.28 28Si 50 670 3He 80 1.5
3He 75 1.67 28Si 82 320 3He 120 0.81
4He 90 1.28 40Ar 140 330
4He 120 0.83 56Fe 190 600
4He 150 0.59 56Fe 300 400
4He 200 0.36 56Fe 500 300
12C 265 5.36 238U 1900 960
16O 418 6.04
19F 600 5.09
38
3.2 Tumour induction in vivo
3.2.1 Modelling tumour induction
Tumour induction is typically modelled using Eq. (38), which is explained in the previous section. The
dose-response curve shows a bell-shaped behaviour as can be seen in Fig. 25. However, here tumour
induction refers now to a whole organ instead of single cells. There are two approaches of modelling
tumour induction: macroscopic (considering the whole organ) and microscopic (considering individual
cells).
Macroscopic consideration
The equation for the tumour induction probability for the macroscopic consideration is given by
Pmacro = T · S =
[
1− exp
(
−αTD − βTD2
)]
· exp
(
−αSD − βSD2
)
(48)
is almost identical to Eq. (38) but without the approximation of T . Although the approximation is
often used to estimate secondary cancer risks, the more exact equation was used in the present study.
Another difference is that the LQ model coefficients αT and βT now refer to the tumour induction
probability of the organ and therefore T represents the probability that a cancer evolves starting from
any of the cells of that organ. The macroscopic LQ model parameters refer now to the probability
that a cell within an organ develops mutations that lead to the cell progressing into a tumour. This
often includes multiple mutations. The probability for cancer evolution is reduced by the fraction of
inactivated cells, as only surviving cells can become tumour cells. Thus, cell kill is mitigating a further
mutation spread and therefore cell survival in Eq. (48) still refers to individual cells instead of the
whole organ. This relation demonstrates clearly, that cell inactivation effectively counteracts tumour
formation.
In Fig. 27 four schematic dose-response curves for tumour induction calculated with Eq. (48) are
shown. Each of the four LQ model coefficients was increased (blue) and decreased (red) by 50%,
respectively. Decreasing the survival coefficients leads to increased cell survival and to an increased
tumour induction probability at higher doses. Increasing the tumour induction coefficients leads to
increased tumour induction probability.
Microscopic consideration
Describing tumour induction in terms of malignant transformations in individual cells in an organ
of N cells, Eq. (48) has to be modified. The probability that an organ develops a tumour is the
complementary probability that no cell mutates and becomes a cancer cell, which is given by (1−pm)N ,
with pm being the cell mutation probability. Typically multiple mutations are needed for macroscopic
tumour formation, which are effectively comprised in pm. The probability that at least one cell mutates
is given by:
Pmicro = 1− (1− pm)N (49)
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The parameter pm can be expressed in the LQ formalism and Eq. (49) becomes:
Pmicro = 1−
{
1−
[
exp
(
−αSD − βSD2
)
· Tmicro
]}N
(50)
with
Tmicro = 1− exp
(
− 1
N
(
αTD + βTD2
))
(51)
The LQ model coefficients in Eq. (51) have to be divided by the number of cells in the organ in order to
refer to the mutation probability on a cellular level. This is plausible since each of theN cells contributes
equally to the overall number of carcinogenic events, which is the argument of the exponential function.
When comparing the dose-response curves for tumour induction for photons for the macroscopic
and microscopic case (Fig. 28), it can be seen that at low doses both curves lie on top of each other.
At higher doses, however, the tumour induction for the microscopic equation is higher than the tumour
induction calculated with the macroscopic approach. This is because the LQ model coefficients in
Eq. (51) for tumour induction were scaled linearly with N .
For the tumour induction calculations performed in this work, the LEM photon input parameters
were obtained not by linearly scaling the macroscopic LQ model parameters but by fitting Eq. (50)
without the 1/N term in Tmicro to the experimental photon data. Similar to the transformation simula-
tions, the exact mathematical description was used to calculate T (D) to which the LQ approximation
was fitted in order to obtain the LQ model parameters for tumour induction. The equations are shown
in Tab. 5.
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Figure 27: Schematic illustration of dose-response curves for tumour induction. The four LQ model
parameters are increased (blue) and decreased (red) by 50%, respectively. Changing the LQ model
parameters for cell survival (upper panel) results in a different dose-response curve at higher doses,
while changing the LQ model parameters for tumour induction (lower panel) changes the dose-response
curve at lower doses. The curves were calculated by means of Eq. (48) with the following photon
parameters: αS = 0.1 Gy−1, βS = 0.05 Gy−2, αT = 0.001 Gy−1, βT = 0.0005 Gy−2.
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As mentioned earlier, the macroscopic approach is often used to calculate tumour induction and sec-
ondary cancer risk after exposure to ionizing radiation. Since LEM calculates the effect of radiation on
a cellular level the microscopic approach should be used. In section 4.2 it will be demonstrated that
modelling tumour induction with the LEM with both the microscopic and the macroscopic formalism
yields good agreement with experimental data. As for neoplastic cell transformation, the tumour induc-
tion probabilities were calculated by means of the exact mathematical description, thus for the tumour
induction calculations Eq. (46) was used.
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Figure 28: Comparison of dose-response curves for the microscopic and macroscopic tumour induc-
tion. At low doses both curves lie on top of each other and deviate at higher doses. The microscopic
tumour induction shows a higher maximum and tends to zero at higher doses compared to the macro-
scopic tumour induction. The LQ model coefficients for an hypothetical organ are αS = 0.1 Gy−1,
βS = 0.05 Gy−2, αT = 0.03 Gy−1, βT = 0.05 Gy−2 and N = 106 cells.
3.2.2 Experimental in vivo data
The tumour induction simulations in the present work were performed for the mouse Harderian gland
data set (Alpen et al., 1993, 1994; Chang et al., 2016; Fry et al., 1985), which is the most extensive study
on the LET dependence of tumourigenesis. The radiation qualities used in the experiments are listed
in Tab. 4. In the experiments, mice received whole-body exposure with photon and particle radiation.
After irradiation, two pituitaries from unirradiated donor mice were implanted into the spleen of each
irradiated mouse, leading to an increased hormone expression and thus to enhanced expression of
Harderian gland tumours as well as decreased latent periods (Alpen et al., 1993). Harderian glands are
glands that are located behind and around the eye in all vertebrates that possess nictitating membranes
(also called third eyelid). These glands secrete a substance that lubricates the eyes and eyelids (Miedel
and Hankenson, 2015). In humans, the Harderian gland is only rudimentary (Norris and Carr, 2013).
The mice were irradiated when they were between 100 and 120 days old, with various radiation qualities
with LET values ranging from 0.4 keV/µm to 464 keV/µm.
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Table 4: Radiation qualities, beam energies and LET values used in the experiments of Alpen et al.
(1993, 1994) and Chang et al. (2016).
Ion LET [keV/µm] Energy [MeV/u]
1H 0.4 250
4He 1.6 228
20Ne 25 670
28Si 70 260
48Ti 100 1000
56Fe 175 600
56Fe 193 600
56Fe 253 350
93Nb 464 600
137La 953 593
3.3 Secondary cancer risk after radiotherapy
Secondary cancer (SC) risk estimations are typically calculated by means of Eq. (38) that was proposed
by UNSCEAR (1993). Equation (38) does not, however, account for fractionated radiation as it is used
in radiotherapy. Thus, Eq. (38) has to be modified in order to be valid for estimating secondary cancer
risks after fractionated radiotherapy. The modified equation is as follows (Daşu et al., 2005):
P =
(
αTD +
βTD
2
n
)
× exp
(
−αSD − βSD
2
n
)
(52)
Here, D is the total absorbed dose after n fractions of ionizing radiation, αT, βT are the LQ model
parameters for carcinogenesis and αS, βS are the LQ model parameters for cell survival. Another aspect
that has to be considered when calculating secondary cancer risk in OARs after radiotherapy is that
the dose distribution in the OARs is often inhomogeneous. Consequently, the OAR has to be divided
into smaller subvolumes, voxels, in which the dose distribution can be assumed to be approximately
homogeneous. The secondary cancer risk of the whole organ is then the average risk over all voxels:
RiskOrgan =
∑
i P (Di)
N
(53)
In Eq. (53) N is the total number of volume elements (voxels) in the organ under consideration and
Di is the dose in voxel i. Equation (53), however, is only valid for photon radiation. For estimating
secondary cancer risk after particle radiotherapy, a so-called weighting factor wR can be applied, so
that
αion = αγ · wR
βion = βγ · w2R
(54)
The weighting factor wR is an estimation for how much more biologically effective different ion species
are compared to photon radiation. For proton radiation the ICRP (2007) recommends a weighting factor
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of 2 for tumour induction. A weighting factor of 1.1 is typically applied in clinics for tumour control
and normal tissue complication. Figure 29 shows the dose-response curves for a single fractionation
of photon radiation (red) and for ten fractions (blue). The maximum of the dose-response curve for
fractionated irradiation is shifted towards higher doses. As described in section 2.2.5, fractionation
leads to an increased cell survival, mostly due to increased repair of DSBs between fractions. This
increased cell survival could be the reason for the increased tumour induction probability at higher
doses as seen in Fig. 29. At lower doses, however, the tumour induction probability is lower for the
fractionated radiation, because due to the increased repair of DSBs, one can assume a decrease in the
induction of mutations, leading to a decreased tumour induction probability. The dose-response curves
for tumour induction for photons and protons as a result of Eq. (52) are shown in Fig. 30. Protons
exhibit a higher tumour induction probability, due to the weighting factor of 2 for tumour induction.
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Figure 29: Probability for tumour induc-
tion as a function of photon dose after a sin-
gle fraction of radiation (red) and ten fractions
(blue). The risk decreases at lower doses for
a single fraction while the risk is still high af-
ter ten fractions. A high number of fractions
shifts the maximum of the curve towards higher
doses. The dose-reponse curves were calculated
by means of Eq. (52) for a hypothetical OAR
with αS = 0.1 Gy−1, αT = 0.01 Gy−1 and
αS/βS = αT/βT = 2 Gy.
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Figure 30: Probability for tumour induc-
tion as a function of a single fraction dose
of photon (blue) and proton (green) radia-
tion. Proton radiation shows increased tu-
mour induction risk compared to photon ra-
diation. The dose-response curve was calcu-
lated by means of Eq. (52) for a hypothetical
OAR with αS = 0.1 Gy−1, αT = 0.01 Gy−1,
αS/βS = αT/βT = 2 Gy and weighting factors
for proton radiation of 1.1 and 2 for cell survival
and tumour induction, respectively.
3.3.1 Modelling secondary cancer risk for biologically optimized treatment plans
As mentioned before, Eq. (52) is only applicable for photon radiation. In order to calculate the secondary
cancer risk for particle radiation, the RBE has to be included. The weighting factor wR which was
introduced earlier is acceptable for proton radiation, since the variation in proton RBE is relatively
small and a constant RBE is usually applied in clinics. For carbon ions, however, the variation in
RBE is much larger and using a constant RBE of 20 for tumour induction as recommended by the
ICRP (ICRP, 2007) would most likely lead to an overestimation of the secondary cancer risk. In this
work therefore, the treatment planning system TRiP98 (section 2.6.3) was used to generate biologically
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optimized treatment plans for both scanned proton and carbon ion beams and to compute the secondary
cancer risk for these ion types. TRiP98 is able to compute a 3D survival cube for the whole CT, i.e.
the survival probability in each voxel of the CT. There is, however, no function for tumour induction
build into TRiP98. What TRiP98 computes is a function that follows the form
f = exp(-Effect) (55)
As the effect of both cell survival and tumour induction can be described in the LQ formalism, Eq. (55)
can also be used to calculate tumour induction with T = 1−f . This means that the direct output from
TRiP98 is the function f that depends on the effect, which in turn depends on the RBE. As mentioned
earlier, TRiP98 needs RBE tables as input. When calculating cell survival TRiP98 receives as input an
RBE table for cell survival and thus f = f(RBES). Analogous for tumour induction: f = f(RBET).
The joint probability of cell survival and tumour induction can then be written as:
P = T · S = [1− f(RBET)n]× f(RBES)n (56)
The quantities f(RBET) and f(RBES) in Eq. (56) are directly calculated within TRiP98 and n is the
number of fractions. Both f(RBET) and f(RBES) are three-dimensional matrices that contain S and
T for each voxel of the CT. The risk of an organ to develop a second cancer is then:
Risk =
∑N
i=1 Ti · Si
N
(57)
where Ti · Si is the risk that the organ develops a secondary cancer when the whole organ receives
the dose of voxel i, and N is the total number of voxels. Modelling of secondary cancer risks is done
in several steps which are illustrated in Fig. 31. The first step is the dose optimization. In this step
photon survival parameters for the target volume are needed in order to calculate the RBE tables with
the LEM. In the second step, individual RBE tables are computed for the different OARs. For each
OAR two tables are calculated, one for cell survival and one for tumour induction. In the last step,
the secondary cancer risks for each OAR are calculated according to Eq. (56), where f(RBET) and
f(RBES) are direct TRiP98 outputs. In total, three RBE tables are needed. One for the tumour tissue
during the optimization process and two for each OAR. Thus, three pairs of α and β parameters for
photon radiation are needed.
The different steps of the secondary cancer risk calculations are as follows:
1. Insert target specific photon input parameters into LEM and calculate the RBE table for the
target volume. The RBE tables store the RBE values for ions from hydrogen to neon for various
energies.
2. Perform dose optimization with TRiP98.
3. Insert OAR specific photon input parameters into LEM and calculate the RBE table for the OAR.
This step is performed twice, once for cell survival and once for tumour induction.
4. Compute T and S with TRiP98, where T and S are 3D matrices.
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5. Calculate T · S on a voxel-by-voxel basis and compute the average risk as in Eq. (57).
The variables and equations used in the present study for simulating neoplastic cell transformation,
tumour induction and secondary cancer risk are summarized in Tab. 5.
Figure 31: Schematic procedure of calculating secondary cancer risks. In the first step the dose for
the tumour has to be optimized. Based on this optimized dose distribution the survival S and tumour
induction T probabilities in each voxel of an OAR are calculated. In order to calculate S and T the
photon parameters are needed. These parameters are taken from literature (see Tab. 8).
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Table 5: Summary of the variables used for modelling neoplastic cell transformation, tumour induction
and secondary cancer risk.
Variable Exact mathematical description LQ approximation
General framework
S 〈S〉k =
∑
k p(k,D) · S(k) exp
(−αSD − βSD2)
T 〈T 〉k =
∑
k p(k,D) · T (k) 1− exp
(−αTD − βTD2)
P 〈T · S〉k =
∑
k p(k,D) · T (k) · S(k) T · S
Neoplastic cell transformation
T˜ 〈T ·S〉k〈S〉k 1− exp
(
−α˜TD − β˜TD2
)
Tumour induction
Pmacro 〈T · S〉k T · S
Pmicro 1− (1− 〈T · S〉k)N 1−
{
1−
[
1− exp
(
− 1N
(
αTD + βTD2
))] · S}N
Secondary cancer
P - T · S
3.3.2 Patient data
The dose optimization and risk calculation was performed for 20 patients that were treated with photon
RT. Ten of these patients had liver metastases and were treated with photon SBRT, whereas the other
ten patients had prostate cancer and received conventional photon RT. The ion treatment plans were
optimized to yield the same dose in the target as for photons while minimizing the dose in the healthy
tissue.
Treatment planning for the liver metastases patients
Treatment plans for ten patients previously treated for metastases in the liver with SBRT at the
Department of Oncology and Pathology at Karolinska University Hospital, Stockholm, Sweden were
generated. These patients were diagnosed with tumours of different PTV volumes (18.6 to 332.3 cm3)
and locations. The planning CT image sets consisted of 3 mm thick slices and each CT voxel had the
dimensions 1×1×3 mm3. The dose calculations, carried out as part of the treatment planning, were
based on patient-composition data from regular free-breathing CT studies. Two distinct treatment
techniques were used to create the photon SBRT plans: 3D-CRT and VMAT (for details see section 2.6).
VMAT was mainly used to treat the patients with large target volumes or when critical structures
were located close to the target. A two-field IMPT technique was used to retrospectively plan all the
patients (Mondlane et al., 2017). In this work, the treatment plans for the liver metastases patients were
retrospectively performed for scanned two-field proton and carbon ion radiotherapy, respectively, with
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the beam angles set according to the IMPT plans by (Mondlane et al., 2017). The αS/βS ratio for cell
survival was set to 15 Gy (Tai et al., 2008) for the tumour volume (αS = 0.1 Gy−1, βS = 0.00067 Gy−2,
Dt,S = 20.5 Gy). For all tissue except the tumour (residual tissue) an RBE of 2 Gy was chosen. The
RBE of the residual tissue had, however, no effect on the secondary risk calculations, since for each
organ a specific set of LQ model parameters as shown in Tab. 8 was chosen. The planning objectives,
such as number of fractions and dose per fraction, for the ten patients were taken from the original
photon plans and are shown in Tab. 6. In agreement with the SBRT treatment few fractions with a
high dose per fraction were used and a higher dose (150% of the prescribed dose) was prescribed to the
CTV, where the more radio-resistant cells are located, for all patients except patient 9, who received
100% of the dose to both the PTV and CTV.
Table 6: Prescribed dose and number of fractions to the PTV for all ten liver cancer patients. Two
distinct treatment techniques were used to create the SBRT photon plans, 3DCRT and VMAT. Patients
with large tumours or tumours with critical structures nearby were treated with VMAT.
Patient # Modality PTV [cm3] Prescribed dose [Gy] Fractions PTV
1 static field 59.6 15 3
2 static field 73.1 17 3
3 VMAT 332.2 8 7
4 static field 302.6 8 5
5 static field 66.4 7 8
6 VMAT 294.1 7 8
7 static field 18.6 15 3
8 VMAT 78.6 7 8
9 static field 30.2 17 3
10 static field 72.3 15 3
Treatment planning for the prostate cancer patients
Treatment plans for ten patients previously treated with conventional radiotherapy for prostate cancer
at Karolinska University Hospital, Stockholm, Sweden were retrospectively generated. The PTVs of
the prostate cancer patients consisted of the prostate and the seminal vesicles. Because prostate cancer
often invades the seminal vesicles, they were included in the PTV. Eight of the ten patients received
72.5 Gy in 29 fractions (2.5 Gy/fraction) to the prostate and 55.1 Gy in 29 fractions (1.9 Gy/fraction) to
the seminal vesicles, while the remaining two patients received 72.5 Gy in 29 fractions (2.5 Gy/fraction)
to both the prostate and seminal vesicles. The treatment plans were performed for scanned proton and
carbon ion radiotherapy, respectively. Two lateral opposing fields were chosen to irradiate the PTV, in
order to reduce the dose to the bladder. The αS/βS ratio was set to 2 Gy for both the target volume
and residual tissue (Brenner and Hall, 1999). The photon input parameters for the target volume were
set to: αS = 0.003 Gy−1, βS = 0.0015 Gy−2 and Dt,S = 22 Gy (Tai et al., 2008; Henderson et al., 2009).
Photon input parameters
The risk coefficients for secondary cancer after exposure to ionizing radiation is listed in Tab. 7. The
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values were taken from ICRP (2007) and are derived from the life span study. The nominal risk
coefficients are given in Sv. Since the weighting factor wR is 1 for photon radiation these nominal risk
coefficients can be directly converted into Gy. The organ-specific cell survival parameters (αS) in Tab. 8
are taken from Schneider et al. (2005).
Table 7: Sex-averaged nominal risk coefficients were taken from (ICRP, 2007) and cell survival param-
eters are derived from cancer incidence rates after Hodgkin’s disease (Schneider et al., 2005). Nominal
risk coefficients are derived by averaging sex and age-at-exposure life time risk estimates for males and
females combined.
Tissue Nominal risk coefficient
(cases per 10000 persons
per Sv)
Organ-specific cell survival
parameter
Esophagus 15 0.274
Liver 30 0.487
Lung 114 0.129
Bone 7 0.033
Skin 1000 0.047
Bladder 43 1.592
Other solid 144 0.080
The photon input parameters, derived from Tab. 7, for cell survival and tumour induction that are
used for the secondary cancer risk calculations for several OARs, are listed in Tab. 8. The α/β ratios
were raken from Mondlane et al. (2017) and Daşu et al. (2005).
Table 8: Photon LQ model parameters for tumour induction (αT) (ICRP, 2007) and for cell survival
(αS) (Schneider et al., 2005) for eight organs at risk. An α/β ratio of 3 Gy was assumed for all tissue
types, except for bladder and rectum (Daşu et al., 2005). The α/β ratios were assumed to be the same
for cell survival and tumour induction. The threshold doses Dt,S and Dt,T were calculated according
to Eqs. (29) and (58).
Organ αT [Gy−1] αS [Gy−1] α/β [Gy] Dt,S [Gy] Dt,T [Gy]
Liver 0.003 0.487 3.0 7 27
Skin 0.1 0.047 3.0 7 27
Lung 0.0144 0.129 3.0 7 27
Esophagus 0.0015 0.274 3.0 7 27
Bones 0.0007 0.033 3.0 7 27
Bladder 0.006 0.25 7.5 12 53.5
Rectum 0.017 0.25 5.4 10 41
Other solid tissue 0.0144 0.080 3.0 7 27
48
4 Results
In this chapter the results for modelling neoplastic cell transformation, tumour induction, and secondary
cancer risk after particle RT are presented. In section 4.1 the evaluation of the LEM to describe and
predict neoplastic cell transformation after irradiation with high-LET particles is shown. In a first step,
the threshold dose Dt,T for neoplastic cell transformation has to be determined in order to be able to
simulate cell transformation with the LEM. Afterwards, the simulated RBE values for transformation
are compared with three experimental data sets. In section 4.2 the applicability of the LEM to model
tumour induction in vivo is analysed. Sections 4.3 and 4.4 examine the estimation of secondary cancer
risks after proton and carbon ion beam therapy. First, the underlying systematics of tumour induction
from protons and carbon ions are analysed by assuming idealized conditions. Afterwards, the risk of
obtaining secondary cancers after radiotherapy with proton and carbon ion beams is assessed for two
patient data sets in accordance with the work of Mondlane et al. (2017).
4.1 Transformation in vitro
4.1.1 Calibration of the method for modelling neoplastic cell transformation
For simulating cell survival related RBE effects after ion radiation, the LEM needs three cell type specific
photon input parameters, namely the LQ coefficients αS and βS and the threshold dose parameter Dt,S.
For modelling neoplastic cell transformation, LEM needs three additional parameters, αT, βT and Dt,T.
While the LQ model coefficients αS, βS, αT and βT are derived from LQ model fits to experimental
photon data, the threshold doses Dt,S and Dt,T, as described in section 2.5.2, have to be derived
empirically from experimental photon data. A linear relationship between Dt,S and the αS/βS ratio
was found, leading to Eq. (29). In order to model cell transformation with the LEM, an equation for
Dt,T had to be derived first, which was performed using a similar approach as for Dt,S. For several
experiments theDt,T values were optimized by least square minimization in order to yield the best
agreement between the simulated and the experimental RBE0.0005 values, which is the RBE at 0.0005
visible transformations per surviving cell. This effect level was chosen because there is experimental
data at this effect level in all data sets considered here, thus ensuring comparability between the data
sets. The optimization process was conducted as follows:
1. RBE0.0005 values were calculated as described in section 3.1 for several ion species of various LET
values and energies for three distinct data sets (Miller et al., 1995; Yang et al., 1985; Hei et al.,
1988). For the data sets by Miller et al. (1995) and Hei et al. (1988) a single Dt,T value was used
to describe the data set, because only a single photon αT/βT ratio existed. For the data set by
Yang et al. (1985), however, nine individual photon αT/βT ratios were measured and therefore
also nine different Dt,T values.
2. The Dt,T values for the different data sets were varied until the maximal agreement between
the simulated and experimental data was achieved. This optimization was performed using a
least-squares minimization.
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3. The optimum Dt,T was then plotted against the photon αT/βT ratio as seen in Fig. 32, and a
linear function of the form Dt,T = x · αT/βT + y was fitted to these data points. The resulting
function (Eq. (58)) describes the dependence of the Dt,T value on the photon αT/βT ratio:
Dt,T = (5.9± 0.7) αT
βT
+ (9.2± 1.5) Gy (58)
With Eq. (58) an equation was established for determining Dt,T values based on experimental photon
αT/βT values. Miller et al. (1995) quotes the energy of the deuterons with an LET of 40 keV/µm as
0.275 MeV/u and for the Helium ions at 200 keV/µm as 0.36 MeV/u. These low energies correspond to
a particle range less than 10 µm. Since the diameter of a cell is in the order of 10 µm and the particle
loses energy along its path, this energy is too small to fulfil track segment conditions, i.e. no constant
LET value can be assumed, which is a prerequisite for LEM calculations. Therefore, these data points
were excluded from the Dt,T fit procedure. For the data set by Yang et al. (1985), the Dt,T values were
optimized for each experiment individually since the authors measured a photon response curve for
every ion species separately due to the long time span between the experiments. However, only for four
experiments it was possible to optimize the Dt,T value. For the remaining experiments the results give
an optimal Dt,T outside of reasonable values. After deriving Eq. (58), all Dt,T values were calculated
accordingly.
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Figure 32: Optimized threshold dose Dt,T as a function of the αT/βT-ratio for three experimental
data sets. As for cell survival, a linear rise with αT/βT was obtained. A linear fit to the data resulted
in an equation for Dt,T: Dt,T = 5.9 (αT/βT) + 9.2 Gy. Six data points from three different data sets
were used for optimizing Dt,T. The two data points at αT/βT = 0 Gy and Dt,T = 8 Gy are overlapping.
Due to the three independent ion and photon curve pairs from Yang et al. (1985) three optimizations
of Dt,T are possible.
4.1.2 Analysis of the data set by Miller et al.
In the work of Miller et al. (1995), mouse embryonic stem cells (C3H 10T1/2 cells) were irradiated with
photons and ions across a range of LET values, measuring dose response for both cell survival and cell
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transformation. The photon dose-response curves for cell survival and cell transformation are shown
in Fig. 33a and 33b. The red lines represent linear-quadratic fits to the data. For both cell survival
and cell transformation, a β term is clearly visible due to a pronounced shoulder of the curve. The
obtained LQ model coefficients are shown in Tab. 9. Equations (29) and (58) were used for calculating
Dt,S and Dt,T, respectively. The survival LQ model parameters have an αS/βS ratio of 2.2 Gy and a
αT/βT ratio of 4.8 Gy. The LQ model parameters for transformation are in the order of 10−5 smaller
than the ones for cell survival, which is to be expected since transformation is a rare event compared
to cell kill.
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Figure 33: (a) Photon survival dose-response relationship. A fit of the LQ model to the data yields
an α value of 0.125 Gy−1 and a β value of 0.058 Gy−2 for cell survival. (b) Photon transformation
dose-response relationship. A fit of the LQ model to the data yields an α value of 0.98·10−4 Gy−1 and
a β value of 0.205·10−4 Gy−2 for neoplastic cell transformation. Data from Miller et al. (1995).
Table 9: Photon LQ-model parameters obtained from fits to experimental data from Miller et al.
(1995) with standard deviation errors and calculated Dt,S and Dt,T values for cell survival and cell
transformation.
αx,S [Gy−1] βx,S [Gy−2] Dt,S [Gy] αx,T [10−5 Gy−1] βx,T [10−5 Gy−2] Dt,T [Gy]
0.125 ± 0.026 0.058 ± 0.004 6.5 0.98 ± 0.32 0.205 ± 0.052 37.5
In Fig. 34 the survival curves for all eleven ion experiments are shown. The radiation qualities range
from protons to iron ions and LET values from 3.8 keV/µm to 600 keV/µm (details are shown in Tab. 3).
This makes the data set one of the most exhaustive existing data sets. Since the visible transformations
per surviving cell T˜ depend on the survival probability, it has to be verified first that the LEM is able
to predict cell survival accurately. Otherwise, the predictions for cell transformation will be incorrect.
As shown in Fig. 34, the LEM predictions (red lines) represent the data points sufficiently well in most
cases. Only for 265 keV/µm and 600 keV/µm does the LEM predictions deviate quite strongly from
the experimental data at higher doses. For 40 keV/µm the LEM predictions are in good agreement
with the experimental data up to 1 Gy, at higher doses the LEM predicts a relatively linear decrease
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of the survival, whereas the experimental data points do indicate a non-linear decrease, thus for higher
doses the LEM predictions will strongly deviate from the experimental data.
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Figure 34: Dose-response curves for cell survival for photons and ions of varying LET (Miller et al.,
1995). The dashed lines show the LQ fit to the corresponding experimental photon survival curve as
shown in Fig. 33a. The black solid lines are LQ model fits to the experimental ion data and the red
lines are the corresponding LEM predictions.
The corresponding cell transformation curves are illustrated in Fig. 35. The LEM simulations were
performed as described in section 3.1. The threshold doses Dt,S and Dt,T values were calculated
according to Eqs. (29) and (58), respectively. The corresponding experimental and simulated LQ
model parameters are shown in Tab. 10.
The LEM tends to predict a βT term of zero or close to zero for intermediate- and high-LET
radiation, while some experiments suggests a pronounced negative bending of the dose-response curves.
As can be seen in Tab. 10, the LEM also predicts negative βT values for several of the experiments,
they are however much smaller than the experimentally observed βT values. A negative βT value could
arise due to the impact of cell survival at higher doses. In order to compare the accuracy of the LEM,
the reduced χ2 for the LEM predictions is shown in Fig. 36 for each ion experiment. For 40 keV/µm
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deuterons, the LEM predictions deviate significantly from the experimental data. As mentioned earlier,
this is most likely due to the very low energy (0.28 MeV/u) at which track segment conditions cannot
be fulfilled. This data point was excluded from the optimization process for deriving Dt,T. The data
point at 200 keV/µm was also excluded from the optimization procedure for the same reasons.
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Figure 35: Dose-response curves for visible transformations per surviving cell T˜ for photons and ions
of varying LET values (Miller et al., 1995). The dashed lines show the LQ fit to the corresponding
experimental photon transformation curve as shown in Fig. 33b. The black solid lines are LQ model fits
to the experimental ion data and the red lines are the corresponding LEM predictions. The parameters
of the experimental and simulated curves are shown in Tab. 10.
LEM predictions of the RBEα and the RBE at 0.0005 visible transformations per surviving cell
(RBE0.0005) were calculated and plotted as a function of LET (Fig. 37a and Fig. 37b). The result-
ing RBE values show a similar dependence on LET as the RBE values for cell survival. The RBE is
increasing with LET until around 100 keV/µm and then decreasing. However, it is important to mention
that the RBE values in Fig. 37a and Fig. 37b were calculated for different ion species, ranging from pro-
tons to iron ions. The RBE values for visible transformations per surviving cell are considerably higher
than the RBE values for cell survival. The maximum experimental RBEα for cell survival is about 17
(results not shown), while it is about 37 for visible transformations per surviving cell. The simulated
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RBE values at 40 keV/µm and 200 keV/µm show a significant deviation from the experimental RBE
values. These data points were excluded from the optimization process described in section 4.1.1. For
the other LET values the LEM predictions show good agreement with the experimental RBE values.
Table 10: Experimental and simulated LQ model parameters for the data set by (Miller et al., 1995).
Both the experimental and the LEM predictions show negative βT values which is atypical for LQ
model coefficients. This could be due to the impact of cell survival at higher doses.
Experimental LEM predictions
Ion LET αT βT αT βT
[keV/µm] [10−4 Gy−1] [10−4 Gy−2] [10−4 Gy−1] [10−4 Gy−2]
2H 3.8 2.9 ± 0.1 0 1.2 0.2
1H 15 6.5 ± 0.7 0 3.9 0.2
2H 40 7.1 ± 1.9 3.1 ± 2.2 24.2 0.058
3He 75 30.4 ± 0.2 -18.7 ± 0.3 25.0 -0.0095
4He 90 36.5 ± 1.5 -25.6 ± 2.4 27.0 -0.031
4He 120 19.7 ± 3.5 5.6 ± 3.7 26.3 -0.035
4He 150 29.3 ± 2.6 -12.7 ± 3.9 21.7 -0.03
4He 200 27.5 ± 2.2 -18.9 ± 3.5 12.5 -0.015
12C 265 3.1 ± 2.0 5.9 ± 2.4 12.2 -0.2
16O 418 3.9 ± 0.6 0 7.5 -0.36
19F 600 4.5 ± 1.0 2.2 ± 1.2 5.1 -0.43
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Figure 36: Reduced χ2 for the LEM predictions for the experiments conducted by Miller et al. (1995).
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Figure 37: RBEα and RBE at 0.0005 visible transformations per surviving cell against LET for
different radiation qualities. The photon input parameters are: αx,S = 0.125 Gy−1, βx,S = 0.058 Gy−2,
αx,T = 0.98·10−4 Gy−1, βx,T = 0.205·10−4 Gy−2, Dt,S = 6.5 Gy, Dt,T = 37.5 Gy. The error bars were
calculated as described in section 3.1.
A sensitivity analysis was performed in order to evaluate how sensitive the simulated RBE for visible
transformations per surviving cell is on the choice of Dt,T. The sensitivity analysis was performed by
increasing and decreasing the Dt,T value by 10%, respectively. The difference in RBE was plotted
as an error bar as shown in Fig. 38. The resulting deviations are relatively small compared to the
absolute values of the RBE and indicate that the choice of Dt,T does not have a significant impact on
the predicted RBE.
101 102
LET [keV/ m]
0
5
10
15
20
25
RB
E 0
.0
00
5
H
H
H
He
He
He
He
He
C
O
F
Miller et al. 1995
Simulation
Figure 38: RBE at 0.0005 visible transformations per surviving cell for an increased and decreased
Dt,T by 10%. The error bars for the simulated RBE values indicate the range of the RBE with varying
Dt,T.
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4.1.3 Analysis of the data set by Yang et al.
The data set by Yang et al. (1985) includes high energetic heavy ions ranging from 12C to 238U with LET
values from 10 keV/µm up to 1900 keV/µm (for more details see Tab. 3). The photon dose-response
curves for cell survival and visible transformations per surviving cell are shown in Fig. 39. The lines
represent LQ model fits to the data. Due to the long time span between the experiments, a photon
reference curve was measured for each ion curve individually. In one approach an LQ function was fitted
to the pooled photon data (upper panels in Fig. 39) resulting in a single photon (αS, βS) and (αT, βT)
pair. In another approach individual LQ functions were fitted to the different photon experiments
(lower panels in Fig. 39), resulting in nine distinct (αS, βS) and (αT, βT) pairs. The obtained photon
LQ model coefficients are shown in Tab. 11.
10 2
10 1
100
0 2 4 6 8 10
Dose [Gy]
10 3
10 2
10 1
100
Su
rv
iv
al
(a)
0
5
10
15
20
25
30
35
0 2 4 6 8 10
Dose [Gy]
0
5
10
15
20
25
30
Vi
sib
le
 tr
an
sf
or
m
at
io
ns
 p
er
 su
rv
iv
in
g 
ce
ll 
(1
0
4 )
(b)
Figure 39: (a) Photon survival curves for the pooled data of all nine experiments (upper panel) and for
each experiment individually (lower panel). (b) Photon dose-response curves for visible transformations
per surviving cell T˜ for the pooled data of all nine experiments (upper panel) and for each experiment
individually (lower panel). The corresponding LQ model coefficients are shown in Tab. 11.
The probability for visible transformations per surviving cell T˜ as a function of dose for the nine photon
and ion experiments are shown in Fig. 40. The dotted lines represent the photon response curves and
the red lines the LEM predictions. At 190 keV/µm the photon βT term is zero and in that case LEM
cannot predict a reasonable RBE. The dose-response curves for the photon LQ model parameters that
were obtained by fitting to all photon data are shown in Fig. 41. The experimental and predicted
αT and βT values are presented in Tab. 12. Using the individual photon parameters results in better
agreement between LEM predictions and experimental data in most cases as can be seen in Fig. 42.
In seven out of the nine experiments the individual photon parameters lead to a lower reduced χ2
compared to the pooled photon parameters.
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Table 11: Photon LQ-model parameters obtained from fits to experimental photon data for the
corresponding ion experiments from Yang et al. (1985) and calculated Dt,S and Dt,T values for cell
survival and cell transformation.
Corr. ion
exp.
αx,S [Gy−1] βx,S [Gy−2]
Dt,S
[Gy]
αx,T
[10−5 Gy−1]
βx,T
[10−5 Gy−2]
Dt,T
[Gy]
All 0.097 ± 0.038 0.05 ± 0.006 6 6 ± 5.7 2.2 ± 0.97 25.5
12C 0.387 ± 0.057 0.028 ± 0.008 19 16.09 ± 22.7 1.043 ± 3.047 100
20Ne 0.286 ± 0.047 0.027 ± 0.009 15.5 0 ± 6.156 2.885 ± 1.159 9
28Si 0.25 ± 0.005 0.022 ± 0.008 16.5 0.296 ± 4.09 1.468 ± 0.708 10.5
28Si 0.15 ± 0.037 0.033 ± 0.007 9 0 ± 4.480 5.195 ± 0.843 9
40Ar 0.17 ± 0.012 0.029 ± 0.002 10.5 0 ± 4.895 1.709 ± 0.830 9
56Fe 0.21 ± 0.028 0.028 ± 0.005 12 32.18 ± 7.75 0 ± 1.342 -
56Fe 0 ± 0.046 0.053 ± 0.008 4 0 ± 3.464 2.130 ± 0.600 9
56Fe 0.06 ± 0.017 0.047 ± 0.003 5.5 0 ± 3.314 1.465 ± 0.564 9
238U 0.04 ± 0.023 0.059 ± 0.004 4.5 0 ± 2.08 7.650 ± 4.139 9
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Figure 40: Visible transformations per surviving cell T˜ as a function of dose for photons and different
radiation qualities with varying LET values from Yang et al. (1985). The photon reference curves
(dotted lines) are derived for each experiment individually. The black solid lines are LQ model fits to
the experimental data and the red lines represent the corresponding LEM predictions. The parameters
of the experimental and simulated dose-response curves are shown in Tab. 12.
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Figure 41: Same as Fig. 40 but for the photon LQ model coefficients derived from the pooled photon
data.
Table 12: Experimental and simulated LQ model parameters for the data set by Yang et al. (1985).
As for the data set by Miller et al. (1995), some βT values are negative.
Experimental LEM single LEM pooled
Ion LET αT βT αT βT αT βT
[keV/µm] [10−5 Gy−1] [10−5 Gy−2] [10−5 Gy−1] [10−5 Gy−2] [10−5 Gy−1] [10−5 Gy−2]
12C 10 26.8 ± 5.0 0 16.8 0.98 7.8 2.1
20Ne 31 0.023 ± 5.6 3.9 ± 1.3 5.5 2.4 14 1.9
28Si 50 1.56 ± 7.78 4.5 ± 2.4 4.2 1.2 12 1.8
28Si 82 83.9 ± 10.4 -13.8 ± 4.1 32 3 19 1.6
40Ar 140 23.8 ± 1.4 0 17 0.45 29 1.1
56Fe 190 94.7 ± 10.6 0 27 -0.28 28 0.87
56Fe 300 36.8 ± 1.7 0 28 0.083 45 0.085
56Fe 500 3.6 ± 5.2 2.4 ± 1.5 15 -0.14 47 -0.58
238U 1900 8.6 ± 2.8 1.1 ± 0.6 16 -0.38 6.7 -0.11
The RBE values for the experimental and simulated visible transformations per surviving cell T˜ when
using the individual photon reference curves are shown in Fig. 43a and for using the pooled photon
data are shown in Fig. 43b. As can be seen in Tab. 11, six of the nine photon αT values are zero and
thus no RBEα can be calculated for most of the experiments.
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Figure 42: Reduced χ2 for the LEM predictions for the experiments conducted by Yang et al. (1985).
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Figure 43: RBE for visible transformations per surviving cell T˜ at an effect level of 0.0005 visible
transformations per surviving cell against LET for different radiation qualities for (a) the individual
photon curves and (b) the pooled photon data. The threshold doses Dt,S and Dt,T were calculated
according to Eqs. (29) and (58), respectively. The α and β values are listed in Tab. 13. The error bars
were calculated as described in section 3.1.
Taking the individual photon reference curves results in a better agreement between the simulated
and the experimental data. The RBE for visible transformations per surviving cell is increasing with
LET for low-LET values and decreases with LET at high-LET values. Compared to the RBE values
calculated for the data set by Miller et al. (1995) the RBE values for the data set by Yang et al. (1985)
are significantly lower (RBE < 8). Additional to the single RBE values RBE curves for the different
radiation qualities were calculated (Fig. 44). In Fig. 44a the RBE curves are overlapping. The light
blue Fe RBE curve is below one. This is most likely due to the nonexistent photon βT (see Tab. 11).
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Figure 44: RBE for visible transformations per surviving cell at an effect level of 0.0005 visible
transformations per surviving cell as a function of LET for different radiation qualities for (a) the
individual photon dose-response curves and (b) the pooled photon data. The data points are the
experimental RBE values from Yang et al. (1985).
4.1.4 Analysis of the data set by Hei et al.
In the experiments of Hei et al. (1988), mouse embryonic C3H 10T1/2 stem cells were used to measure
cell survival and neoplastic cell transformation for photons and light ions from protons to helium ions.
Figure. 45 shows the experimental photon data and the corresponding LQ model fits.
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Figure 45: Photon dose response curves for (a) cell survival and (b) visible transformations per
surviving cell. The LQ parameters obtained from LQ fits are: αS = 0.18 Gy−1, βS = 0.04 Gy−2,
αT = 1.5·10−5 Gy−1 and βT = 0.5·10−5 Gy−2.
The LQ model parameters obtained from these fits are shown in Tab. 13 together with the calculated
Dt,S and Dt,T values. The experimental and simulated visible transformations per surviving cell T˜
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as a function of dose for the three experiments are shown in Fig. 46 and the corresponding reduced
χ2 values are presented in Fig. 47. For 40 keV/µm deuterons, the simulated dose-response curve
deviates significantly from the experimental values, which is reflected by a large reduced χ2, where the
experimental data shows a strong bending of the curve while the LEM predicts a more linear dose-
response curve. In this case the energy of the beam is 0.5 MeV/u and thus track segment conditions
might not be guaranteed. Furthermore, LEM tends to predict small βT values for intermediate and
high LET values. This has also been observed for the previously shown data sets. The LQ model
parameters for the simulated and experimental dose-response curves are listed in Tab. 14.
Table 13: Photon LQ model parameters obtained from fits to experimental photon data from Hei
et al. (1988) and calculated Dt,S and Dt,T values for cell survival and cell transformation. The photon
dose-response curves are shown in Fig. 45.
αx,S [Gy−1] βx,S [Gy−2] Dt,S [Gy] αx,T [10−5 Gy−1] βx,T [10−5 Gy−2] Dt,T [Gy]
0.18 ± 0.03 0.04 ± 0.004 9 1.5 ± 0.03 0.5 ± 0.06 27
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Figure 46: Visible transformations per surviving cell T˜ against dose for protons, deuterons and helium
ions for four different LET values. The dashed lines show the LQ fit to the corresponding experimental
photon transformation curve as shown in Fig. 45b. The black solid lines are LQ model fits to the
experimental ion data and the red lines are the corresponding LEM predictions.
The corresponding RBE values at an effect level of 0.0005 visible transformations per surviving cell are
shown in Fig. 48. Except for the data point at 40 keV/µm the LEM predictions show good agreement
with the experimental data. No RBEα is shown here since one of the four experimental αT values is
zero and thus it was not possible to calculate RBEα values for the whole data set.
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Figure 47: Reduced χ2 for the LEM pre-
dictions for the experiments conducted by Hei
et al. (1988).
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Figure 48: RBE at an effect level of 0.0005
transformations per surviving cell against LET
for different ions. The photon input parame-
ters are: αS = 0.18 Gy−1, βS = 0.04 Gy−2,
αT = 1.5·10−5 Gy−1, βT = 0.5·10−5 Gy−2,
Dt,S = 9 Gy, Dt,T = 27 Gy. The error bars
were calculated as described in section 3.1.
Table 14: Experimental and simulated LQ model parameters for the data set by Hei et al. (1988).
Experimental LEM predictions
Ion LET αT βT αT βT
[keV/µm] [10−4 Gy−1] [10−4 Gy−2] [10−4 Gy−1] [10−4 Gy−2]
1H 10 0.084 0.082 0.45 0.049
2H 40 0 1.19 4.15 0.016
3He 80 2.9 0.617 4.61 0.002
3He 120 5.1 0 4.48 -0.0009
4.1.5 Correlation between cell survival and neoplastic cell transformation
An important feature of the implemented model is the application of the correlation between cell
survival and cell transformation as described in section 3.1. In order to evaluate the impact of this
correlation on the simulated RBE values, RBEα as a function of LET was calculated for two ion species,
both by using the exact mathematical description in Eq. (46), and by assuming the induction of lethal
and transforming events as statistically independent events T˜ ∗:
T˜ ∗ = 〈T 〉 · 〈S〉〈S〉 (59)
The corresponding RBE curves are shown in Fig. 49. The solid lines represent the simulated RBE values
without correlation T˜ ∗ and the dotted lines represent RBE curves with correlation T˜ . The data points
in Fig. 49a show the experimental RBEα values for helium radiation taken from Miller et al. (1995). In
49a, the RBE curve for T˜ reaches a maximum at around 100 keV/µm, similar to the experimental data
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points. The RBE curve for T˜ ∗ increases further, beyond 100 keV/µm. As illustrated in Fig. 49b, the
RBE curve for carbon radiation with inclusion of the correlation shows higher RBE values in particular
for LET values larger than 100 keV/µm and the maximum RBE is shifted towards higher LET values.
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Figure 49: RBEα as a function of LET for simulations that consider and neglect a correlation between
cell survival and transformation for (a) 4He radiation (data points are taken from Miller et al. (1995))
and (b) 12C radiation. When neglecting the correlation between cell survival and tumour induction
the RBE is overestimated for LET values higher than 200 keV/µm and the maximum RBE is shifted
towards larger LET values.
4.2 Tumour induction in Harderian gland
In the previous section, the ability of the LEM to model neoplastic cell transformation on a cellular
level was analysed. In contrast, macroscopic observable tumour development is a complex multistep
process and in order to predict tumour induction in tissues after particle radiation, the LEM has to be
validated on experimental in vivo data. The most extensive experimental data set on tumour induction
for a wide range of LET values is the data set on tumour prevalence in Harderian glands in mice (Alpen
et al., 1993, 1994; Fry et al., 1985; Chang et al., 2016). This data set contains various radiation qualities
with LET values ranging from 0.4 keV/µm to 464 keV/µm. For more details about this data set see
section 3.2.2.
Photon dose-response curve. The tumour prevalence in Harderian glands as a function of the
photon dose is shown in Fig. 50. Between 0 and ∼0.8 Gy there is only small increase in tumour
induction whilst between 1 and 2 Gy the dose-response curve increases steeply, indicating a quadratic
term for tumour induction. At doses above 2 Gy a reduction in the slope of the dose-response curve is
visible, indicating the impact of cell survival on tumour induction at higher doses. In order to obtain
the photon LQ model parameters for tumour induction, Eq. (50) was fitted to the experimental photon
data shown in Fig. 50. This means fitting four parameters to the experimental data (assuming the
number of cells N in the organ is known). This results in parameters with large uncertainties as shown
in Tab. 15, which means that multiple parameter sets exist, that all describe the experimental data
63
well as illustrated by the different dose-response curves in Fig. 50. The dose-response curves were
obtained by first choosing αS and βS values that lie within the standard error listed in Tab. 15, and
then performing a two-parameter fit to determine αT and βT.
Table 15: Photon LQ-model parameters obtained from fits to experimental data from Alpen et al.
(1994) with standard deviation errors for cell survival and tumour induction.
αx,S [Gy−1] βx,S [Gy−2] αx,T [Gy−1] βx,T [Gy−2]
0.278 ± 0.3 0.0007 ± 0.03 10−15 ± 5.8 10−8 8.5 10−8 ± 7.9 10−8
For multiple sets of photon parameters, tumour induction probabilities were simulated and compared
to the experimental data. One example is shown in Fig. 51. Not all of the parameter sets resulted
in simulated dose-response curves that were in good agreement with the experimental data. Here, a
single parameter set was chosen, which resulted in tumour induction probabilities that were in good
agreement with the experimental data.
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Figure 50: Photon dose-response curve for tumour induction in the Harderian gland. Experimental
data from Alpen et al. (1994). The tumour induction probability was calculated using the microscopic
equation (Eq. (50)).
Ion fluence-response and dose-response curves. The tumour prevalence for ion radiation was
calculated according to section 3.2 for nine experiments with varying LET values, using the microscopic
formalism with N = 106 cells, which lies in the order of magnitude of the number of cells in mouse
Harderian glands (Neess et al., 2010; Bek et al., 2015). The tumour prevalence as a function of dose
is illustrated in Fig. 51. The photon LQ model coefficients that were used for the simulations are:
αS = 0.25 Gy−1, βS = 0.0023 Gy−2, αT = 1·10−9 Gy−1, βT = 7.73·10−8 Gy−2 and N = 106. The
αS/βS ratio is 109 Gy and the αT/βT ratio is 0.013 Gy. When looking at the model predictions in Fig. 51,
it can be seen that the model underestimates the tumour induction probability for low to intermediate-
LET radiation, while for high-LET radiation (175 keV/µm and higher), the model predictions are in
good agreement with the experimental data.
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Figure 51: Tumour induction probability as a function of dose for eight different radiation qualities
and nine distinct LET values (Alpen et al., 1993, 1994; Chang et al., 2016). Data points show the
experimental tumour prevalence of Harderian gland tumours in mice and the dotted lines are the
corresponding LEM predictions. The photon input parameters are: αS = 0.25 Gy−1, βS = 0.0023 Gy−2,
αT = 1·10−9 Gy−1, βT = 7.73·10−8 Gy−2 and N = 106. The tumour prevalence was calculated using
the microscopic formalism as described in section 3.2.
Figure 52 shows the same tumour induction probability as in Fig. 51 but plotted against the particle
fluence F . When plotting the tumour induction probability against the particle fluence the response
curves are distributed over a large range of fluences (high-LET data points are shifted towards lower
particle fluences). That way the effects of single particle traversals on the tumour induction probability
can be assessed. In order to evaluate whether the separation of the response curves in particle fluence is
only an effect of the LET, and not of the RBE, the photon dose-response curve was shifted according to
the LET values of the different ion curves (dashed lines in the lower panel of Fig. 52). This demonstrates
that the separation in particle fluence is not only the result of the LET, but of the RBE.
In the next step, the tumour prevalence was calculated using the macroscopic equation in order to
assess whether the two concepts yield different results. In that case Eq. (48) was used as a fit function
for the experimental photon data, resulting in different LQ model coefficients: αS = 0.105 Gy−1,
βS = 0 Gy−2, αT = 0.027 Gy−1, βT = 0.045 Gy−2. The resulting tumour prevalence as a function of
particle fluence is shown in Fig. 53. For low LET radiation (up to 25 keV/µm) there is no significant
difference between the macroscopic and the microscopic formalism. For intermediate LET values (70
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Figure 52: The upper panel shows the experimental and simulated dose-response curves as in Fig. 51
but as a function of the particle fluence. The dose can be converted into the particle fluence by means
of Eq. (5). This leads to a separation of the fluence-response curves in particle fluence, where high-LET
radiation fluence-response curves are shifted towards lower particle fluences. The lower panel shows
additionally the photon fluence-response curves scaled with LET according to Eq. (5) (dashed lines),
showing that the separation of the individual ion fluence-response curves is not only due to the LET,
but RBE effects are clearly visible.
and 107 keV/µm) there is a small deviation which is, however, small compared to the deviation from
the experimental data. For high LET radiation (175 keV/µm and higher) a clear deviation from the
microscopic simulations are seen. In order to describe the photon data well, the αS coefficient for the
macroscopic tumour induction cannot be larger than approximately 0.1 Gy−1.
The tumour induction predictions for N = 100 cells are shown in Fig. 54. Using N = 100 or
N = 106 cells in the organ has only minor impact on the results, because when changing the cell
number N , new photon input parameters were obtained by performing new fits to the experimental
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Figure 53: Same as the upper panel in Fig. 52 but showing additionally the macroscopic tumour
induction (dashed lines). The macroscopic tumour induction was calculated using Eq. (38) with the
following photon input parameters: αS = 0.105 Gy−1, βS = 0 Gy−2, αT = 0.027 Gy−1, βT = 0.045 Gy−2.
data points, i.e. each N results in different photon input parameters.
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Figure 54: Tumour induction probabilities as a function of particle fluence for eight different radia-
tion qualities and nine distinct LET values (Alpen et al., 1993, 1994; Chang et al., 2016), calculated
with the microscopic formalism of Eq. (50) using N = 100 cells. Data points show the experimen-
tal tumour prevalence of Harderian gland tumours in mice and the dotted lines represent the corre-
sponding LEM predictions with the following input parameters: αS = 0.234 Gy−1, βS = 0.005 Gy−2,
αT = 3.25·10−5 Gy−1, βT = 7.7·10−4 Gy−2 and N = 100.
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4.3 Secondary cancer risk after particle therapy - Systematic analysis
After having assessed the ability of the LEM to model both neoplastic cell transformation and tumour
induction, the aim is to model SC risk after particle RT with protons and carbon ions. In section 4.3
treatment plans were performed for an idealized geometry in order to better understand the underlying
mechanisms of SC induction after scanned proton and carbon ion therapy. In section 4.4 the SC risks
for retrospectively planned patient plans were calculated.
4.3.1 Dose-response curves for tumour induction
Before looking at treatment plans, dose-response curves for tumour induction after irradiation with
a single fraction of monoenergetic photons, protons and carbon ions for different LET values were
simulated (Fig. 55). The tumour induction probabilities were calculated using Eq. (38). The LQ model
coefficients for the ion curves were calculated using the LEM. For photon radiation, the dose-response
curve is wide and flat, while with increasing LET the dose-response curve becomes narrower and the
maximum shifts towards lower doses (see Fig. 55a). Thus, at high LET values low doses result in a
higher tumour induction probability compared to low-LET radiation. On the other hand, higher doses
yield a lower risk compared with photons due to the higher effectiveness in cell kill. At the same LET,
protons show an increased tumour induction probability at low doses compared to carbon ions and a
narrower dose-response curve (Fig. 55b). These simulations show that with the LEM it is possible to
compare dose-response curves for different radiation qualities.
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Figure 55: Dose-response curves for tumour induction probability for photons, protons and carbon ions
with different LET values. (a) With increasing LET value the dose-response curves become narrower
and are shifted towards lower doses. (b) At the same LET, protons show a higher tumour induction
probability at lower doses compared to carbon ions. The calculations were performed with the LEM
for the following photon input parameters: αS = 0.1 Gy−1, βS = 0.05 Gy−2, αT = 0.002 Gy−1,
βT = 0.001 Gy−2, Dt,S = 6 Gy and Dt,T = 21 Gy.
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4.3.2 Risk assessment in 2D
Irradiation with a single beam. To better understand the underlying systematics of tumour in-
duction after particle RT, treatment plans for the irradiation of a water cube with a single scanned
proton or carbon ion beam were generated. A schematic illustration of the geometry is shown in Fig. 56.
To reduce simulation time, a small target cube of size 4×4×4 = 64 cm3 was chosen, contained in a box
of 10×25×25 = 6250 cm3. A total target dose of 36 Gy (RBES) in 18 fractions (2 Gy per fraction) was
chosen, as these are typical values for treating Hodgkin lymphoma (Eley et al., 2016). The αS and βS
values for the target were set to 0.1 Gy−1 and 0.0125 Gy−2, respectively, and Dt,S is 13 Gy (calculated
with Eq. (29)). The parameters are summarized in Tab. 16. The ion pencil beams have typical focal
spot sizes in air of 10 mm full-width at half-maximum (FWHM) for protons and 6 mm FWHM for
carbon ions. Due to decreased lateral scattering of carbon ions, narrower pencil beams are possible
compared to protons. It should be stressed here that the precise choice of the input parameters is only
of minor importance for this study, especially since most of the parameters have large uncertainties.
The main focus here is the comparison of the secondary cancer risk probabilities of protons and carbon
ions.
Figure 56: Schematic illustration of the geometrical set-up. A cubic water target of size
4×4×4 = 64 cm3 is irradiated with a single ion field coming from the left side (indicated with the
arrow). The whole volume in which the target is contained is 10×25×25 = 6250 cm3 in x-y-z.
Fig. 57 shows the optimized dose distribution for protons (left) and carbon ions (right). The dose
distribution in the entrance channel is narrower for carbon ion beams due to the smaller beam spot
size. Carbon ion beams deposit a lower dose in the entrance channel compared to protons, but a higher
dose behind the target, the fragmentation tail. The mean RBES-weighted dose per voxel in the whole
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volume as illustrated in Fig. 56 is 1.8 Gy for protons and 1.62 Gy for carbon ions and thus, protons
deposit a higher total RBES-weighted dose compared with carbon ions (in this case 12% higher). When
looking at the physical dose, protons deposit a mean dose of 1.61 Gy per voxel and carbon ions 0.86 Gy,
hence protons deposit almost twice as much physical dose compared with carbon ions. The fraction
of voxels that receive RBES-weighted doses between 1 mGy and 1 Gy is 7% for protons and 27% for
carbon ions. These low doses are of special interest, because at these low doses cell killing effects are
not dominant but cell mutations can still occur. Protons deposit a larger fraction of high energies in
the entrance channel, while carbon ions deposit a larger fraction of low energies in the fragmentation
tail. This can be seen in the depth dose distribution in Fig. 58, where the RBES-weighted (solid lines)
and physical (dotted lines) doses are shown as a function of penetration depth. The next step is to see
how these different dose distributions translate into SC risk distributions.
Table 16: Photon input parameters for the dose optimization. The αS/βS ratio of 8 Gy was taken
from Eley et al. (2016).
αS [Gy−1] βS [Gy−2] Dt,S [Gy] Dose per fraction [Gy] # fractions
0.1 0.0125 13 2 18
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Figure 57: Two-dimensional dose distribution after proton (left) and carbon ion (right) beam irradia-
tion with the beam coming from the left side. The black lines denote the target contours. The photon
LQ model parameters for the target volume are: αS = 0.1 Gy−1, βS = 0.0125 Gy−2 and Dt,S = 13 Gy.
The plan was optimized for a target dose of 2 Gy and 18 fractions.
The SC risk distributions for the proton and carbon ion treatment plans were calculated as described
in section 3.3. As mentioned before, one RBE table is needed for the optimization process and two
RBE tables are needed for each OAR for the risk calculations, one for cell survival and one for tumour
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induction. The risk was calculated for the whole volume with the photon input parameters shown in
Tab. 17. One slice of the risk distribution is presented in Fig. 59. At the distal end of the target the
risk is increased in the area of the fragmentation tail. In contrast, protons do not show an elevated
risk in that area. An OAR lying behind the target would be at an increased risk for secondary cancer
induction after irradiation with carbon ions, while there would be almost no risk for protons. Inside the
entrance channel the risk is also slightly elevated for carbon ions. The total SC risk in the whole volume
is roughly 1.4 times higher for the carbon ion treatment plans compared with the proton treatment
plans.
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Figure 58: Depth-dose distributions for RBES-weighted dose (solid lines) and physical dose (dotted
lines) along the (a) z-axis and the (b) y-axis (at z = 8 cm) as depicted in Fig. 56 for proton and carbon
ions. Both the RBES-weighted dose and the physical dose of protons are higher in the entrance channel
compared with carbon ions. Carbon ions, on the other hand, deposit a significantly higher dose at the
distal end of the SOBP.
Table 17: Photon input parameters for the SC risk calculations. The LQ model coefficients are taken
from Eley et al. (2016).
αS [Gy−1] βS [Gy−2] αT [ Gy−1] βT [ Gy−2] Dt,S [Gy] Dt,T [Gy]
0.067 0.0223 0.0226 0.0075 8 27
Figure 60 shows SC risk maps for three cell types with different αS/βS ratios. The upper panels
show the SC risks for radioresistant cell types with an αS/βS ratio of 0.2 Gy and the lower panels for
radiosensitive cell types with an αS/βS ratio of 10 Gy, while the middel panels show SC risk maps for
intermediate radiosensitivity with an αS/βS ratio of 2 Gy. The left panels show the risk maps for the
proton plans while on the right side, the risk maps for the carbon ion plans are shown.
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Figure 59: Two-dimensional risk distribution for protons (left) and carbon ions (right). The LQ
model parameters for calculating the secondary cancer risk are: αS = 0.067 Gy−1, βS = 0.0223 Gy−2,
αT = 0.0226 Gy−1, βT = 0.0075 Gy−2, Dt,S = 8 Gy and Dt,T = 27 Gy. The SC risk is elevated at
the edges of the radiation fields and in the area of the fragmentation tail of carbon ions. In the target
volume the SC risk is zero since the cell survival inside the target is zero.
For the radioresistant cells with an αS/βS ratio of 0.2 Gy, the SC risk in the entrance channel is higher
for protons than for carbon ions. For the intermediate cells, the SC risk inside the entrance channel is
lower for protons and the risk inside the fragmentation tail is higher compared to the risk inside the
entrance channel. Pronounced SC risk at the edges of the radiation fields in the entrance channel are
visible. For very radioresistant cell types the cell survival probability inside the entrance channel is so
low that the SC risk is zero except at the field margins. In that case the largest contribution to the
total SC risk makes the fragmentation tail. When looking at these risk maps it should be kept in mind
that the scale of the colour map is changing with cell type. That means that in the upper panels the
risk inside the fragmentation tail seems low but is, however, higher than for the other two cell types.
For radioresistant cell types carbon ions seem to yield a lower SC risk compared to protons, while for
more radiosensitive cell types the proton plans yield lower SC risks.
Irradiation with two opposing beams. For the single-field treatment plans it could be seen that
the secondary cancer risk probability is elevated in the fragmentation tail of carbon ions. But what
happens when irradiating with two opposing fields? To shed light on this question, treatment plans
with the same parameters as before but for two opposing proton and carbon ion beams were generated.
The resulting optimized dose distribution is shown in Fig. 61 and the corresponding depth dose profile
on the z-axis in Fig. 62. For the two opposing beams, the average RBES-weighted dose per voxel is
1.8 Gy for protons and 1.7 Gy for carbon ions. Hence, the RBE-weighted dose is roughly 6% higher for
protons compared with carbon ions. In comparison, for the single-field treatment plans the proton dose
was 12% higher. This means that the difference in dose is reduced when using two opposing fields. The
fraction of voxels that receive RBES-weighted doses between 1 mGy and 1 Gy is 11% for protons and
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Figure 60: 2D risk maps for cell types with three different radiosensitivities after RT with protons
(left) and carbon ions (right). Upper panel: Radioresistant cells with αS = 0.01 Gy−1, αS/βS = 0.2 Gy
and Dt,S = 4 Gy. Middle panel: αS = 0.1 Gy−1, αS/βS = 2 Gy and Dt,S = 6 Gy. Lower panel:
Radiosensitive cells with αS = 0.2 Gy−1, αS/βS = 10 Gy and Dt,S = 15 Gy. The tumour induction
parameters for all three cell types are: αT = 0.0226 Gy−1, βT = 0.0075 Gy−2 and Dt,T = 27 Gy.
40% for carbon ions. Thus, even for two opposing fields, carbon ions show a large area of low doses.
When looking at the dose distributions in the entrance channel, the RBES-weighted dose is higher for
carbon ions but the physical dose is higher for protons.
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Figure 61: Dose distribution after irradiation with protons (left) and carbon ions (right) for two
opposing beams. The input parameters are: αS = 0.1 Gy−1, βS = 0.0125 Gy−2 and Dt,S = 13 Gy.
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Figure 62: Depth-dose distribution for RBES-weighted dose (solid lines) and physical dose (dotted
lines) for proton and carbon ions for two opposing fields.
The 2D risk maps for the two-field treatment plans are shown in Fig. 63. The tissue LQ model
parameters are the same that were used before (see Tab. 17). The total secondary cancer risk after
carbon ion beam radiation is about 9% lower than for protons. Thus, irradiation with two opposing
beams results in carbon ions having a lower total secondary cancer risk than protons, while irradiation
with a single beam result in a 40% higher total risk for carbon ions.
74
1H 12C 0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
Ri
sk
 [a
.u
.]
Figure 63: Risk distribution after irradiation with protons (left) and carbon ions (right) for two
opposing beams. The LQ model parameters for the tissue are shown in Tab. 17.
In Tab. 18 the single- and opposing-field treatment plans are compared. For the single-field treatment
plans, the average dose per voxel is higher for the proton plans, while it is the other way around for the
opposing fields. Using two fields increases the number of voxels which receive dose. For both the single-
and opposing-field plans, the carbon ion plans show an increased number of voxels that receive low
doses. When looking at the average SC risk per voxel, protons show a reduced risk for the single-field
plans and an increased risk for the opposing-fields plan.
Table 18: Comparison between single field and opposing fields. The input parameters for the risk
calculations are shown in Tab. 17.
Single field Opposing fields
1H 12C 1H 12C
Avg. RBE-weighted dose per voxel
[Gy (RBES)]
1.8 1.6 1.8 1.7
Percent of voxels that receive doses
between 0.001 and 1 Gy (RBES) [%]
7 27 11 40
Avg. risk per voxel [a.u.] 2.82 3.89 5.36 4.86
As for the single-field plans, the SC risk depends strongly on the cell survival of the tissue. The
secondary cancer risk for three different radiosensitivities was calculated for two opposing beams and
the corresponding risk maps are shown in Fig. 64. On the left the secondary cancer risk after proton
radiation is shown, and on the right for carbon ion radiation. The upper panel shows the risk for
radioresistent cell lines, where the risk is considerably higher for the proton plans, in particular close to
the tumour. The middle panel shows the risk for intermediate radioresistant cell lines. And the lower
panel shows the risk for radiosensitive cell lines with an increased risk at the edges of the radiation field
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and low risks near the target, where doses are high enough to contribute significantly to cell kill.
Figure 64: 2D risk maps for cell types with three different radiosensitivities after RT with protons
(left) and carbon ions (right). Upper panel: Radioresistant cells with αS = 0.01 Gy−1, αS/βS = 0.2 Gy
and Dt,S = 4 Gy. Middle panel: αS = 0.1 Gy−1, αS/βS = 2 Gy and Dt,S = 6 Gy. Lower panel:
Radiosensitive cells with αS = 0.2 Gy−1, αS/βS = 10 Gy and Dt,S = 15 Gy. The tumour induction
parameters for all three cell types are: αT = 0.0226 Gy−1, βT = 0.0075 Gy−2 and Dt,T = 27 Gy.
With increasing radiosensitivity the SC risk at the edges of the entrance channel increases and the risk
near the target decreases. For radioresistant cell types the risk inside the entrance channel is higher
for carbon ions while it is lower for radiosensitive cells. Thus, for radiosensitive organs carbon ions
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may yield a lower SC risk, while for radioresistant organs protons could yield a lower risk. It is worth
mentioning here, that the risk depends on many factors and thus conclusions can only be drawn for
the specific set of input parameters under consideration.
4.3.3 Risk assessment in OAR
To better understand the dependence of the risk on the location of the OAR in the radiation field, a
small OAR (4×4×1 = 16 cm3) was placed at the edge of the entrance channel at d = 2.5 cm in front of
the target as illustrated in Fig. 65. This particular position was chosen since, as shown in the previous
section, the risk behind the target is always higher for carbon ions due to the fragmentation tail, while
it is not clear how the risk changes inside and at the edges of the radiation field in the entrance channel.
This section, therefore, focuses on the SC risk ratios after proton and carbion ion beam therapy in an
OAR that lies at the edge or inside the radiation field of the entrance channel.
When looking at the RBES-weighted dose and risk distributions at the field margins in the entrance
channel, one can see that the RBES-weighted dose is lower for carbon ions and goes down to zero faster
than for protons (Fig. 66). When looking at the risk distribution, carbon ions show an increased risk
inside the entrance channel (y < 2.5 cm) but a lower risk at the field margins. This is illustrated in
Fig. 67, where the predicted risk ratios (Rp/RC) for proton and carbon ion beam treatment plans are
shown as a function of the position of the center point of the OAR on the y-axis (e.g. y = 0 cm means
that the OAR lies completely inside the radiation field as demonstrated in 65). When the OAR lies
completely inside the radiation field (y = 0 cm), Rp is lower than RC. When moving the target out of
the entrance channel, Rp becomes larger than RC. When the OAR is halfway inside the radiation field
(y ≥ 2 cm), the carbon ion treatment plans predict a lower SC risk compared to protons.
Figure 65: Schematic illustration of the geometrical set-up. An OAR (light blue rectangle) with
the dimensions 4×4×1 cm3 is located d = 2.5 cm in front of the target and moved in and out of the
radiation field as indicated by the arrows. The current position of the OAR is y = 0 cm. When the
OAR is halfway inside the radiation field then y = 2 cm and when the OAR is completely outside the
radiation field then y = 4 cm.
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Figure 66: RBES-weighted dose and
risk distribution after proton and carbon
ion beam irradiation. The position y in
the radiation field refers to the y-axis in
Fig. 65 and the distance to the target on
the z-axis is d = 2.5 cm.
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Figure 67: Predicted risk ratio (Rp/RC) for pro-
ton and carbon ion beam treatment plans for an
OAR that is located 2.5 cm in front of the target
as shown in Fig. 65. The position y refers to the
position of the center point of the OAR on the y-
axis. At y = 4 cm the OAR lies outside at the edge
of the radiation field and the SC risk is lower for
the carbon ion treatment plans, while it is higher
at y = 2 cm, when half of the OAR lies inside the
radiation field. At this point Rp/RC is almost one.
The parameters used for the risk calculations in Figs. 66 and 67 are shown in Tab. 17. In order to
better understand the dependence on the input parameters SC risks were calculated for various input
parameters as demonstrated in Fig. 68. The first image shows the SC risk as a function of the αT/βT
ratio for tumour indction for an OAR at the edge of the radiation field (y = 4 cm, d = 2.5 cm).
Increasing the αT/βT ratio results in a decreased cancer induction probability and an increasing risk
ratio (Rp/RC). The next image shows the SC risk as a function of the absolute value of αT. As
expected, increasing αT, which is the initial slope of the dose-response curve, results in an increased SC
risk. In the last image, the SC risk is plotted against the number of fractions for three different positions
on the y-axis. Increasing the number of fractions (at the same biological equivalent dose) results in an
elevated risk. When the number of fractions decreases the dose per fraction increases. This results in
a lower survival probability explaining the decrease in SC risk for low numbers of fractions.
While the choice of the input parameters has a significant impact on the absolute risk value for
cancer induction, there are some visible systematics. a dominating effect on the relative risk ratio
(Rp/RC) of protons and carbon ions is the location of the OAR. Behind the target, carbon ions always
show an increased SC risk, while at the edge of the radiation field inside the entrance channel protons
show an increased SC risk. When moving the OAR further into the entrance channel, protons become
more beneficial regarding SC risk.
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Figure 68: Sensitivity analysis of the secondary cancer risk in the OAR at d = 2.5 cm and y = 4 cm.
(a) SC risk as a function of α/β for tumour induction with αS/βS = 3 Gy and αS = 0.067 Gy−1,
αT = 0.0226 Gy−1. (b) SC risk as a function of αT. The input parameters are: αS/βS = αT/βT = 3 Gy
and αS = 0.067 Gy−1. (c) SC risk as a function of the number of fractions. The dose per fraction for each
fractionation scheme was calculated using Eq. (11). The input parameters are: αS/βS = αT/βT = 3 Gy,
αS = 0.067 Gy−1, αT = 0.0226 Gy−1 and d = 2.5 cm.
Cancer risk ratios (Rp/RC) in the OAR for different positions on the y-axis (as illustrated in Fig. 56)
were calculated for irradiation with a single beam (69a) and two opposing beams (69b). In both cases
the cancer risk is lower after carbon ion beam RT at the edges of the radiation field (y = 0 cm).
When moving the OAR further into the radiation field the risk ratio decreases and depending on the
radiosensitivity of the cell line in the OAR even becomes smaller than 1, which means that carbon ions
yield a higher risk compared to protons. Only for very radioresistant cell lines (αS = 0.01 Gy−1) the
risk ratio stays above 1. Very radiosensitive cell lines (αS = 0.2 Gy−1) show the biggest dependence
on the location of the OAR, where the cancer induction probability is almost 1.6 times higher for
proton therapy at y = 4 cm and about 1.7 times higher for carbon ion beam therapy at y = 0 cm,
which corresponds to the OAR being completely inside the radiation field. For two opposing fields the
situation changes. While the risk ratio is decreasing with increasing depth in the entrance channel for
radioresistant cell lines as for a single beam, the risk increases with depth for very sensitive cell lines.
Since the risk depends on many parameters, such as the location of the OAR and the four LQ model
parameters, deriving any clear systematics is difficult and could possibly lead to wrong predictions.
However, what was found shows that for OAR that have a high carcinogenic potential and a low
survival rate, carbon ions show a tendency towards a decreased risk compared to protons. But as
demonstrated in Fig. 69 the location of the OAR can reverse this. It also shows that the cell survival
parameters of the OAR can significantly affect the choice of radiation quality for the treatment. It was
also found that for OARs situated completely inside the entrance channel protons yield a lower SC risk
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in most cases compared to carbon ions.
Figure 70 shows SC risk ratios for a hypothetical OAR at the lateral field margin with different α/β
ratios for cell survival and tumour induction for irradiation with either a single or two opposing fields.
Increasing αS/βS leads to a lower SC risk estimate for protons compared to carbon ions, while increasing
αT/βT leads to a lower SC risk for carbon ions compared to protons. These results demonstrate the
complex nature of SC risks. Depending on the radiosensitivity parameters and the spatial location of
the OAR, using opposing beams can shift the SC risk ratio in favour of carbon ions.
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Figure 69: Predicted secondary cancer risk ratios (Rp/RC) after scanned proton and carbon ion
beam irradiation for (a) one single beam and (b) two opposing beams. Single beam: At the edge
of the radiation field the secondary cancer risk is lower for carbon ion radiation whereas inside the
entrance channel the risk is lower for protons except for very sensitive cell types. Opposing beams: For
radiosensitive cell types regarding cell survival the secondary cancer risk is lower for carbon ions both
at the edge and inside the entrance channel. For more radioresistent cell types the risk is lower for
carbon ions at the edge and higher inside the entrance channel. The distance between the OAR and
the target on the z-axis is d = 2.5 cm as shown in Fig. 65.
The reason why the carbon ion treatment plans result in a reduced SC risk at the field margins is the
narrower pencil beam, which is 6 mm at FWHM, compared to 11 mm FWHM for protons. This leads
to a reduced dose at the lateral field margins in the entrance channel, as well as in a reduced irradiated
volume, as seen in Fig. 66. To emphasize this, the carbon ion beam width was reduced to 5 mm, while
keeping the proton beam width constant. The results are shown in Fig. 71. Reducing the beam width
of carbon ions from 6 mm to 5 mm FWHM, results in a 43% increased risk ratio at the edge of the
radiation field (y = 4 cm). At y = 3 cm the risk ratio is increased by 18.5% an inside the entrance
channel (y = 0 cm) there is almost no difference between 5 mm and 6 mm beam width. This is expected
since the effect of the beam width is mostly of importance at the lateral field margins.
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Figure 70: Risk ratio for secondary cancer after scanned proton and carbon ion beam therapy for
a hypothetical OAR of varying αS/βS and αT/βT ratios. The target was irradiated with 36 Gy in
18 fractions, using either a single or two opposing fields. The OAR is located 2.5 cm in front of the
target as illustrated in Fig. 65. Left panel: αS = 0.1 Gy−1, αT = 0.001 Gy−1 and αT/βT = 3 Gy.
Middle panel: αT = 0.001 Gy−1, αS = 0.1 Gy−1 and αS/βS = 3 Gy. Right panel: Changing both
αS/βS and αT/βT, with αS = 0.1 Gy−1 and αT = 0.001 Gy−1. Increasing αS/βS leads to a lower SC
risk estimate for protons while increasing αT/βT leads to a lower SC risk for carbon ions compared
to protons. Changing both αS/βS and αT/βT at the same time does not affect the systematics much,
because both effects partly compensate each other.
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Figure 71: Predicted secondary cancer risk ratios (Rp/RC) after scanned proton and carbon ion beam
irradiation for two different carbon ion beam widths, 5 mm and 6 mm FWHM. The proton beams have
a beam width of 10 mm FWHM. The photon parameters are: αS = 0.067 Gy−1, βS = 0.0223 Gy−2,
αT = 0.0226 Gy−1, βT = 0.0075 Gy−2, Dt,S = 8 Gy and Dt,T = 27 Gy. The OAR is located d = 2.5 cm
in front of the target.
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4.4 Secondary cancer risk after particle therapy - Patient data
In the previous section (section 4.3) it was demonstrated how the SC risk after RT changes with
varying parameters, such as the number of fractions and spatial location of the OAR. In this chapter
the secondary cancer risk after RT will be analysed for 20 patients previously treated with conventional
photon RT, of which ten patients suffered from liver metastases while the other ten were diagnosed
with prostate cancer.
4.4.1 Liver metastases patients
The dose planning for the patients with liver metastases was performed as described in section 3.3. The
optimized RBES-weighted dose distribution after proton and carbon ion beam therapy for patient 1 is
shown in the upper panel of Fig. 72, with the dose distribution for protons on the left and for carbon
ions on the right. The red contour shows the outline of the healthy part of the liver. As mentioned
before, carbon ions deposit a significant amount of dose behind the target. This dose ranges from
20-30 Gy close to the target to a few mGy at the edge of the fragmentation tail for patient 1. This can
be seen clearer in Fig. 73 where the dose distribution is shown on a log scale, revealing that the biggest
part of the fragmentation tail consists of doses below 1 Gy.
The risk distribution in the healthy part of the liver for patient 1 is shown in the lower panel of
Fig. 72. Note that only the risk in the healthy part of the liver is shown. Due to the high doses per
fraction of the SBRT treatment (see section 3.3.2 for details), cell survival is low inside the entrance
channel and thus the secondary cancer risk is low as well. An increased cancer risk can be seen at
the field margins where the dose falls off, allowing for a higher cell survival. When looking at the risk
distribution after carbon ion beam RT, an increased risk is visible in the area of the fragmentation tail.
Hence, it seems that carbon ion beam therapy results in an increased secondary cancer risk in the liver
due to the increased SC risk in the fragmentation tail.
The predicted SC risk ratios (Rp/RC) for the proton and carbon ion treatment plans for five OARs
and other soft tissue are shown in Fig. 74. Other soft tissue is all remaining tissue. For all OARs except
the skin the median risk ratio is below 1, i.e. in these cases the proton plans result in lower predicted SC
risks compared to carbon ions. The predicted risk ratios for bones range from 0 to above 1.2, showing
that the SC risk depends strongly on the treatment plan parameters, such as dose per fraction, location
of the tumour and the directions of the two radiation fields. Fig. 75 demonstrates the variation in size
and location of the tumour for the ten patients. The tumour size ranges from 18.6 cm3 to 332 cm3
(Tab. 6). As was seen in the previous chapter, the calculated SC risk after proton and carbon ion beam
therapy is almost identical at the beginning of the entrance channel. The main differences arise near
the target. Consequently, in regions far away from the target effects of the dose fall-off at the edge
of the radiation field become more important. This could be a reason why carbon ion beam therapy
yields a lower risk in the skin on average.
The SC risk ratios after proton RT were computed for two methods. One is assuming a constant
RBE of 1.1 for cell survival and 2 for tumour induction, as is typically used in clinics, and the other
is using a variable RBE calculated with the LEM as described in section 3.3. The results are shown
in Fig. 76. In most cases the constant RBE values resulted in larger predicted SC risks, especially for
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Figure 72: Upper panels: RBES-weighted dose distribution in patient 1 after irradiation of a liver
metastasis with two proton (left) and carbon ion fields (right). The delivered dose was set to 45 Gy
to the PTV (yellow area) and 67.5 Gy to the CTV (red area) in three fractions. The red lines denote
the contours of the healthy part of the liver. The angle between the two fields is 62 degrees. Carbon
ions show a large dose bath behind the target due to fragmentation. Lower panels: Secondary cancer
risk distribution in the healthy part of the liver for the proton (left) and carbon ion (right) treatment
plans. Carbon ions show an increased SC risk in the fragmentation tail.
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Figure 73: RBE-weighted dose distribution after irradiation of a liver metastasis with protons (left)
and carbon ion beams (right) on a logarithmic scale. The dose in the fragmentation tail of carbon ions
is in the order of 10 Gy close to the target to 10−5 Gy at the edge of the fragmentation tail.
the skin. These results suggest that the SC risk is overestimated using constant weighting factors for
protons as recommended by the International Commission on Radiological Protection (ICRP).
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Figure 74: Ratio of secondary cancer risks after irradiation with proton (Rp) and carbon ion (RC)
beams. The risks were evaluated for six OARs. For all OARs the median secondary cancer risk is lower
after proton radiation except for the skin.
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Figure 75: Cross sections of the liver metastases PTVs (red areas) of the ten patients. The outer
contours represent the contours of the body and the inner contours show the liver contours. The PTV
cross sections were chosen so that they are approximately in the center of the PTVs.
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Figure 76: Ratio of the secondary cancer risk assuming a constant RBE of 1.1 for cell surival and
2 for tumour induction for protons and a variable RBE calculated with TRiP98. A constant RBE is
overestimating the secondary cancer risk in most cases.
4.4.2 Prostate cancer patients
The treatment plans for the prostate cancer patients were generated for two laterally opposing scanned
proton and carbon ion fields as described in section 3.3.2. The SC risks were calculated as described
in section 3.3. The optimized RBES-weighted dose distribution is exemplarily shown for patient 1 in
Fig. 77. The red and orange areas in Fig. 77 denote the prostate and seminal vesicles, respectively. As
seen in the previous section, the fragmentation tail of carbon ions results in a large area of low doses.
The dose around the prostate and seminal vesicles is increased for the proton plan, whereas the dose
distribution is more conform for the carbon ion plan.
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Figure 77: RBE-weighted dose distribution in the prostate (red area) and seminal vesicles (orange
area) for one prostate cancer patient after dose optimization with proton (left) and carbon ion (right)
beams. The target dose for the prostate was set to 72.5 Gy and to 55.1 Gy for the seminal vesicles in
29 fractions.
In Fig. 78 the corresponding predicted SC risk distributions are shown in bone for patient 1. The SC
risk close to the target volume is higher for the carbon ion plan, while at larger distances from the
target the risk distribution seems equal for both plans. Overall, the risk values per voxel are, however,
very small compared to other OARs and the resulting risk difference between the proton and carbon ion
plan is almost negligible. This can also be seen in Fig. 79, where the predicted SC risk ratios (Rp/RC)
for four OARs (bladder, rectum, skin and bone) for the ten patients with prostate cancer are shown.
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Figure 78: Risk distribution in the bone after irradiation with proton (left) and carbon ion (right)
beams. The bone shows an increased SC risk for the carbon ion treatment plan compared to the proton
plan.
These four OARs were chosen since they are the most critical organs that receive dose during RT for
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prostate cancer. For both bone and skin the proton plans yield only a slightly lower SC risk compared
to the carbon ion plans. The median risk ratio for bone is 0.97 and 0.95 for skin. Considering the large
uncertainty of the input parameters these results are not significant. For bladder and rectum, however,
the proton plans result in significantly lower SC risks compared to the carbon ion plans, 0.73 and 0.54
for bladder and rectum, respectively. Noteworthy is also the large spread in the data points for bladder
and rectum, while the variation is small for bone and skin.
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Figure 79: Ratio of secondary cancer risks (Rp/RC) after irradiation with proton and carbon ion
beams. The risks were evaluated for four organs. For the radiosensitive organs such as bladder and
rectum the secondary cancer risk is lower after proton radiation while the risk is lower after carbon ion
beam radiation for the more radioresistant organs such as bone and skin.
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5 Discussion
In this work, a novel approach for modelling carcinogenesis related radiation effects for high-LET
radiation, ranging from neoplastic cell transformation on a cellular level, over tumour induction in mice
to SC induction after RT, is presented. In the following section the obtained results will be discussed.
5.1 Neoplastic cell transformation
A novel method for simulating RBE values for neoplastic cell transformation for particle radiation was
implemented, including a number of features relevant for particle radiation, such as the competition
between the induction of lethal and mutagenic events that lead to transformation, and the weighted
summation over all particle hit classes as described in section 3.1. An important aspect of this method
is the double use of the LEM, once for simulating cell survival and once for simulating neoplastic cell
transformation. Additionally, an empirical equation for the threshold dose Dt,T in the LQL model was
derived based on three individual experimental studies (Miller et al., 1995; Yang et al., 1985; Hei et al.,
1988).
A higher RBE for cell transformation than for cell survival was predicted with the double use of
the LEM, which is conform with experimental findings (Yang et al., 1985; Hei et al., 1988; Suzuki et al.,
1989; Miller et al., 1995; Yatagai, 2004; Wang et al., 2015). The RBE for cell transformation as a
function of LET exhibits a similar shape as the RBE for cell survival, showing an increase in RBE with
LET for LET values up to 100 to 1000 keV/µm and then a decrease of the RBE at higher LET values
(Fig. 44). The experimental RBE for cell transformation for the data set by Miller et al. (1995) reaches
a maximum around 100 keV/µm and is about 20 for 0.0005 visible transformations per surviving cell.
The experimental RBE for the data set by Yang et al. (1985) had a maximum value of about 5 when
using the individual photon reference curves, and the experimental RBE for the data set by Hei et al.
(1988) had a maximum RBE of about 8. Despite the fact that in all three data sets the same cell line
was used, different RBEs were found for similar LETs. A possible explanation for this range in RBE
values between the data sets is the difference in ion energies as well as in radiation quality. The LEM
was shown to be able to model this difference in RBE for the different data sets. The simulated RBE
values were often in the order of magnitude of the experimental RBE values and correctly described
the trend in RBE between the data sets. For very low energies (below approximately 0.5 MeV/u),
track segment conditions are not fulfilled in which case the simulated RBE values deviate from the
experimental values. This is the case for the 2H ions in the data set by Miller et al. (1995) and Hei
et al. (1988) and for 4He at 200 keV/µm from Miller et al. (1995).
For the RBE calculations in the present work, an effect level of 0.0005 transformations per surviving
cell was chosen. This particular effect level was chosen to ensure comparability between the three
experimental data sets as well as between the individual experiments in each data set. To inspect
the impact of this particular effect level on the RBE, the RBE for transformations per surviving cell
for 120 keV/µm 4He from the data set by Miller et al. (1995) was calculated for multiple effect levels
(Fig. 80). As usually observed, with increasing effect level the RBE decreases. With varying effect level
the deviation between the simulated and experimental RBE values changes, and since the equation
for Dt,T was derived by optimizing the RBE at 0.0005 transformation per surviving cell, the equation
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for Dt,T depends on the chosen effect level. Thus, strictly speaking, the equation for Dt,T that was
derived in the present work is only valid for RBE values at an effect level of 0.0005 transformations per
surviving cell. But as demonstrated in Fig. 38, the RBE predictions are robust to variations in Dt,T.
Another possible way of deriving an equation forDt,T is to minimize χ2 for the dose-response curves
instead of the RBE. This would possibly lead to a slight change of the equation for Dt,T. Deriving and
comparing different methods for the equation for Dt,T could be performed in the future.
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Figure 80: RBE for visible transformations per surviving cell as a function of the effect level for
120 keV/µm 4He ions (Miller et al., 1995).
Most photon dose-response relationships for neoplastic cell transformation of the three data sets con-
sidered in the present work showed a linear-quadratic shape. For the data set by Yang et al. (1985),
however, many experimental dose-response curves show a negative or very small initial slope when
performing an LQ fit. Since LEM can only handle positive LQ input parameters, all photon LQ model
coefficients were set to positive values in the fit procedure described in section 3.1. For one experiment,
the photon βT coefficient for neoplastic cell transformation was zero. In that case, the LEM often
underestimates the RBE as shown for iron ions in Fig. 43a.
When analysing the ion dose-response relationships, a negative βT term was found for some of the
transformation experiments by Miller et al. (1995) and Yang et al. (1985). A possible explanation for
this is the uncertainty in the experimental data, since in some cases the downwards bending appears to
be induced by the position of a single outlying data point, as seen for example for 4He ions in Fig. 35.
Furthermore, not all ion dose-response curves show a negative βT term, strengthening the assumption
further that the reason is experimental uncertainty. None of the above mentioned authors commented
on the negative βT term and assumed either a positive βT or a βT of zero, suggesting that they assumed
the downwards bending of the dose-response curves is a consequence of the experimental uncertainties.
Hence, the observed negative experimental βT values are probably not realistic. The double use of the
LEM also predicts a negative βT for some experiments. The reason for this could be the impact of
cell kill at higher doses. The absolute values of the predicted negative βT terms are, however, much
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smaller than the absolute values of the corresponding experimental βT terms. The negative βT terms
make it difficult to infer the dose-response relationship at higher doses. However, the effect level of
0.0005 transformations per surviving cell that was chosen in the present work is low enough so that the
downwards bending of the dose-response curves has little impact on the RBE value, since at low doses
the dose-response curves show almost no downwards bending as can be seen in Figs. 35, 40 and 41.
As mentioned above, an important feature of the model in the present work is the application of
the correlation between cell survival and cell transformation. As shown in Fig. 49, assuming statisti-
cal independence between the induction of lethal and transforming events leads to RBE simulations
that deviate from the experimental data, in particular for high-LET radiation, while for low- and
intermediate-LET radiation, both formalisms result in similar RBE values. These results suggest that
the exact mathematical description in Eq. (46) should be used when modelling cell transformation.
Limitations
Due to the scarcity of the available data on neoplastic cell transformation for high-LET radiation, the
validation of the model was performed on only three data sets and the data were often restricted to
only a few data points, which makes fitting to these data less reliable. The quality of the experimental
photon data affects the quality of the LEM predictions, which means that uncertainties in the exper-
imental photon data transfers to the predicted ion data. As mentioned above, some LQ model fits
to experimental dose-response curves yield negative LQ model parameters. Thus, more experimental
data is needed in order to evaluate the accuracy of the implemented method. Although the model
predictions are overall in good agreement with the experimental data, evaluation of the model on more
data should be performed.
Moreover, the equation for Dt,T is based on only three data sets and is therefore afflicted with
some uncertainty. In order to obtain a higher accuracy for Dt,T, more experimental data is needed.
Furthermore, the equation for Dt,T should be analysed for multiple RBE effect levels in order to get a
more accurate description of Dt,T for cell transformation.
Comparison with other models
Similar work has been done in the field of modelling neoplastic cell transformation. In a study by
Waligórski et al. (1987), the Katz model (section 2.5.1) was used to simulate neoplastic cell transfor-
mation for the data set by Yang et al. (1985) resulting in an overall good agreement with experimental
data. In contrast to the LEM, the Katz model uses four free fit parameters as input: m, D0, σ0 and k,
which are derived from experimental photon and ion dose-response curves. The LEM uses only two fit
parameters, α and β, which are derived from photon dose-response curves only, and a threshold dose
Dt, which is calculated from the photon LQ model coefficients using an empirically derived equation
(Eqs. (29) and (58)). Both models are based on the amorphous track structure as described in sec-
tion 2.1.3, but use different parametrizations for the local dose distribution. Compared to the LEM IV,
which assumes that the response of a cell to ionizing radiation is directly linked to the spatial DNA
damage distribution, the Katz model uses the spatial dose distribution to determine the effect of ion
radiation.
In order to describe the transition from a shouldered dose-response curve to a linear dose-response
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curve on a semi-logarithmic scale, the Katz model introduced two action modes, ion-kill and γ-kill mode
(section 2.5.1). In the LEM, it was not necessary to explicitly implement this transition. In the γ-kill
mode, which is described by the MTSH formalism, the initial slope of the curve is zero. Consequently,
the Katz model will predict a higher RBE at low doses compared to the LEM, which uses the LQL
model.
Although Waligórski et al. (1987) assumed statistical independence between the induction of lethal
and transforming events, the simulated dose-response curves for neoplastic cell transformation describe
the experimental data well. One reason could be the higher number of input parameters as men-
tioned above, which could compensate for neglecting the correlation between cell survival and tumour
induction.
There have been prior attempts in modelling neoplastic cell transformation with the LEM (Scholz
and Elsässer, 2007), however, no detailed methods were published. The calculations were performed
for a single data set from Miller et al. (1995) with the LEM I. No equation for the threshold dose Dt,T
was derived. In contrast, the newest version of the LEM (LEM IV) was used in the present work to
model neoplastic cell transformation for three data sets. Due to the differences in methodology, it was
not feasible to perform direct comparisons.
5.2 Tumour induction
Tumour induction probabilities in mouse Harderian glands after irradiation with photons and particles,
ranging from protons to niobium ions of various LET values and energies, was modelled by means of
the double use of the LEM as described in section 3.2. The four photon input parameters αS, βS,
αT and βT were obtained by fitting Eq. (38) to the experimental data. In contrast to the in vitro
experiments, where cell survival and neoplastic cell transformation was measured separately, in vivo
experiments show the combined effect of cell survival and tumour induction. This is the reason why all
four LQ model parameters have to be fitted simultaneously to the experimental data. This results in
large uncertainties of the obtained LEM input parameters as shown in Tab. 15. The standard errors of
the fit parameters are larger than the values themselves for αS, βS and αT. Only for βT the standard
error is smaller than βT itself. This leads to multiple parameter sets that describe the photon curve
well (Fig. 50). As described in section 4.2, one set of photon parameters was chosen that resulted in
tumour induction probabilities that were in agreement with the experimental data (Fig. 52). These
parameters show uncharacteristic α/β values, with αS/βS being 109 Gy and αT/βT being 0.013 Gy.
For low- to intermediate-LET radiation, the LEM underestimates the tumour prevalence, while for
high-LET radiation (≥ 175 keV/µm) the LEM describes the experimental data points well as shown in
Fig. 51.
When comparing the microscopic and macroscopic approach for modelling tumour induction in
Harderian gland, it was found that using the microscopic formalism yields slightly better predictions
compared to the macroscopic approach as demonstrated in Fig. 53. In particular for high-LET radiation,
while for low- to intermediate LET radiation the difference is only minor. However, using N = 100 or
N = 106 cells in the microscopic formalism, had only minor impact on the results as demonstrated in
Fig. 54). Reducing the cell number further (N = 10 cells) leads to a slightly larger deviation from the
experimental data (results not shown). From these results it follows that when considering radiation
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with a low to intermediate LET, as is usually the case in particle RT, then it is legitimate to use the
macroscopic equation to model tumour induction.
Another relevant aspect is the transition from neoplastic cell transformation on a cellular level to
observable tumour induction in tissue. Typical cell transformation probabilities are small and cannot
explain the observable tumour incidence. Waligórski et al. (1987) estimated that 150 cell transforma-
tions are needed in order to initiate an observable tumour in Harderian glands. This makes sense when
looking at the multiple capabilities a cell must acquire in order to become a tumour cell (section 2.4).
Uncontrolled cell growth alone is not enough for a cell to develop into a macroscopic tumour. Typically,
multiple mutations are needed. Although these steps are not modelled explicitly, the macroscopic LQ
model parameters contain the mean probabilities that a cell undergoes all these multiple mutations
until it becomes a cancer cell and therefore the development over time is indirectly considered in this
model. Knowing the number of cells in an organ, one can estimate how many cell transformations are
needed in order to initiate an observable tumour, assuming a linear relationship between cell transfor-
mation and tumour induction. From the data from Miller et al. (1995) it can be seen that for 1 Gy
of 120 keV/µm 4He ions 0.003 cells transform per surviving cell at a survival rate of 10%. From this
it follows that out of 106 irradiated cells 300 cells both survive and transform. The tumour induction
probability in Harderian gland at 1 Gy of 120 keV/µm 4He ions was calculated with the method de-
scribed in section 3.2 and is 78%. This means that 300 transformed cells have a 78% probability of
developing into a macroscopic tumour. It should be mentioned here, that in vivo experiments with
120 keV/µm 4He ions are not feasible due to the low penetration depth of this radiation quality.
Comparison with other models
Another model for simulating tumour induction in vivo for high-LET radiation is the Cucinotta model
(Cucinotta et al., 2013; Cacao et al., 2016; Cucinotta and Cacao, 2017), which is based on the Katz track
structure model (sections 2.5.1 and 2.5.3). Cucinotta and Cacao (2017) modelled tumour prevalence in
Harderian glands in mice after irradiation with a variety of radiation qualities, using the same data set
as described in section 3.2.2. The model exhibits better agreement with experimental data compared
with the model provided in the present work, in particular for intermediate-LET radiation. However,
the Cucinotta model is more complex than the model presented here and has more free fit parameters.
The model used eight fit parameters as input for simulating targeted effects: four parameters for cell
survival and four parameters for tumour induction. Two additional parameters were used for modelling
non-targeted effects. The model introduced in the present study, in contrast, uses only four free photon
fit parameters and two threshold doses Dt,S and Dt,T, which can be calculated using the empirical
equations Eqs. (29) and (58), and are thus only based on the photon input parameters. No experimental
ion data is needed as is the case for the Cucinotta model. The general limitations of the Katz model
in comparison with the LEM were mentioned earlier in section 5.1.
Limitations
Many models assume no quadratic term for tumour induction, whereas the Harderian gland data set
shows a clear quadratic term. The LEM needs a photon β value as input parameter. A βT term of zero
can result in an underestimation of the predicted ion RBE, which can be seen for the RBE predictions
for the data set by (Yang et al., 1985) in section 4.1.3, where the simulated RBE for iron ions with
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an LET of 300 keV/µm was below one. The need of a βT term for RBE predictions can be a limiting
factor of the LEM when no βT term can be extracted from experimental data, as is the case for the
atomic bomb survivors study.
The accuracy of the tumour induction predictions in this work was only assessed using a single
experimental data set based on Harderian gland tumours in mice. Any inference from these simulations
have to be considered with caution since it is unknown how these tumour induction probabilities
translate to human tissue. Furthermore, the large uncertainties of the photon input parameters make
the determination of these parameters difficult. The Harderian gland data set is, however, the most
extensive data set on tumour induction after low- and high-LET radiation exposure. It shows that there
is an RBE greater one for tumour induction and that heavy ions show an increased RBE compared
to low-LET radiation. The model introduced in the present work is able to qualitatively describe and
predict tumour induction probabilities after particle radiation. This is of utmost importance when
experimental data are scarce.
In this work, tumour induction was modelled using a simple linear-quadratic formalism, focusing
on the initiating event while not explicitly including long-term effects. Cancer is, however, a complex
multi-stage process and is often observed several years or even decades after the initiating event has
taken place (Preston et al., 2007). As demonstrated above, multiple transformations are needed in
order to produce a macroscopic tumour. This effect is indirectly incorporated in the model presented in
this work through the LQ model parameters. The LQ model parameters for tumour induction contain
the probability that multiple mutations lead to the formation of a macroscopic tumour.
5.3 Secondary cancer risk
SC risk estimates after scanned proton and carbon ion beam therapy were calculated using the TRiP98
treatment planning system. Based on the biologically optimized dose distribution it was then possible
to estimate SC risks for multiple OARS after particle radiation for patients previously treated for liver
metastases and prostate cancer with photon RT (section 4.4). Complementary to the patient data, a
systematic analysis was performed on an idealized geometry in order to gain a deeper understanding
of the underlying mechanisms (section 4.3). This analysis revealed some general systematics of SC
induction after proton and carbon ion beam RT, such as the strong dependence on the spatial location
as well as the radiosensitivity parameters of the OAR. Due to the strong inter-patient variability in
estimated SC risks, treatment plans have to be evaluated individually. In particular, the field margins
where the dose is falling off has to be considered when evaluating treatment plans. Particle therapy
allows for a higher dose confirmation, resulting in an enhanced sparing of normal tissue. At the same
time, particle radiation is inflicted with a higher probability of inducing secondary malignancies due to
an elevated RBE for tumour induction.
Since the input parameters obtained from the LSS are afflicted with large uncertainties, absolute
risk values have to be considered with care. Risk ratios are less dependent on the input parameters and
are therefore more robust. They can be misleading, however, when the absolute risk values for protons
and carbon ions are very small. In that case even small differences in the absolute values can result
in large risk ratios. Risk ratios are useful when comparing different treatment modalities but not to
estimate absolute risks after RT. Therefore it should be stressed here that the aim of the model presented
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in this work is not to predict accurate SC risk values, but to provide a tool for comparing different
treatment strategies for particle RT. In the following paragraphs the main discovered systematics will
be discussed.
A major finding of the present study is the elevated SC risk in the fragmentation tail at the distal
end of the Bragg peak for carbon ions (Fig. 57). This low-dose bath contributes significantly to the SC
risk behind the tumour and should thus be considered when generating treatment plans with carbon
ion beams. This can be done by making sure that no OAR is lying directly behind the tumour. Using
two opposing beams results in a higher RBES-weighted dose around the target volume for carbon ions
compared to protons. This results in an elevated SC risk for carbon ions for radioresistant cell lines,
where a higher dose leads to a higher SC risk, and in a decreased SC risk for radiosensitive cell lines,
due to the impact of cell kill.
Another factor that affects the risk ratio, is the radiosensitivity of the organ under consideration.
As seen in Figs. 60, 64 and 70, increasing αS/βS leads to a lower SC risk estimate for protons compared
to carbon ions, while increasing αT/βT leads to a lower SC risk for carbon ions compared to protons.
These results demonstrate the complex nature of SC risks. These results also show that, depending on
the radiosensitivity parameters and the spatial location of the OAR, using opposing beams can shift
the SC risk ratio in favour of carbon ions.
Due to the increased beam spot size and lateral scattering of protons compared to carbon ions, the dose
for the proton plans is increased at the lateral field margins. This increased area of low doses leads to
a higher SC risk at the lateral field margins and hence, OARs that are located there are at increased
risk of obtaining secondary malignancies (Fig. 66). Carbon ions are thus favourable when the OAR lies
at the edge of the radiation field. For OARs located behind the tumour, however, the SC risk is higher
for carbon ions due to the fragmentation tail as mentioned above. Therefore, the location of the OAR
is a major determinant of whether the SC risk is lower for protons or carbon ions.
A slightly lower SC risk was predicted after hypofractionated RT compared to conventional frac-
tionated RT (Fig. 68). This is likely due to the increased survival probability after conventional frac-
tionated RT, which leads to an increased SC risk. Hyopfractionated RT uses high doses per fraction,
resulting in a lower survival probability in the high-dose regions and this leads to a reduction of the
SC risk. This is in agreement with experimental in vivo data. Alpen et al. (1994) demonstrated this
effect experimentally for iron ions, where a single dose of 0.4 Gy resulted in a lower tumour prevalence
than six fractions of 0.07 Gy. Wang et al. (2015) found a slightly higher tumour incidence after a single
fraction of 1 Gy compared to five fractions of 0.2 Gy in mice, the results were, however, not significant.
Another study found a decrease in RBE with increasing dose per fraction for carbon ion radiation
(Ando et al., 2005). However, different end-points were used, namely tumour growth delay and early
skin reaction. Saager et al. (2020) showed a decrease in RBE with increasing dose per fraction for rat
spinal cord. Up to now, clinical studies were not able, however, to demonstrate a significant difference
in SC risk after hypofractionated and conventional RT (Widmark et al., 2019).
When looking at the SC risk calculations for the patients plans performed in this work, it was found
that for the liver metastases patients, the proton plans yield overall lower SC risk estimates as compared
to carbon ions (Fig. 74), which is most likely due to the increased risk in the area of the fragmentation
tail for carbon ions. Only skin shows a reduced SC risk for carbon ions compared to protons, where the
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fragmentation tail is of minor significance. Additionally, the entrance channel is narrower for carbon
ions and therefore the skin receives a lower total dose compared to protons. However, inter-patient
variability for the liver metastases patients is high. The risk ratio for bones ranges for example from 0 to
above 1.2 and it is therefore difficult to draw general conclusions. These large inter-patient variabilities
are mainly due to differences in patient anatomy and beam angles. The aim of this study is rather to
better understand SC risk after proton and carbon ion RT and to implement a model which can help
to evaluate treatment plans in regard to SC risk. In the SC risk simulations, liver SBRT employs such
high doses that many cells inside the radiation field are inactivated according to the model presented
in this work. Due to a high volume effect, the liver is able to sacrifice a large part of its volume without
losing its function (Dawson and Tenhaken, 2005; Pan et al., 2010; Miften et al., 2018). This makes it
possible to use such high doses when treating liver metastases.
The SC risk ratios for the prostate cancer patients are in favour of protons for bladder and rectum,
while for skin and bone both radiation qualities yield almost the same SC risk (Fig. 79). The inter-
patient variability is small for skin and bones and large for rectum and bladder. The low variability
for bones and skin could be due to the fact that the same beam configuration, two lateral opposing
fields, was used for all patients and that the anatomic differences in skin and bone are smaller than in
bladder and rectum. These results show that patients could benefit from either proton or carbon ion
RT depending on the type and location of the OAR.
Limitations
A major limitation when it comes to calculating SC risk after particle radiation is the uncertainty of the
input parameters. As demonstrated in this work, the calculated SC risk estimates depend strongly on
the radiosensitivity parameters αS, βS, αT and βT. These parameters are inflicted with uncertainties,
especially the ones for tumour induction, which are based on the LSS (section 2.4.2). Since the doses
in the LSS are very low (< 4 Gy), only αT is known and in order to use the LEM, an appropriate
value for βT has to be chosen. For the SC risk calculations in the present work, the same α/β ratios
for cell survival and tumour induction were taken. This is justified when assuming that the underlying
mechanisms of tumour induction and cell survival are the same and therefore the repair capability is
similar for both end points. Nevertheless, further analysis of the impact of the αT/βT ratio is required.
The applicability of the LQ model parameters derived from the LSS is debatable. As mentioned above,
the doses in the LSS are low compared to doses applied in RT and come from atomic bombs. In RT, high
doses are delivered to the patients and total doses of 70 Gy or more to the tumour are not uncommon.
Another aspect is that the majority of the population in the LSS are healthy, while cancer patients, in
contrast, might have some genetic differences, e.g. mutations in genes relevant for cancer development.
Furthermore, different populations have different background cancer incidences, and therefore the risk
coefficients from the LSS have to be transferred to the other populations. Thus, the risk coefficients
obtained from the LSS might be a good estimate for general SC risk induction, but not for predicting
accurate risk values for cancer patients. However, the LSS is the largest cohort presently available and
consists of a wide range of ages and doses and is therefore the most comprehensive study currently
available. In contrast, due to a typically much smaller cohort size, clinical studies are inflicted with
much larger uncertainties.
As mentioned above, the LSS shows a linear increase in cancer risk, and the existence of a quadratic
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term is currently under debate. In a recent update of the solid cancer incidence within the LSS, a
quadratic term for tumour induction was found for the atomic bomb survivors, but only for males
(Grant et al., 2017). In a recent study, Cologne et al. (2019) demonstrated that analysing individual
cancer sites yields different dose-response curves compared to the pooled data of multiple cancer sites.
Some cancer sites show an upwards bending of the dose-response curve at higher doses. However,
considering individual cancer sites is decreasing the statistical power of the data and therefore pooled
data is commonly used. Thus, the actual dose-response relationship is unknown.
The above mentioned limitations are based on the uncertainty of the input parameters. There
are, however, a few uncertainties regarding the method used in this work. First, no repopulation in
normal tissue was included in the model presented in this work. Cells that get inactivated by radiation
cannot become tumour cells and hence, with increasing number of inactivated cells the probability for
tumour induction decreases. This results in low tumour induction probabilities in high-dose regions near
the target. It is, however, more likely that cells repopulate, which would shift the maximum tumour
induction towards higher doses, yielding results closer to clinical observations (Shuryak et al., 2009).
There are several risk models that incorporate repopulation (Sachs and Brenner, 2005; Schneider,
2009; Shuryak et al., 2009). Schneider (2009) found that assuming a high repopulation probability
results in a dose-response relationship that is linear at low doses and reaches a plateau at high doses.
When switching off repopulation the dose-response falls off exponentially at high doses. This model is
biologically more realistic but also more complex and needs an additional parameter, the repopulation
rate.
Second, the contribution of the neutron dose is not implemented in TRiP98 and therefore no
neutron dose was considered in the risk calculations. Including the neutron dose could lead to different
SC risk estimates, therefore it would be interesting to see whether and how the risk estimates would
change when including the neutron. According to La Tessa et al. (2014) and Kaderka et al. (2012) the
absorbed neutron dose after scanned carbon ion beam therapy is almost two orders of magnitude lower
than the dose of the ions. Schneider et al. (2002) found that the neutron dose is approximately 1% of
the treatment dose. Hence the effect of the absorbed neutron dose on the SC risk is expected to be very
low. On the other hand, the neutron RBE is relatively high. In mouse spinal cord a neutron RBE for
tissue damage of up to 6 was found (Hornsey, 1982). The ICRP recommends a continuous weighting
factor as a function of neutron energy with a maximum value of 20. The enhanced RBE could lead to
some moderate contribution to the SC risk.
Third, the competition model as proposed by UNSCEAR (1993) is using the LQ model, whose
applicability for doses exceeding 10 Gy is under discussion. During RT higher doses per fraction can be
delivered to the patients, e.g. in SBRT, and it is thus questionable whether the LQ model can be used
in these cases. The LEM uses the LQL model, which is in agreement with experimentally observed cell
survival curves. Thus, the SC risks predicted with the LEM and TRiP98 might be more accurate than
the risks calculated with models that use the LQ model. However, in most cases the doses per fraction
are low enough so that the validity of the LQ model remains.
Dose-response relationship
The shape of the dose-response relationship, which is currently under debate, affects strongly the
results of the model presented in this work. Therefore, this aspect will be discussed in more detail.
96
The majority of the epidemiologic data consists of risk estimates for only small doses (< 4 Gy) and
thus does not allow for predictions for high doses. The findings from patient data show a linear or
nearly linear dose-response even up to very high doses (e.g. 50 Gy). However, challenges arise when it
comes to assigning a risk to each dose value. First, the dose is usually averaged over the whole organ.
Second, reconstruction of the organ dose is not always accurate. Third, organ motion during treatment
can lead to a different organ dose than in the treatment plan. Further aspects are the change in cell
radiosensitivity and repopulation between fractions.
Animal studies allow for more controlled studies of tumour induction and many of these studies
show a clear bell-shaped dose-response relationship (Sasaki and Fukuda, 1999; Mole et al., 1983). In
cancer patients however, this has only been found for thyroid cancer (Bhatti et al., 2010). Other studies
indicate a decrease of the slope of tumour induction at higher doses such as seen in the LSS (Fig. 16)
or CCSS, but due to the large uncertainty of the data no firm conclusions can be drawn. Diallo et al.
(2009) and Dörr and Herrmann (2002) found that the frequency of SCs after photon RT is highest at
the edge of the irradiated volume and is falling rapidly inside the irradiated volume. The authors also
found that most SCs arise in volumes that received doses between 0 and 2.5 Gy. These results are in
agreement with the findings in the present work as seen for example in Fig. 59, and strengthen the
assumption of a bell-shaped dose-response curve. Schneider et al. (2006a) found that out of 30 dogs
treated with proton RT, two dogs developed an SC. Both cancers were located at the border of the
high-dose regions. Although the results are not statistically significant, they indicate a higher SC risk
in the intermediate-dose areas compared to the high-dose areas.
A difficulty of determining the dose-response relationship at high doses is the scarce data as well as
the large uncertainty of these data. Cohort studies show huge error bars, especially at high doses, thus
making it cumbersome to infer the shape of the dose-response curve at high doses. Limiting factors
of cohort studies are the often small population sizes as well as the short follow-up times. Especially
for particle radiotherapy, only few clinical studies exist. RT is a fast developing treatment technique,
thus, as soon as enough data is accumulated, the technique which the data is based on, is often already
outdated and data for newer treatment techniques are needed. Another factor is the large latency
period between the induction of a carcinogenic event and the observation of a macroscopic tumour.
As illustrated in Fig. 81, the shape of the dose-response curve depends strongly on the radiosensi-
tivity parameters of the cell type under consideration, as well as the fractionation scheme. Increasing
the number of fractions and thus decreasing the dose per fraction results in a broader dose-response
curve and a shift of the maximum to higher doses. This can be a reason why it is difficult to see a
decrease of the secondary cancer prevalence at high doses for patients undergoing RT where the dose
is mostly delivered in multiple fractions. Thus, depending on the input parameters, the dose-response
curve can appear to increase nearly linear with dose. In particular, radioresistant cell lines regarding
cell survival show a flat dose-response curve with no prominent peak. In a recent modelling study,
Schneider et al. (2018) showed that dosimetric uncertainties due to inhomogeneous dose distributions
in the tumour can be sufficient for obscuring an underlying non-linear dose-response relationship. In
conclusion, the true dose-response relationship at high doses is currently not known and more clinical
data is needed in order to develop more accurate risk models.
97
0.1
0.2
S = 0.1 Gy 1 S = 0.08 Gy 1 S = 0.04 Gy 1
S = 0.02 Gy 1
0.2
0.4
T = 0.01 Gy 1 T = 0.04 Gy 1 T = 0.05 Gy 1 T = 0.1 Gy 1
0.1
0.2
n = 1 n = 10 n = 20 n = 30
0 20
0.2
0.4
S = 0.2 Gy 1
T = 0.1 Gy 1
n = 1
0 20
S = 0.2 Gy 1
T = 0.1 Gy 1
n = 20
0 20
S = 0.01 Gy 1
T = 0.01 Gy 1
n = 1
0 20 40
S = 0.01 Gy 1
T = 0.01 Gy 1
n = 20
Total dose [Gy (RBES)]
Tu
m
ou
r i
nd
uc
tio
n 
pr
ob
ab
ilit
y T =
 0
.0
1 
Gy
1
 n
 =
 1
0
S =
 0
.1
 G
y
1
 n
 =
 1
0
S =
 0
.0
4 
Gy
1
T =
 0
.0
1 
Gy
1
Figure 81: Tumour induction probability as a function of photon dose for different input parameters.
The α/β-ratio for both cell survival and tumour induction is 2 Gy. The parameter n is the number
of fractions. The tumour induction probability was calculated with Eq. (52). The dose-response
relationship depends strongly on the choice of input parameters, ranging from a very narrow bell-
shaped curve to an almost linear increase with dose.
For organs outside the radiation field, where doses are low, the LNT model seems a valid model, since
it is more robust with regard to uncertainties in the dose distribution compared to the competition
model. Depending on the input parameters, the competition model shows a narrow maximum in
the dose-response relationship. This means that slight uncertainties in the dose can lead to large
uncertainties in the risk. Consequently, the competition model is more sensitive to dose uncertainties
than the LNT model.
Comparison with other studies
The work presented here was inspired by the study of Mondlane et al. (2017), who compared SC risks
for proton and photon treatment plans for ten patients with liver metastases. They assumed a constant
RBES of 1.1 and RBET of 2 for proton radiation. The results showed a significant decrease in SC risk for
the proton plans compared to photons. This decrease is most likely due to the reduced integral dose of
the proton plans. Comparing the risk ratios for variable RBEs calculated with the method implemented
in the present work and constant RBEs of 1.1 and 2 for cell survival and tumour induction, respectively,
shows that in most cases these constant RBEs are higher than the SC risks calculated with the variable
RBE (Fig. 76). The RBE of 2 for tumour induction is based on the radiation weighting factor for
radiation protection recommended by the ICRP (2007) and is a conservative estimate, which explains
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the overestimation of the SC risk. Only for the esophagus an underestimation was visible. This might
be due to the fact that part of the esophagus is close to the target volume where the RBE is higher than
1.1 and 2, for cell survival and tumour induction, respectively. For the skin the deviation between the
two methods was largest. The skin lies in the plateau region, where the RBE is low. In this case the
constant RBE values of 1.1 and 2 are higher than the RBE values predicted with the LEM, resulting
in larger risks.
The proton risk values for the constant RBEs calculated in the present work were in the same order
of magnitude as the risks reported by Mondlane et al. (2017), which were obtained using a different
TPS. Since TRiP98 is unable generate photon treatment plans, it was not possible to directly compare
photon and particle treatment plans. Another drawback is that it is not possible to validate the method
presented here on photon data, which is more abundant than data on particle RT.
Another study analysed SC risk estimates in breast for proton and carbon ion plans for Hodgkin
lymphoma patients (Eley et al., 2016). The scanned proton and carbon ion fields were planned to
irradiate the target volume using a single anterior-to-posterior beam direction. A model which considers
competition between cell kill and tumour-initiating events was used. The treatment planning was
performed with TRiP98 and the RBES for cell survival was calculated with TRiP98 as well. The
RBE for tumour induction was calculated using a linear-quadratic formalism, for which the LQ model
parameters for tumour induction have to be known. The authors investigated the SC risk distribution
in the breast and found that due to the reduced lateral scattering of carbon ions, both the dose and
SC risk distributions were narrower at the field margins inside the breast for carbon ions compared
to protons. This leads to a reduced breast cancer risk for Hodgkin lymphoma patients after carbon
ion RT. However, due to a high inter-patient variability the authors found no significant difference in
breast cancer induction between the proton and carbon ion plans, but carbon ions tended to result in
lower SC risk estimates.
It should be noted that only the cancer induction in the breast was considered, which was located
at the lateral field margins of the ion beams. As demonstrated in the present work, OARs that are
located at the lateral field margins benefit more from carbon ion treatment, while OARs behind the
tumour benefit more from proton RT. In the study by Eley et al. (2016), the fragmentation tail of
carbon ions was not considered, since the OAR was located in front of the target. Taking into account
OARs behind the tumour that are affected by the low-dose bath of the fragmentation tail, such as the
lung, heart and esophagus, could lead to a higher SC risk for carbon ions.
The general systematic found in the present work that OARs located at the lateral field margins
benefit from carbon ion treatment and that the spatial location of the OAR determines which radiation
quality yields a lower SC risk, are in agreement with the findings reported by Eley et al. (2016). This is
demonstrating that the systematics found in the present work can be used to explain the results from
other studies.
Stokkevåg et al. (2016) performed a systematic analysis of SC induction for scanned proton and
carbon ion treatment plans for prostate cancer patients. For each of the ten patients, treatment plans
were generated for photons using VMAT, protons and carbon ions, respectively. Radiation-induced
SC risk ratios (Rion/Rphoton) for the bladder and rectum were calculated using a bell-shaped dose-
response curve. Fractionation effects and RBE were incorporated into the model using a minimum
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and maximum RBE. The mean minimum and maximum RBE values were 1.25 and 6, respectively, for
carbon ions and 1.03 and 1.25, respectively, for protons. The authors performed a systematic analysis
of the contribution of the different parameters to the risk ratio. Again, large inter-patient variability
was found. The mean risk ratio (VMAT/12C) for all ten patients was 1.31 for the bladder and 0.58 for
the rectum. For the rectum the risk ratios of all ten patients were below one, suggesting that carbon
ions induce a higher SC risk in the rectum compared to photons. In contrast, the mean risk ratios
(VMAT/1H) for protons were 1.72 and 1.10 for bladder and rectum, respectively. This means that the
risk ratios (VMAT/particles) for both organs are higher for the proton plans than the carbon ion plans,
indicating that protons yield lower SC risks compared to carbon ions. This is in agreement with the
results shown in the present study. The authors also found that the radiosensitivity parameter for cell
survival αS had the strongest influence on the results with decreasing risk ratio for increasing values
of αS. In Stokkevåg et al. (2015), SC risks for prostate cancer patients were calculated for proton and
carbon ion plans using three different dose-response models: a linear, linear-plateau and a bell-shaped
competition model. The authors found that the linear model resulted in the highest estimated SC risks,
while the competition model yielded the lowest risks. The risk values for the linear model were higher
than the highest overall SC incidence associated with RT (Brenner et al., 2000; Murray et al., 2014).
For all three models very low (< 4%) SC risk values were estimated, which is in accordance with the
absolute values found in the present study, were the majority of the observed absolute risk values were
below 1%.
Timlin et al. (2011) computed 3D SC risk maps for photon and proton radiation, based on the
competition between cell kill and tumour induction. A minimum RBE of 1.05 and a maximum RBE of
1.2 was used for proton radiation. For the simulations, equal numbers of radiation fields were used for
both radiation qualities. When comparing the photon and proton plans, Timlin et al. (2011) found that
for typical cell sensitivity parameters protons produced a higher SC risk in 80% of the cases compared
to photons. This was mainly because the photon dose in the entrance channel was so high that cell kill
was dominating, resulting in a lower SC risk. The authors also found that protons exhibited the lowest
SC risk for superficial targets due to the lack of an exit dose as compared to photons. Adding a dose
bath to the normal tissue resulted in an increase of the SC risk of up to an order of magnitude. The
authors suggested that in order to yield a low SC risk, the number of radiation fields and the number of
cells at risk should be kept as low as possible. These findings are in agreement with the results shown
in the present work. However, using the same amount of fields for both the photon and proton plans as
was done by the authors is not a realistic scenario. Due to the fact that photons deposit a large amount
of energy in the entrance channel as shown in Fig. 1, using only a few photon fields results in a very
high dose in the entrance channel. In RT, typically many fields (IMRT) or a continuous rotation of
the field (VMAT) is used for photon RT, resulting in a large volume of low doses in the normal tissue.
This low dose bath would lead to a higher SC risk for photons compared to protons, since the volume
of normal tissue that receives radiation is much smaller for particle radiation.
General aspects of proton and carbon ion RT
While the integral dose is lower for the carbon ion treatment plans compared to the proton plans,
the total volume that receives low doses (< 1 Gy) is larger for carbon ions, due to the fragmentation
tail (Tab. 18). However, carbon ions have a higher RBE and thus higher tumour induction capability
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compared to protons. Whether carbon ions or protons are favourable with regard to SC risk depends
on several factors. Patients with radioresistant tumours might benefit more from carbon ion treatment,
due to the increased RBE, while other patients might benefit more from proton RT due to the absence
of a fragmentation tail. The reduced dose in the entrance channel of carbon ions can lead to fewer
acute side effects compared to proton RT. Acute side effects can be more crucial for some patients, in
particular older patients, than the risk of obtaining a secondary tumour several years to decades after
the treatment. All these aspects have to be taken into account when choosing a treatment strategy and
the model implemented in the present work can help making this choice by allowing a deeper insight
into SC risk associated with particle RT.
When looking at clinical data on carbon ion RT, Mohamad et al. (2019) found an overall lower
incidence of secondary malignancies for prostate cancer patients treated with carbon ion RT compared
to photons. However, for some organs carbon ion RT showed an increased SC risk compared to photons.
When looking at proton RT, other clinical studies suggest that proton RT can have a benefit over photon
radiotherapy due to the reduced integral dose (Chung et al., 2013; Sethi et al., 2013). Modelling studies
indicate that spot-scanned proton therapy could lead to a SC risk reduction of 50% compared to
conventional photon RT (Schneider et al., 2006b). These studies show that trends are visible but that
the uncertainties are still large until more data is available.
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6 Conclusion and outlook
The method provided in this work offers a tool for quantitatively describing carcinogenesis related end-
points after particle radiation, such as neoplastic cell transformation, tumour induction and secondary
cancer risk after particle therapy. The predicted RBE values for cell transformation and tumour induc-
tion are in consistent agreement with experimental data. The results presented here provide further
support for the predictive power of the LEM and expand its applicability to carcinogenic end-points. A
major strength of this work is its simplistic approach combined with established and validated models.
Well accepted concepts for describing the RBE for cell survival and clinical endpoints such as tumour
control or normal tissue complications were transferred to carcinogenesis related radiation effects. Al-
though the precise calculation of absolute secondary cancer risk values is currently not feasible due to
the large uncertainties of the input parameters, the model implemented in the present work is a useful
tool for obtaining a better understanding of the underlying systematics of secondary cancer induction
after particle radiotherapy.
Secondary cancer risk after particle radiotherapy is a complex quantity that depends on several
factors. Whether protons or carbon ions are beneficial with regard to secondary cancer risk depends
strongly on the spatial location of the organ at risk under consideration and its radiosensitivity param-
eters regarding cell survival and tumour induction. Closely behind the tumour, the risk for secondary
malignancies is elevated for carbon ions due to the low-dose bath of the fragmentation tail. At the
lateral field margins, instead, the secondary cancer risk is predicted to be lower for carbon ions, due
to reduced lateral scattering. Based on these findings, the optimum irradiation modality can be deter-
mined for each patient individually based on the spatial location of the organ at risk. Especially for
young patients, secondary cancer risk estimates should be included either directly in the dose optimiza-
tion process or in the evaluation of different treatment strategies. The different treatment plans, with
and without inclusion of secondary cancer risk, can then be compared with each other. But even with-
out implementing secondary cancer risk in the optimization process, 3D risk maps can be calculated
for each treatment plan in order to assess whether organs at risk lie in regions where secondary cancer
risk is high. That way existing treatment plans can be re-evaluated.
Additional to secondary cancer risk estimation for cancer patients after radiotherapy, other appli-
cations of the model will be possible in the field of radiation protection, such as cancer risk estimation
for astronauts, which are exposed to high-energy particles coming from galactic cosmic rays. Another
application could be for patients undergoing pain therapy with alpha particles. In these cases, the per-
son is typically exposed to low doses of radiation over a longer period time, in contrast to radiotherapy,
where the patient receives a high dose in a very short time. Therefore, it has to be investigated whether
further effect modifying factors, e.g. adaptation to low dose-rate effects, must be included in addition
to the provided method.
In future work, additional features could be implemented in the model in order to allow for more
accurate and patient-specific risk estimations. This could include:
• Repopulation between fractions in normal tissue. This would allow for more realistic risk estima-
tions.
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• Inclusion of patient-specific parameters such as gender, attained age and age at exposure could be
incorporated into the model, since these parameters can have an impact on the risk calculations
(Preston et al., 2007).
• Evaluation of the dose-response curve at higher doses. The shape of the dose-response curve is
currently discussed and more research is needed in order to assess the tumour induction probability
at high doses. In the next decade, more clinical data on particle RT will be available, which can
help to validate the method provided in this work.
• Neutron dose. The dose contribution from neutrons was not considered in this work. Despite the
absorbed neutron dose being low after actively scanned particle therapy, the effect of the absorbed
neutron dose on the secondary cancer risk is not yet clear and should thus be analysed in future
research. In particular, it should be assessed whether the contribution of the neutron dose would
shift the risk ratio in favour of protons or carbon ions.
Since clinical data is more abundant for photon radiotherapy compared to particle radiotherapy, apply-
ing the model to photon radiation would allow to validate the model on clinical data and to compare
secondary cancer risk estimates after particle and photon radiotherapy. This would also help to in-
vestigate whether particle radiotherapy has a lower probability for inducing secondary malignancies
compared to photon radiotherapy, which only few clinical studies have investigated (Chung et al., 2013;
Mohamad et al., 2019).
Another interesting aspect to analyse is the secondary cancer risk for other particle radiation
such as helium ions. Helium ions offer a new possibility for particle radiotherapy, because they have
a lower lateral scattering and a higher RBE compared to protons and show a significantly reduced
fragmentation tail (Grün et al., 2015; Krämer et al., 2016; Tessonnier et al., 2018). The reduced RBE
and the lower dose in the fragmentation tail of helium ions compared to carbon ions could lead to an
improved secondary cancer risk while offering higher dose conformity compared to protons. Therefore,
it would be interesting to compare the secondary cancer risks for proton and carbon ions calculated in
this work with secondary cancer risks for helium ions.
Since RT treatment modalities are continuously evolving, the need for assessing and understanding SC
risks after radiotherapy remains important. Insights gained by the method provided in the present work,
together with more preclinical and clinical data, might be helpful to optimize treatment strategies in the
future. Furthermore, the provided methods may help to develop a consistent quantitative understanding
of radiation carcinogenesis after arbitrary doses and radiation qualities.
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Erratum
Page 47 - Treatment planning for the prostate cancer patients
Unfortunately, wrong input parameters and corresponding references for the target volume are quoted
here; the actually used parameters were: αS = 0.1 Gy−1, βS = 0.05 Gy−2 and Dt,S = 8 Gy (Friedrich
et al., 2013a).
